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ABSTRACT
Effect-size heterogeneity is a commonly observed phenomenon when aggregating
studies from different ancestries to conduct trans-ethnic meta-analysis. Irrespective
of the sources of heterogeneity, classical meta-analysis approaches cannot appropri-
ately account for the expected between-study heterogeneity. Therefore, to bridge
the methodological gap, in the first two projects, I develop statistical methods for
modeling the heterogeneous effects in trans-ethnic meta-analysis for genome-wide as-
sociation studies (GWASs). In the third project, I extend the methods in trans-ethnic
GWAS meta-analysis to a general statistical framework for modeling heterogeneity
in biomedical studies.
In the first project, I develop a score test for the common variant GWAS trans-
ethnic meta-analysis. To account for the expected genetic effect heterogeneity across
diverse populations, I adopt a modified random effects model from the kernel re-
gression framework, and use the adaptive variance component test to achieve robust
power regardless of the degree of genetic effect heterogeneity. From extensive sim-
ulation studies, I demonstrate that the proposed method has well-calibrated type I
error rates at very stringent significance levels and can improve power over traditional
meta-analysis methods.
In the second project, I extend the common variant meta-analysis approach to
the gene-based rare variant trans-ethnic meta-analysis. I develop a unified score
test which is capable of incorporating different levels of heterogeneous genetic effects
across multiple ancestry groups. I employ a resampling-based copula method to
estimate the asymptotic distribution of the proposed test, which enables efficient
xv
estimation of p-values. I conduct simulation studies to demonstrate that the proposed
approach is well-calibrated at stringent significance levels and improves power over
current approaches under the existence of genetic effect heterogeneity. As a real data
application, I further apply the proposed method to the Type 2 Diabetes Genetic
Exploration by Next-generation sequencing in multi-Ethnic Samples (T2D-GENES)
consortia data to explore rare variant associations with several traits.
In the third project, I develop a supremum score test for jointly testing the fixed
and random effects in a generalized linear mixed model (GLMM). The joint testing
framework has many applications in biomedical studies. One example is to use such
tests for ascertaining associations under the existence of heterogeneity in GWAS meta-
analysis; another example is the nonparametric test of spline curves. The supremum
score test first re-parameterizes the fixed effects terms as a product of a scale parame-
ter and a vector of nuisance parameters. With such re-parameterization, the joint test
is equivalent to testing whether the scale parameter is zero. Since the nuisance pa-
rameters are unidentifiable under the null hypothesis, I propose using the supremum
of score test statistics over the nuisance parameters. I employ a resampling-based
copula method to approximate the asymptotic null distribution of the proposed score
test statistic. I first investigate the performance of the method through simulation
studies. Using the Michigan Genomics Initiative (MGI) data, I then demonstrate
its application by assessing whether the genetics effects to Low Density Lipoprotein
Cholesterol (LDL-C) can be modified by age.
xvi
CHAPTER I
Introduction
1.1 Mapping Human Complex Traits
The development of recombinant DNA and other molecular techniques in the 1970s
have profoundly altered the practice of human biology. Since then, new findings in
genetics and molecular biology are emerging at an unprecedented clip. These find-
ings provide new insights into the human genome, and are continuously shaping our
understanding of the genetic basis of health and disease. As of April 2018, the genes
underlying 76% of 6,727 known monogenic Mendelian disorders have been identified
(Amberger et al., 2014). Despite the success in gene mapping of Mendelian disor-
ders, identifying the genetic risks for complex diseases/traits remains a challenging
task, since those disorder/phenotype susceptibilities are usually influenced by genetic
variants in multiple genes, environmental/behavioral factors, as well as their possible
interactions.
In 1996, Risch and Merikangas (Risch and Merikangas, 1996) predicted that as-
sociation studies, which compare the frequency of alleles in a particular variants
between affected and unaffected individuals, can be effective tools for studying com-
plex traits because of their statistical power to detect genes of small effect. However,
such an approach was constrained due to the limited number of polymorphisms that
could be genotyped at that time. For example, the available number of markers was
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typically in the tens, and the sample size was usually in the hundreds. In the begin-
ning of the 21st century, advances in the genotyping technology and the dramatically
decreased genotyping cost began to facilitate the detection of a large number of poly-
morphisms across the entire human genome. Since then, genome-wide association
studies (GWAS) have led to a plethora of discoveries for various human complex
diseases/traits (MacArthur et al., 2016).
Early GWAS mainly focused on identifying common genetic variants using single
nucleotide polymorphism (SNP) arrays, but the success of these GWAS has been
primarily confined to European populations. The ability to aggregate cohort-specific
summary statistics from multiple studies via meta-analysis techniques has further
promoted more GWAS findings in populations of European descent. However, ac-
cumulating evidence has demonstrated that, for a variety of complex diseases/traits,
there is substantial overlap in trait-associated loci between different ethnicities (Farrer
et al., 1997; Dumitrescu et al., 2011; Carlson et al., 2013). Therefore, it is expected
that the efficiency of complex-trait association studies can be further improved when
populations of non-European descent are analyzed in conjunction with the European
populations via trans-ethnic meta-analysis. However, the classical meta-analysis ap-
proaches – both fixed-effects and random-effects models – are not appropriate for
combining data across race and ethnicity, and quite limited research exists in de-
veloping powerful multi-ethnic GWAS meta-analysis methods for common variants.
Thus, trans-ethnic meta-analysis methods for common variant associations are greatly
needed.
As of April 2018, while GWASs have successfully identified 53,069 unique SNP-
trait associations (MacArthur et al., 2016), most tend to have low to moderate effect
and explain only a fraction of the overall heritability (Manolio et al., 2009). The
fact that array-based GWAS findings have not been able to fully explain the trait
variations led to the widely debated “missing heritability” question after the 1st wave
2
of GWAS. A natural conjecture for the possible explanation to this problem is that the
missing disease heritability is due to rare and low-frequency variants, some with large
effects, which could not be captured in the genotyping array platforms (Frazer et al.,
2009; Eichler et al., 2010). While the array-based GWAS continues to unearth trait-
associated variants, accessibility in terms of cost and technology of next-generation
sequencing has opened up the entire spectrum of genome variations for the analysis
of complex diseases/traits. In 2014, the cost for whole-genome sequencing (WGS)
reached the US$1000 per genome milestone. In contrast to the array-based GWAS,
which focus on SNPs that are in linkage disequilibrium (LD) with the causal variants,
whole-genome sequencing shifts our research interest toward analyzing causal variants
and genes directly. Recent advances in sequencing technology, availability of high-
quality human reference panels, and improvements in genotyping imputation accuracy
have made it possible to comprehensively catalog genetic variation in population
samples. In fact, sequencing studies have successfully identified rare variants that
are involved in complex traits, including prostate cancer (Gudmundsson et al., 2012),
Alzheimer disease (Cruchaga et al., 2014), lipids and coronary artery disease (Peloso
et al., 2014) and many others.
Despite its potential contributions to solving the “missing heritability” problem,
one inevitable challenge for the design and analysis of sequencing-based GWAS is that
rare variant tests are usually underpowered without an exceptionally large sample size
or a sufficient number of rare alleles captured (Bansal et al., 2010). One practical
strategy to improve power is to conduct trans-ethnic meta-analysis, which combines
summary statistics across studies from different ethnicities to increase sample sizes.
However, under the presence of inter-study genetic effect heterogeneity across an-
cestries, existing meta-analysis approaches may be unsatisfactory because they do
not take into consideration that studies from the more closely related ancestries can
be more homogeneous than those that are more distantly related. In order to take
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full advantage of the strengths of multi-ethnic meta-analysis, powerful trans-ethnic
GWAS meta-analysis methods for rare variant associations are greatly needed.
1.2 The Need for Trans-Ethnic Meta-Analysis
Meta-Analysis is a practical tool to aggregate studies that have already been con-
ducted. In ideal situations, meta-analysis can achieve eventually equal power as the
joint analysis (Liu et al., 2014). Besides its ability of increasing sample sizes with-
out the cost of additional genotyping, meta-analysis has several logistic and ethical
advantages over the joint analysis of individual level data. First, meta-analysis only
requires summary statistics from each participating study, which avoids the cumber-
some integration of genotype and phenotype data from different studies, and protects
the privacy of study participants. Second, different studies may require different sets
of covariates, which can be difficult to accommodate in a joint analysis, but can be
easily incorporated at the summary level statistic in meta-analysis.
Initially, GWAS meta-analyses were mostly European-based, and have proved to
be worthwhile in identifying additional complex trait loci (Bustamante et al., 2011).
Recently, GWAS have been undertaken in other ethnic groups including Africans, East
and South Asians and Hispanics (Popejoy and Fullerton, 2016). With the increasing
availability of GWAS from distinct ethnicities, trans-ethnic meta-analysis offers an
exciting opportunity to enrich the association strengths with the further increased
sample sizes and fine mapping through different LD patterns (Li and Keating, 2014).
In fact, trans-ethnic meta-analyses have successfully identified novel loci that are
associated with common oncologic diseases, including breast cancer (Siddiq et al.,
2012) and prostate cancer (Kote-Jarai et al., 2011); metabolic and cardiovascular
diseases/ traits, including high-/low- density lipoprotein (HDL/LDL) levels(Coram
et al., 2013), blood pressure (Franceschini et al., 2013) and coronary artery disease
(Dichgans et al., 2014); immune diseases such as rheumatoid arthritis (RA) (Okada
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et al., 2014) and asthma (Lasky-Su et al., 2012); and many others.
For trans-ethnic GWAS meta-analysis, in addition to its primary objective on dis-
ease/trait locus discoveries, several other goals can be simultaneously accomplished
using the features of trans-ethnic study designs. Firstly, trans-ethnic GWAS meta-
analysis provides an independent replication sample set that can be used to validate
single-population GWAS findings and to eliminate concerns about sub-/cryptic- pop-
ulation stratification in the single GWAS discoveries (Campbell et al., 2005). Those
validated variants can be further used to prioritize loci for secondary replication and
sequencing studies (Cantor et al., 2010). Secondly, in trans-ethnic GWAS meta-
analysis, differences in LD structures across genetically diverse populations is po-
tentially a powerful tool for fine mapping the rare or causal variants that underlie
disease associations (Teo et al., 2010). Despite the promising potential, however, the
between-study genetic effect heterogeneity among different ethnic groups, e.g. un-
equal genetic effect sizes among studies (Wang et al., 2013), presents new challenges
in performing trans-ethnic meta-analysis.
In GWAS meta-analysis of common variants, several reasons can contribute to the
emergence of complex between-study heterogeneity patterns. First, it is highly possi-
ble that the queried SNP is not the underlying causal SNP, but rather is correlated to
the causal SNP through LD. Therefore, due to variations in the LD structures across
ancestry groups, the same high-risk allele may have different patterns of association
with the causal allele among different populations, leading to the observed unequal
genetic effects at the marker alleles. This phenomenon can be particularly relevant
under the common disease – common variants (CD-CV) model (Cargill et al., 1999;
Chakravarti, 1999), in which differential recombination histories can occur due to
the varying age of the mutations in the different populations (Pritchard and Prze-
worski, 2001). Moreover, the presence of hidden stratification in some populations
may produce spurious associations or alter the patterns of true associations, and
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therefore further complicate the between-study heterogeneity (Morton and Collins,
1998; Pritchard and Przeworski, 2001; Thomas and Witte, 2002; Stumpf and Gold-
stein, 2003; Freedman et al., 2004). In addition, the genetic variant of interest may
interact with other environmental, dietary and lifestyle factors. Thus, the difference
in these factors among populations can generate variability in the marginal genetic
effects between studies (Morris, 2011).
For rare variant GWAS meta-analysis, even if the same variant selection crite-
ria are employed, different studies may still present different sets of rare variants,
since rare variants are often population specific. Therefore, the gene-level association
power will likely be unequal among studies, even when effect size across studies is the
same for each variant. The possible gene-environment interaction, which contributes
to heterogeneous genetic effects in common variant GWAS meta-analysis, also adds
to the complex between-study heterogeneity patterns in rare variant meta-analyses.
Irrespective of the sources of genetic heterogeneity, classical GWAS meta-analysis ap-
proaches cannot appropriately account for the expected between-study heterogeneity.
Therefore, to bridge this methodological gap, in the first two projects of this disserta-
tion I present two novel statistical methods for modeling the heterogeneous effects in
genetic association studies – for both common variants and rare variants – to improve
the power of trans-ethnic meta-analysis.
1.3 A General Statistical Framework for Modeling Hetero-
geneity in Biomedical Studies
The key idea in modeling the between-study heterogeneity in GWAS meta-analysis
is to decompose the magnitude of the effect size into two components: a fixed con-
stant which represents the mean effect size over all populations, and a random vari-
able which measures deviation of the study-specific effect from the population mean.
6
Consequently, assessing associations in trans-ethnic meta-analysis is essentially a joint
testing of fixed and random effects.
The statistical framework of jointly testing the fixed and random effects has many
applications in the field of biomedical studies. One such example is the likelihood
ratio test proposed by Han and Eskin (2011) for ascertaining association signals un-
der the existence of between-study heterogeneity in GWAS meta-analysis. Another
example is the SKAT-O test proposed by Lee et al. (2012), which optimally com-
bines the burden (Madsen and Browning, 2009) and SKAT (Wu et al., 2011) tests
for assessing the gene-/region-based rare variant association strengths. It can be
shown that an alternative way of deriving the score statistic for SKAT-O is to jointly
test the mean (i.e. the fixed effect) and variance component (i.e. the random ef-
fect) of the regression coefficient of the genetic variant. To assess the age-varying
genetic effect, one can incorporate age (or any non-genetic modifier of interest) into a
non-parametric functional form in the varying coefficient model and reformulate the
problem of testing the varying coefficient into jointly testing the fixed and random
effects in a generalized linear mixed model (GLMM) (Zhang and Lin, 2003; Wang
and Chen, 2012). Last but not least, the joint testing framework can be employed in
the non-parametric test of spline curves in a semi-parametric additive mixed model
(SAMM).
Testing the random effects involves constraints on the variance component param-
eters, in which classical inference with a standard null distribution no longer holds,
because those parameters under the null hypothesis lie on the boundary of the main-
tained hypothesis (Lin, 1997; Andrews, 2001). Although the statistical literature
offers an array of methods for testing the fixed and random effects jointly for Gaus-
sian responses, corresponding methods for non-Gaussian outcomes remain limited. In
response, in my last project, I propose to extend the methods in trans-ethnic GWAS
meta-analysis to a general statistical framework with a score test for the joint testing
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problem in a GLMM.
1.4 Dissertation Outline
In Chapter II, I develop a score test for the common variant associations in trans-
ethnic meta-analysis. To account for the effect-size heterogeneity across diverse popu-
lations, I adopt a modified random effects model from the kernel regression framework.
Specifically, I treat the genetic effect coefficients as random variables and construct
their correlation structure to reflect the level of genetic effect similarities across an-
cestry groups. In addition, I use an adaptive variance component test to achieve
robust power regardless of the degree of genetic effect heterogeneity. Through ana-
lytical approximation of the asymptotic distribution of the proposed test, I achieve
efficient computing time for genome-wide datasets, as the method requires less than
3 hours on a Linux cluster node with 2.80 GHz CPU to analyze one million vari-
ants. Using extensive simulation studies, I demonstrate that the proposed method
has well-calibrated type I error rates at very stringent significance levels and im-
proves power over the traditional meta-analysis methods. Re-analyzing a published
type 2 diabetes GWAS meta-analysis (Mahajan et al., 2014), I successfully identify
one additional SNP which exhibits genetic effect heterogeneity across ethnicities.
In Chapter III, I extend the score test in Chapter 2 to the gene-/region-based
rare variant trans-ethnic meta-analysis in sequencing association studies. The pro-
posed method is capable of not only accounting for the expected heterogeneous ge-
netic effects among studies, but also flexibly modeling varying levels of heterogeneity
according to the relatedness between the populations. The proposed method only
requires sharing of study-specific summary statistics, such as the score statistics for
each variant and the corresponding information matrices which summarize the LD
structures between the variants. I employ a resampling-based copula method to es-
timate the asymptotic null distribution of the proposed test, which enables efficient
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estimation of p-values. I conduct simulation studies to demonstrate that the proposed
approach is well-calibrated at stringent significance levels and improves power over
current approaches under the existence of genetic effect heterogeneity. As a real data
application, I further apply the proposed method to the Type 2 Diabetes Genetic
Exploration by Next-generation sequencing in multi-Ethnic Samples (T2D-GENES)
consortia data to explore rare variant associations with several traits.
In Chapter IV, I develop a supremum score test for jointly testing the fixed and
random effects in a generalized linear mixed model (GLMM) for both Gaussian and
non-Gaussian outcomes. The framework of jointly testing the fixed and random effects
has many applications in biomedical studies. One example is to use such tests for as-
certaining associations under the existence of heterogeneity in GWAS meta-analysis;
another example is the nonparametric test of spline curves. Although extensive re-
search has been conducted on testing random effect terms only, little work has been
done for the joint test of fixed and random effects, especially for non-Gaussian out-
comes. Hence, I propose a score test for the joint test in a GLMM to handle both
the Gaussian and non-Gaussian response types, and use analytical derivation as well
as numerical simulation to demonstrate that the proposed score test is asymptoti-
cally equivalent to the corresponding likelihood-ratio test (LRT). The method first
re-parameterizes the fixed effects terms as a product of a scale parameter and a vector
of nuisance parameters. With such re-parameterization, the joint test is equivalent
to testing whether the scale parameter is zero. Since the nuisance parameters are
unidentifiable under the null hypothesis, I propose using the supremum of score test
statistics over the nuisance parameters. I employ a resampling-based copula method
to approximate the asymptotic null distribution of the proposed score test statistic.
I first investigate the performance of the method through simulation studies. Using
the Michigan Genomics Initiative (MGI) data, I then demonstrate its application by
assessing whether the genetics effects to Low Density Lipoprotein Cholesterol (LDL-
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C) can be modified by age. Finally, in Chapter V, I discuss the implications of my
work and propose potential future directions to pursue.
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CHAPTER II
A Novel Random Effect Model for GWAS
Meta-Analysis and its Application to Trans-Ethnic
Meta-Analysis
Abstract
Meta-analysis of trans-ethnic genome-wide association studies (GWAS) has proven
to be a practical and profitable approach for identifying loci that contribute to the
risk of complex diseases. However, the effect-size heterogeneity cannot be easily ac-
commodated through existing fixed-effects and random-effects methods. In response,
we propose a novel random effect model for trans-ethnic meta-analysis with flexi-
ble modeling of the expected genetic effect heterogeneity across diverse populations.
Specifically, we adapt a modified random effect model from the kernel regression
framework, in which genetic effect coefficients are random variables whose correlation
structure reflects the genetic distances across ancestry groups. In addition, we use the
adaptive variance component test to achieve robust power regardless of the degree of
genetic effect heterogeneity. Simulation studies show that our proposed method has
well-calibrated type I error rates at very stringent significance levels and can improve
power over the traditional meta-analysis methods. We re-analyze the published type
2 diabetes GWAS meta-analysis (Mahajan et al., 2014) and successfully identify one
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additional SNP that clearly exhibits genetic effect heterogeneity across different an-
cestry groups. Furthermore, our proposed method provides scalable computing time
for genome-wide datasets, in which an analysis of one million SNPs would require
less than 3 hours on a Linux cluster node with 2.80 GHz CPU to analyze one million
variants.
Keywords: Common variants; Effect-size heterogeneity; GWAS; Kernel regression;
Random effect model; Trans-ethnic meta-analysis.
2.1 Introduction
Although genome-wide association studies (GWAS) have successfully identified
more than 50,000 loci that influence the severity of human health outcomes, those
identified loci account for only a small fraction of the genetic contribution to most
complex diseases and traits (McCarthy et al., 2008; MacArthur et al., 2016). It
has been argued that numerous loci with very small effects can explain additional
disease risk or trait heritability, and the challenge is to find those loci that can be
identified only with very large numbers of samples (Eichler et al., 2010). Since it
can be challenging to design and conduct a single study with tens or hundreds of
thousands of samples, a more practical alternative is to combine studies that have
already been conducted through a meta-analysis (Evangelou and Ioannidis, 2013).
A natural extension of the single-ancestry-based meta-analysis is to include sam-
ples from as many studies as possible, even if they come from genetically disparate
ancestries. With the further enlarged sample size, trans-ethnic meta-analysis is ex-
pected to be more powerful at detecting novel loci without the cost of additional
genotyping (Cooper et al., 2008). In fact, several trans-ethnic meta-analyses have
been performed in the past few years with success in discovering risk alleles across
ancestry groups. For example, five consortia (Mahajan et al., 2014) aggregated pub-
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lished GWAS meta-analyses of type 2 diabetes (T2D) from four ancestry groups and
successfully identified seven new loci with very small effect sizes.
To take full advantage of the profitability of trans-ethnic meta-analysis, improved
statistical methods are required to account for the distinctive ancestral origins among
data. Existing methods for GWAS meta-analysis include the classical fixed-effects
and random-effects methods, as well as the recently introduced new random-effects
method by Han and Eskin (2011) and the Bayesian approach by Morris (2011). The
fixed-effects method (FE) (Hedges and Vevea, 1998) is the most popular approach
for synthesizing single-ancestry GWAS data. It assumes that the true effect of each
risk allele is the same in each data set, and as a result, it has limited power in
the presence of genetic effect heterogeneity (Evangelou and Ioannidis, 2013; Wang
et al., 2013). The random-effects method (RE) was developed explicitly to model
the between-study heterogeneity; however, it implicitly assumes heterogeneity under
the null hypothesis, which causes it to have much lower power than FE (Han and
Eskin, 2011). To relax the conservative assumption of RE, Han and Eskin (2011)
developed a new random-effects model (RE-HE) which achieves higher power than
RE. Morris (2011) developed a trans-ethnic meta-analysis method by means of a
Bayesian partition model (MANTRA). MANTRA accounts for the relatedness of
studies by grouping them into different ethnic clusters. Specifically, studies that are
grouped into the same ethnic cluster share the same underlying genetic effect, while
different ethnic clusters have different underlying genetic effects.
The aforementioned T2D trans-ethnic meta-analysis (Mahajan et al., 2014) was
carried out using the FE method. In addition to identifying novel T2D susceptibil-
ity loci, they analyzed 69 established T2D susceptibility loci using Cochran Q test
(Cochran, 1954) to evaluate their genetic effect heterogeneity. Among the 69 loci, 3
had very strong evidence of the heterogeneity (Cochran Q p-value < 10−3), and 12
had some evidence of the heterogeneity (10−3 ≤ Cochran Q p-value < 0.05). For
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those 15 loci, FE may not be sufficiently powerful to detect the association signals.
To improve power, we develop a new trans-ethnic meta-analysis approach, referred
to as TransMeta, and use it to reanalyze the T2D trans-ethnic meta-data.
As mentioned above, one challenge in trans-ethnic GWAS meta-analysis is to ap-
propriately account for the effect-size heterogeneity. There can be several reasons for
the heterogeneous effect sizes. First, it is highly possible that the queried SNP is not
the underlying causal SNP, but rather is correlated to the causal SNP through linkage
disequilibrium (LD). Variations in the LD structures across ancestry groups can lead
to the observed genetic effect heterogeneity. Second, the environmental risk factors
may differ between ancestry groups. With the possibility of interaction between the
causal variants and the environmental factors, marginal genetic effects may vary be-
tween populations (Morris, 2011). To address the heterogeneity issue, we consider
a modified random effect model based on a kernel machine framework (Liu et al.,
2007). Specifically, we treat the genetic effect coefficients as random variables, with
their correlation structure across ancestry groups reflecting the expected heterogene-
ity (or homogeneity) among ancestry groups. To test for associations, we derive a
data-adaptive variance component test with adaptive selection of the degree of het-
erogeneity. This adaptive test combines models of homogeneous and heterogeneous
genetic effects, and provides robust power regardless of the genetic effect distribution.
We provide details of our proposed method in Section 2.2.
The rest of this chapter is organized as follows: In Section 2.3, we first perform
simulation studies to compare the performance of TransMeta with FE, RE, RE-HE
and MANTRA for meta-analyzing GWAS across genetically diverse populations. We
then illustrate application of TransMeta by reanalyzing the T2D GWAS in Mahajan
et al. (2014). We conclude this chapter with a discussion in Section 2.4. Supplemen-
tary texts, tables and figures are presented in Section 2.5.
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2.2 Methods
2.2.1 Statistical Models for GWAS Meta-Analysis
In this section, we first introduce statistical models of the existing GWAS meta-
analysis methods. Let β̂ = (β̂1, . . . , β̂n)
T be the effect-size estimates, such as the log
odds ratios or regression coefficients, in n independent studies. If the sample sizes in
each study are sufficiently large, then
β̂|β ∼MVN(β,Σ), (2.2.1)
where β = (β1, . . . , βn)
T , with βi being the true effect size in the ith study; and
Σ = diag(σ21, . . . , σ
2
n), with σ
2
i being the variance of β̂i.
FE assumes that all the studies share a common effect-size µ (i.e. β1 = · · · =
βn = µ). FE is powerful at detecting genetic effects that are present in most, if not
all, of the studies with homogeneous effect sizes. The RE model assumes that the
true effect size βi for the ith study is generated from a normal distribution with mean
µ and variance τ1,
βi = µ+ ηi, ηi ∼ N(0, τ1). (2.2.2)
RE typically assumes that even under the null hypothesis of no association, βis can
be different across studies, since τ1 is not assumed to be zero under the null hypoth-
esis. Due to this conservative assumption, RE tends to be less powerful at detecting
association signals than FE, although it is proposed to account for the expected
heterogeneity. Han and Eskin (2011) developed a new RE approach (RE-HE) that
assumes no genetic effect heterogeneity under the null hypothesis. Specifically, they
assumed that βis are zero among all the studies under the null hypothesis (i.e. µ = 0
and τ1 = 0), and they allowed varying effect sizes among studies under the alternative
hypothesis. The likelihood ratio test was employed to evaluate the null hypothesis
of µ = 0 and τ1 = 0. Since asymptotic p-values of RE-HE are only accurate when
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the number of studies (n) is very large, they provided tabulated p-values precom-
puted with an assumption of equal sample sizes across studies. In the presence of
between-study effect-size heterogeneity, RE-HE yields higher power than FE.
The aforementioned three frequentist meta-analysis methods can all be summa-
rized under model (2.2.2) with certain assumptions on τ1. With τ1 = 0 under both
the null and the alternative hypotheses, model (2.2.2) is exactly the same as FE.
RE assumes that τ1 is non-zero under both the null and the alternative hypotheses,
and tests whether µ = 0 or not, while accounting for the between-study variance τ1.
RE-HE assumes that τ1 = 0 under the null hypothesis, and tests whether both µ and
τ1 are zero under the alternative hypothesis.
Unlike the frequentist approaches, the Bayesian meta-analysis approach, MANTRA,
assigns studies into ethnic clusters under model (2.2.1). It assumes that studies that
are grouped into the same ethnic cluster share the same underlying genetic effect.
If we fix the number of clusters as one, all the studies are grouped into one ethnic
cluster with homogeneous genetic effects; in this case, MANTRA can be viewed as a
Bayesian implementation of the fixed-effects method. If the number of cluster is fixed
to be the same as the number of studies (n), each study is assigned to be its own
cluster; in this case, MANTRA can be viewed as a Bayesian implementation of the
random-effects method. MANTRA uses the Bayesian partition model to adaptively
determine the number of ethnic clusters and the cluster membership and assesses the
association evidence by means of the Bayes factor.
2.2.2 New Model Framework for GWAS Meta-Analysis
The existing frequentist meta-analysis methods based on (2.2.2) are not optimal
when the effect sizes exhibit certain structures across studies. In multi-ethnic meta-
analysis, for example, the studies can be grouped by their ethnicities. Genetically
similar groups may have more homogeneous genetic effects compared to genetically
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diverse groups. In response, we propose a statistical framework that can accommodate
prior assumptions on genetic effect distributions. Specifically, we adapt the kernel
machine framework (Liu et al., 2007) to flexibly model the genetic effect distributions.
Instead of assuming ηis are i.i.d normal samples, we assume that ηis jointly follow a
mean zero Gaussian process with kernel function τ1K(·, ·), where K(·, ·) is a bivariate
function to represent genetic similarity between two groups. This kernel regression
framework has been successfully applied in many areas of genetic studies, including
rare variant association analysis (Wu et al., 2011) and pathway analysis (Liu et al.,
2007). In Section 2.2.3, we will discuss choices of kernels for trans-ethnic meta-
analysis.
We first propose to extend (2.2.2) to a hierarchical model by modeling µ as a
random variable with distribution N(0, τ2). From this extension, our proposed model
framework can be summarized as
β̂|β ∼ MVN(β,Σ)
β|τ1, τ2 ∼ MVN(0, τ1K + τ211T ), (2.2.3)
where K is an n × n kernel matrix and 1 = (1, · · · , 1)T . We then apply a re-
parameterization τ1 = τ(1− ρ) and τ2 = τρ, where ρ reflects whether genetic effects
are homogeneous (ρ = 1) or heterogeneous (ρ = 0) across ancestry groups, and τ rep-
resents the size of the regression coefficients β. From this re-parameterization, testing
for both µ and τ1 being zero becomes testing for the common variance component τ
being zero. Our final model framework is
β̂|β ∼ MVN(β,Σ)
β|τ ∼ MVN(0, τVρ)
Vρ = (1− ρ)K + ρ11T , 0 ≤ ρ ≤ 1 (2.2.4)
where Vρ is an n × n (scaled) covariance matrix of β. We note that Vρ is a linear
combination of two matrices, 11T and K, with coefficient ρ that determines the degree
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of heterogeneity. ρ = 0 indicates that the covariance structure of βis is the same as
the kernel matrix K, and ρ = 1 indicates that βis are perfectly correlated (and hence
homogeneous).
Our proposed model includes the three frequentist meta-analysis approaches as
special cases. For example, if ρ = 1 (i.e Vρ = 11
T ), the model is effectively the
same as FE since all βis should be the same under the alternative hypothesis. We
show in Section 2.2.4 that the variance component score test for τ = 0 with ρ = 1
is exactly the same as the inverse-variance weighted meta-analysis test, the most
popular test for the FE approach. As a result, one of the important features of
our model is that it includes FE regardless of the choice of K. We believe this is
a desirable feature since numerous disease-associated SNPs in various meta-analysis
scenarios including trans-ethnic meta-analysis exhibit homogeneous genetic effects
across studies (Marigorta and Navarro, 2013). RE and RE-HE are equivalent to
testing for τ2 = 0 and τ1 = τ2 = 0 under (2.2.3), respectively, with K = I. This
indicates that RE is equivalent to testing for ρ = 0, and RE-HE is equivalent to
testing for τ = 0 while adaptively selecting ρ under the re-parameterized model
(2.2.4) with K = I.
2.2.3 Choice of the Kernel Matrix K for Trans-Ethnic Meta-Analysis
Suppose the GWAS meta-analysis has B ancestry groups from n studies, based
on this assumption, we propose two choices for the kernel structure K:
Choice 1. Group-wise independent kernel structure:
We consider a simple assumption in which genetic effect sizes are independently
distributed across ancestry groups, but homogeneous within the same ancestry group.
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In particular,
Kij =

1 if study i and j belong to the same ancestry group
0 otherwise
,
where i, j ∈ {1, . . . , n}. In Supplementary Materials Section 2.5.1, we provide the
general form of matrix K under this group-wise independent structure.
Choice 2. Genetic similarity (Fst) kernel structure:
The fixation index (Fst) is a widely used measure of population differentiation
due to genetic structure (Wright, 1949). Fst = 0 indicates there is no allele frequency
differentiation between populations, whereas a large value of Fst indicates that pop-
ulations are genetically very different. Fst has been used as a genetic distance among
populations. For example, MANTRA uses Fst to group studies to ethnic clusters.
For each cluster, it is assumed that studies share the same genetic effect. We adapt
the strategy of using Fst in constructing the kernel matrix K to incorporate genetic
similarity into modeling the genetic effect similarity. In particular, we set
Kij = 1−
Fst
bb
′
D
, with D = max
b,b
′∈{1,...,B}
{Fst
bb
′ },
where study i and j belong to ancestry group b and b
′
respectively, and Fst
bb
′ is the
pairwise Fst between the corresponding ancestry groups. In Supplementary Materials
Section 2.5.1, we provide the general form of K under this genetic similarity (Fst)
kernel structure. Unlike MANTRA, which adaptively groups studies based on the
prior model of relatedness and observed effect sizes via the Bayesian partition model,
our method constructs the genetic similarity (Fst) kernel using only the genotype data
and fixes it prior to carrying out the data analysis.
2.2.4 Hypothesis Test
Under the proposed model (2.2.4), testing for H0 : β1 = · · · = βn = 0 is the same
as testing for the variance component τ = 0 (i.e. H0 : τ = 0). We first consider a
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situation in which ρ is given before carrying out the test. Following Zhang and Lin
(2003), the score test statistics of the variance component τ with a given ρ is
Sρ = β̂
T
Σ̂−1VρΣ̂−1β̂ = β̂
T
Σ̂−1[(1− ρ)K + ρ11T ]Σ̂−1β̂, (2.2.5)
where Σ̂ = diag(σ̂21, . . . , σ̂
2
n), and σ̂
2
i is an estimate of σ
2
i . When ρ = 1, the test
statistic Sρ becomes
(∑n
i=1 β̂i/σ̂
2
i
)2
, which is the test statistics of the inverse variance
weighting.
For any given ρ, Sρ asymptotically follows a mixture of χ
2 distributions under the
null hypothesis. Specifically, if (λ1, . . . , λn) are the eigenvalues of Σ̂
−1/2VρΣ̂−1/2, the
null distribution of Sρ can be closely approximated by
∑n
j=1 λjχ
2
1,j, where {χ21,j} are
independent χ21 random variables. Several methods exist to obtain tail probabilities
of the mixture of χ2 distributions. Among them, the method to invert a characteristic
function (Davies, 1980) provides very accurate estimates of tail probabilities and is
widely used in many recently developed genetic association tests (Wu et al., 2011).
We employ this approach to approximate the asymptotic distribution of Sρ when ρ
is given.
In practice, however, we rarely have prior information on which ρ is optimal in
terms of maximizing power. Lee et al. (2012) have studied a similar problem within a
context of rare variant association analysis; they proposed to use the minimum p-value
over a grid of ρ as a test statistics. We adopt the same strategy here. Specifically,
we set the test statistic as T = inf
0≤ρ≤1
pρ, where pρ is the corresponding p-value of Sρ
for the given ρ. T can be obtained by a simple grid search across a range of ρ values:
set a grid 0 ≤ ρ1 ≤ ρ2 ≤ . . . ≤ ρν ≤ 1, then the test statistic becomes
T = min{pρ1 , . . . , pρν},
and the optimal ρ is set as the one whose corresponding p-value (pρ) equals to T . We
observe that a dense grid of ρ does not necessarily improve power (Supplementary
Figure 2.10). Therefore, we suggest using ρ = (0, 0.32, 0.52, 1) for simulations and real
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data analysis. Once the test statistic T is calculated, the next step is to obtain the
corresponding p-value for ascertaining the association evidence. If we had just used
the minimum p-value (which is denoted as our test statistic T ) to assess significance,
we would ignore the multiple comparisons between different pρ values, which would
result in inflated type I error control. Thus, we propose to use numerical integration
to approximate the asymptotic distribution of T , details provided in Supplementary
Materials Section 2.5.2.
2.2.5 Using Z-scores Instead of Effect-size Estimates
In previous sections, we construct our methods based on estimates of effect sizes
and their standard errors. However, Z-score based approaches are also very popular in
GWAS. Z-score based approaches use p-values (pi), sample sizes (ni) and direction of
effects (∆i) to construct Z-scores for each study, and then calculate a weighted sum of
Z-scores to carry out meta-analysis. A major advantage of the Z-score based approach
is that it allows meta-analysis of data when effect size estimates are not available
or measurements of traits are difficult to standardize, ex. tobacco or alcohol use
(Evangelou and Ioannidis, 2013). In this section, we extend TransMeta to incorporate
Z-score based data input.
Given the input summary statistics (pi, ni, ∆i), a signed Z-score is constructed as
Zi = Φ
−1(1− pi/2) ∗ sign(∆i) for each study, where Φ(·) is the standard normal dis-
tribution function. For continuous traits, it can be shown that the effect size estimate
β̂i is asymptotically equivalent to Zi/
√
niqi(1− qi) (up to a scalar factor), where qi
is a minor allele frequency (MAF) of the SNP (details provided in Supplementary
Materials Section 2.5.3). For binary traits, the log odds ratio estimate β̂i is asymp-
totically equivalent to Zi/
√
niri(1− ri)qi(1− qi), where ri = ncase,i/ni is a proportion
of case samples (Supplementary Materials Section 2.5.3). If all studies have similar
ratios of cases and controls, the ri(1 − ri) term can thus be ignored. Consequently,
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β˜i = Zi/
√
niqi(1− qi) and its standard error σ˜i = 1/
√
niqi(1− qi) can be used as in-
puts for both continuous and binary traits. To differentiate between the two types of
input summary statistics, if effect size estimates β̂is and the corresponding standard
errors σ̂is are used as input data for our proposed method, we denote it as effect-size
based TransMeta; if transformed Z-scores β˜is and the corresponding standard errors
σ˜is are used as input data for our proposed method, we denote it as Z-score based
TransMeta.
2.3 Results
2.3.1 Simulation Studies
To investigate the performance of TransMeta, we ran a series of simulations with
varying assumptions on genetic effect heterogeneity across multiple ancestry groups.
To generate SNPs with realistic MAF spectrums across different ancestry groups,
we used Phase III of the HapMap Project (HMP3) data (Consortium et al., 2010).
HMP3 consists of approximately 1.6 million SNPs, obtained from 1,184 subjects from
11 populations. We excluded the admixed African American population, combined
the Japanese and Chinese as one population, and used the resulting 9 populations as
seed populations to generate SNP genotypes.
The retrospective binary phenotype Yik of the kth individual in the ith study was
generated using the following logistic regression model
logit Pr(Yik = 1) = β0 + βigik, (2.3.1)
where gik is a genotype of the selected SNP, and βi is a log odds ratio parameter.
The intercept β0 was chosen to have disease prevalence 0.05. In each replication, we
randomly chose a SNP with a MAF of at least 1% in all populations, and generated
SNP genotypes as gik ∼ Binomial(2, qi), where qi denotes the MAF of the selected
SNP. We also used model (2.3.1) to estimate log odds ratio β̂i and its standard error
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Table 2.1: Type-I error rate estimates for TransMeta at different α levels,
with three studies in each ancestry group. Type-I error rate es-
timates at different α levels based on 20 million replicates. Each entry
represents an estimated type I error rate calculated using the proportion
of empirical p-values smaller than the given level α. Three studies are sim-
ulated per ancestry group, and each study had 500 cases and 500 controls.
α = 10−2 10−3 10−4 10−5 10−6
TransMeta.Fst 9.7× 10−3 1.1× 10−3 9.6× 10−5 1.0× 10−5 9.5× 10−7
TransMeta.Indep 9.8× 10−3 0.9× 10−3 7.6× 10−5 5.8× 10−6 4.0× 10−7
σ̂i as the input data. In addition, we recorded ∆i = sign(β̂i), the direction of effect
and the p-value pi for testing H0 : βi = 0. We generated 500 cases and 500 controls
for each of the 9 ancestry groups in triplicate, which resulted in a total of 27 studies
with a total sample size of 13,500 cases and 13,500 controls.
2.3.2 Type I Error Simulations
To estimate type I error rates at stringent α levels, we generated 20 million repli-
cates from model (2.3.1) with βi = 0. Table 2.1 showed that the proposed methods
yields controlled type I error rates at different significance levels under the Fst ker-
nel (denoted as TransMeta.Fst), although slightly conservative under the independent
kernel (denoted as TransMeta.Indep). We also considered a setting where there is only
one study per ancestry group. Each study then had 1500 cases and 1500 controls.
We again used model (2.3.1) with βi = 0 to simulate a total of 100 million replicates,
and observed that empirical type I error rates were well controlled (Table 2.2 in the
Supplementary Materials).
2.3.3 Power Simulations
Recently, Wang et al. (2013) carried out comparisons of trans-ethnic meta-analysis
methods under five different scenarios, which cover a wide range of possible scenarios
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of genetic effect heterogeneity. We adopted these five scenarios to compare perfor-
mances of TransMeta with existing approaches:
(a) ‘Trans-ethnic fixed-effect’, where no heterogeneity exists in genetic effects at the
causal SNP between populations, specifically that, each of the 27 studies carries a
genetic relative risk of 1.12 at the causal SNP.
(b) ‘Out-of-Africa effect’, where each of the 18 studies from the non-African popu-
lations carries a genetic relative risk of 1.08, whereas the 9 studies from the African
populations (LWK, MKK and YRI) present no genetic effects.
(c) ‘Europe and south Asia effect’, where the 12 studies from the European and south
Asian populations (CEU, GIH, MEX and TSI) share the same genetic relative risk of
1.2, whereas the 15 studies from the remaining populations present no genetic effects.
(d) ‘Heterogeneous Out-of-Africa effect’, where the causal variant has genetic effects
only in non-African populations, with the 6 studies from the east Asian populations
(CHB+JPT and CHD) each carrying a genetic relative risk of 1.15 while the Euro-
pean and south Asian populations carry a genetic relative risk of 1.12.
(e) ‘Environment modifying effect’, where the causal variant has a genetic effect only
in the populations living in Europe and USA, with the 9 studies from CHD, CEU
and TSI each carry a genetic relative risk of 1.2.
In all scenarios, causal SNPs had the same direction of associations across ancestry
groups. For each scenario, we generated 2,000 replicates to obtain empirical power.
To perform a fair comparison between the frequentist and Bayesian methods, we
generated 20 million SNPs under the null hypothesis and compute Bayes factors
using MANTRA. We observed that a log10 Bayes factor threshold larger than 5
corresponds to a p-value threshold less than α = 1.8 × 10−6. To find a log10 Bayes
factor threshold corresponding to the genome-wide significance level, we carried out
a simple regression analysis between empirical type I error rates and log10 Bayes
factors, and observed that log10 Bayes factor= 6.34 corresponds to α = 5× 10−8 (see
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Supplementary Materials Section 2.5.5 for details).
Figure 2.1 showed the empirical power of TransMeta as well as existing approaches
(FE, RE, RE-HE and MANTRA) under all five scenarios. It can be seen that Trans-
Meta.Fst yielded the highest or near highest power among the five methods, except
in scenario (e). In scenario (a) where no heterogeneity exists, all five methods per-
formed similarly, with FE having the highest power, as expected. In the remaining
three scenarios with heterogeneous genetic effects that are not due to the environment
modification, TransMeta.Fst outperformed the four existing meta-analysis methods.
Unsurprisingly, RE yielded the lowest power across all five approaches. In scenario (e)
where the genetic effect was influenced by environmental exposures, populations that
shared similar genetic architectures did not necessarily share similar genetic effects.
This violated the assumption of using the Fst to take account of the variability in
genetic effects, and in this case, TransMeta.Indep yielded the highest power.
Figure 2.2 showed the empirical power of the five methods with one integrated
study per ancestry group. The patterns of empirical power in this setting were very
similar to what we observe in Figure 2.1 with three sub-studies per ancestry group,
except for RE-HE, which had slightly higher power than that of TransMeta.Indep.
Since TransMeta.Indep has the identity matrix as the kernel structure (i.e K = I)
under this setting, the similar performance of TransMeta.Indep and RE-HE is not
surprising. Overall, TransMeta.Fst attained similar or higher power over competing
methods except in scenario (e).
The barplots in Figure 2.7 and 2.8 of the Supplementary Materials summarized
the power of the five methods at the more stringent level α = 5 × 10−8; the results
were quantitatively similar to the patterns we observe in Figure 2.1 and 2.2.
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Figure 2.1: Empirical power for TransMeta under different effect-size het-
erogeneity configurations, with three sub-studies in each ances-
try group, and significance level at α = 1.8 × 10−6. Empirical
power for TransMeta and existing methods under the five effect-size sce-
narios. Three studies are simulated per ancestry group, each with 500
cases and 500 controls. The empirical power is obtained based on 2000
replicates with the level of significance defined as a p-value less than
1.8 × 10−6 or as a log10 Bayes factor larger than 5. The five-effect size
scenarios are (a) ‘Trans-ethnic fixed-effect’, where no heterogeneity exists
in allelic effects at the causal SNP between populations; (b) ‘Out-of-
Africa effect’, where only studies from the non-African populations carry
the causal variant; (c) ‘Europe and south Asia effect’, where only studies
from the European and south Asian populations carry the causal variant;
(d) ‘Heterogeneous Out-of-Africa effect’, where the causal variant has ge-
netic effects only in non-African populations, but the effect size in the
east Asian populations is different from that in the European and south
Asian populations; (e) ‘Environment modifying effect’, where the causal
variant has genetic effect only in the populations living in Europe and
USA.
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Figure 2.2: Empirical power for TransMeta under different effect-size het-
erogeneity configurations, with one integrated study in each an-
cestry group, and significance level at α = 1.8× 10−6. Empirical
power for TransMeta and existing methods under the five effect-size sce-
narios. One integrated study is simulated per ancestry group, each with
1500 cases and 1500 controls. The empirical power is obtained based on
2000 replicates with the level of significance defined as a p-value less than
1.8×10−6 or as a log10 Bayes factor larger than 5. The five effect-size sce-
narios are (a) ‘Trans-ethnic fixed-effect’, where no heterogeneity exists in
allelic effects at the causal SNP between populations; (b) ‘Out-of-Africa
effect’, where only studies from the non-African populations carry the
causal variant; (c) ‘Europe and south Asia effect’, where only studies
from the European and south Asian populations carry the causal variant;
(d) ‘Heterogeneous Out-of-Africa effect’, where the causal variant has ge-
netic effects only in non-African populations, but the effect size in the
east Asian populations is different from that in the European and south
Asian populations; (e) ‘Environment modifying effect’, where the causal
variant has genetic effect only in the populations living in Europe and
USA.
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2.3.4 Comparison Between Effect-size-based and Z-score-based Trans-
Meta
To demonstrate that Z-scores can be used as input summary statistics for Trans-
Meta without loss of efficiency, we compared the power of the effect-size based and
Z-score based TransMeta. Since the proportion of case samples was one (i.e ri = 1)
for all studies, we ignored ri in the transformation. We also considered using only
the transformed Z-scores and sample sizes as the input, which is equivalent to assume
that MAFs of SNPs are the same across all studies. In this case, the transformation
simplifies to β˜i = Zi/
√
ni with standard error s˜ei = 1/
√
ni. We included this setting
because Z-scores are typically obtained without MAFs.
The scatter plot in Figure 2.3 compared the power of the effect-size-based and the
Z-score-based TransMeta under the five scenarios as outlined in Section 2.3.3. The
plot was generated under the settings where we had three sub-studies per ethnic group,
with the level of significance as a p-value less than 1.8×10−6. The power of these two
approaches was nearly identical when we incorporate both sample sizes and MAFs
in the Z-score transformations, and the power of the Z-score based TransMeta was
slightly lower than the effect-size based TransMeta when only sample sizes are used in
the Z-score transformations. For the one integrated study per ancestry group setting,
the results were quantitatively similar to the patterns in Figure 2.3 (Figure 2.9 in the
Supplementary Materials). At the genome-wide significance level, we again observed
similar patterns as in Figure 2.3 and Supplementary Figure 2.9 (data not shown).
2.3.5 Computation Time
TransMeta provides scalable computation time for genome-wide datasets. To ana-
lyze 2,000 SNPs in the power simulations, both TransMeta.Fst and TransMeta.Indep
took 20 seconds on average on a Linux cluster node with 2.80 GHz CPU. To an-
alyze one million SNPs in a genome-wide dataset, TransMeta would require less
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Figure 2.3: Power comparison of the effect-size-based and Z-score-based
TransMeta, with three sub-studies in each ancestry group, and
significance level at α = 1.8× 10−6. Power comparison of the effect-
size-based and Z-score-based TransMeta under the five effect size scenar-
ios. Three studies are simulated per ancestry group, each with 500 cases
and 500 controls. The empirical power is obtained based on 2000 repli-
cates with the level of significance defined as a p-value less than 1.8×10−6.
The left panel is based on TransMeta.Fst and the right panel is based on
TransMeta.Indep. In each plot, the x-axis denotes empirical power of the
the Z-score-based TransMeta and the y-axis denotes empirical power of
effect-size-based TransMeta. The solid dots represent the power of trans-
formed Z-scores using only sample sizes, and the solid squares represent
transformed Z-scores using both sample sizes and MAFs.
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than 3 hours. Among the competing methods, MANTRA was computationally
expensive and took 45 and 95 minutes on average to analyze 2,000 SNPs with 9
and 27 studies, respectively. An R package ‘TransMeta’ has been developed to
implement our proposed method and can be downloaded at the authors’ website
(https://sites.google.com/a/umich.edu/leeshawn/software).
2.3.6 Application to Type 2 Diabetes (T2D) GWAS
Large scale GWAS of T2D have successfully identified many risk-associated loci,
including a landmark meta-analysis on T2D by the DIAGRAM consortium with over
110,000 genotyped individuals (Mahajan et al., 2014). Most of those studies have
applied one or a combination of the classical FE or RE meta-analysis approaches,
with limited use of the more powerful RE-HE or MANTRA methods. In this section,
we re-analyzed the published T2D GWAS meta-analysis (Mahajan et al., 2014), in
which the FE was employed in the trans-ethnic discovery-stage GWAS meta-analysis.
The aggregated data included 69 lead SNPs from the previously established T2D
susceptibility loci, with 26,488 cases and 83,964 controls from four major ancestry
groups of Europeans (12,171 cases and 56,862 controls), east Asians (6,952 cases and
11,865 controls), south Asians (5,561 cases and 14,458 controls), and Mexican and
Mexican-Americans (1,804 cases and 779 controls). Association summary statistics
– such as MAFs, effect size estimates, and standard errors – of the lead 69 SNPs
were available for all four ancestry groups (Supplementary Table 3 of Mahajan et al.
(2014)).
We applied TransMeta to the aggregated data along with the other existing meta-
analysis approaches. Due to the small number of SNPs in the aggregated dataset,
estimates of Fst may be unreliable. Instead, we used the pairwise Fst from HMP3 to
construct the genetic similarity kernel (Table 2.3 in the Supplementary Materials).
Supplementary Tables 2.4 and 2.5 listed p-values (or Bayes factors) of the 69 SNPs
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Figure 2.4: Comparison of p-values of TransMeta.Fst and FE for 69 lead
SNPs in the T2D meta-analysis data. The left panel displays p-
values of SNPs whose TransMeta.Fst ρ is zero; the right panel displays p-
values of SNPs whose TransMeta.Fst ρ is one. In each plot, the x-axis de-
notes − log10(FE p-values), and the y-axis denotes − log10(TransMeta.Fst
p-values).
with selected optimal ρs of TransMeta. Among those 69 SNPs, 37 had optimal ρ < 1
under TransMeta.Fst. Figure 2.4 compares p-values of TransMeta.Fst and FE for
different selected optimal ρs. When the selected optimal ρ = 0, our method yielded
a smaller p-value than FE, which indicated that TransMeta can be more powerful
than FE. When the selected ρ = 1, and hence FE was the optimal test, FE yielded a
smaller p-value than TransMeta, but the difference was minimal.
At the significance level α = 1.8×10−6 or a log10 Bayes factor > 5, TransMeta.Fst,
TransMeta.Indep, FE and RE-HE all identified 31 SNPs, while RE and MANTRA
identified 18 and 28 SNPs, respectively. At the genome-wide significance level of
α = 5×10−8 or a log10 Bayes factor> 6.34, both TransMeta.Fst and TransMeta.Indep
identified 24 SNPs, while FE, RE, RE-HE and MANTRA identified 23, 12, 22 and
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Figure 2.5: Forest plot of the estimated OR and 95 % CI for rs10830963 in
each ancestry group in the T2D meta-analysis data. The associ-
ation signal of rs10830963 is detected by TransMeta only.
19 SNPs respectively.
At the genome-wide significance level, TransMeta was able to identify one more
SNP, rs10830963, with TransMeta.Fst p-value= 2.98 × 10−8 (selected optimal ρ =
0.25) and TransMeta.Indep p-value=3.76× 10−8 (selected optimal ρ = 0.25), respec-
tively. In contrast, p-values of FE, RE and RE-HE were all larger than 10−7, and
MANTRA log10 Bayes factor was 5.6. The SNP rs10830963 is located in Melatonin
receptor 1-B, which belongs to the seven transmembrane G protein-coupled receptor
superfamily, and previous studies have shown that this SNP is associated with fasting
glycemia and T2D (Ro¨nn et al., 2009; Sparsø et al., 2009; Kan et al., 2010; Vlassi
et al., 2012).
Figure 2.5 displayed a forest plot of odds ratios and their corresponding con-
fidence intervals for this SNP (extracted from Supplementary Table 3 in Mahajan
et al. (2014)). The odds ratios of Europeans, south Asians and Mexicans were all
close to 1.1, although the odds ratio for Mexicans was non-significant due to small
sample size. In contrast, the odds ratio in east Asians was close to one. Since east
Asians are genetically more distant than other populations (Table 2.3 in the Supple-
mentary Materials), this result indicated that our approach to modeling genetic effect
heterogeneity using genetic distance can increase power.
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2.4 Discussion
In this chapter, we proposed a novel trans-ethnic meta-analysis framework to
flexibly model the genetic effect heterogeneity across ancestry groups. The frame-
work incorporates the genetic distances to model the genetic effect heterogeneity and
adaptively uses variance component test to achieve robust power. Simulations and the
trans-ethnic T2D GWAS application suggest that our approach can improve power
when genetic effect-size heterogeneity exists.
Since TransMeta.Fst accommodates genetic similarity to model the effect size
similarity, we recommend TransMeta.Fst as the primary test. However, if there is
evidence suggesting that the genetic effects are modified by non-genetic exposures
(such as environmental or lifestyle factors), TransMeta.Indep may be a better choice.
To avoid data fishing, the choice of using TransMeta.Fst or TransMeta.Indep needs
to be made prior to data analysis. For the sequence of ρ values used in the grid
search, we observe that using a dense grid of ρs does not necessarily increase power.
In fact, in Supplementary Figure 2.10 , we employ a denser grid with eleven evenly
spaced points of ρ = (0, 0.1, . . . , 0.9, 1) in the power simulations and observe that
the resulting power is very similar or even identical to the power based on ρ = (0,
0.09, 0.25, 1). So we suggest using ρ = (0, 0.09, 0.25, 1) as the default sequence of ρ
values. We note that it is not required to select ρ from the grid prior to perform the
analysis, since TransMeta automatically selects the optimal ρ, and calculate p-values
while accounting for the selection.
Unlike the I2 statistic (Higgins et al., 2002), which is developed to measure the
extent of heterogeneity, the optimal ρ is set as the value (over a pre-specified grid)
whose score statistic has the smallest p-value among all. As a result, the optimal ρ
should not be interpreted as a measurement of heterogeneity. For example, we count
the number of optimal ρ values in each of the five scenarios in the power simulations
(Table 2.7 in the Supplementary Materials) and observe that in the homogeneous
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effect size scenario, only less than half of the optimal ρ values in TransMeta.Fst are
determined to be 1. (Please recall that ρ equals to 1 models homogeneous effect
sizes; the closer ρ is to 0, the stronger the indication of heterogeneity.) However, the
optimal ρ does provide some insights into the extent of heterogeneity. For example,
in our power simulations, we observe that the I2 statistic tends to decrease as the
optimal ρ increases, as shown in Supplementary Table 2.6. (Please recall that I2 = 0
means homogeneity; and the level of heterogeneity increases as I2 approaches to
1.) In addition, we observe in Supplementary Table 2.7 that when heterogeneity
does exist, such as scenarios (b) - (e) in the power simulations, the majority of the
optimal ρ values in TransMeta.Fst are selected to be 0. Similar trends are observed
in TransMeta.Indep, data not shown.
Our score statistics Sρ is a linear combination of two components, each models
the genetic effect homogeneity and the genetic effect heterogeneity, respectively. As a
result, although TransMeta is designed to tackle heterogeneous effect sizes situations,
it can also handle homogeneity scenarios. In fact, the right panel of Figure 2.4
demonstrates that under genetic effect homogeneity, our approach achieves almost
the same statistical significance as FE.
We note that the empirical power of MANTRA is similar or lower than that of
TransMeta.Fst in scenarios (b)-(d), but is higher in scenario (e)(Figure 2.1 and 2.2).
This occurred because under scenario (e), the genetic distance does not provide
guidance to the genetic effect similarity, which violates the key assumption in both
MANTRA and TransMeta.Fst. Since MANTRA groups studies into clusters data-
adaptively, it is more robust than TransMeta.Fst under this situation. As a result,
MANTRA had higher power than TransMeta.Fst.
RE-HE is equivalent to testing for τ = 0 while adaptively selecting ρ under model
(2.2.4) with K = I. When we have one integrated study per ancestry group, the K
matrix in TransMeta.Indep is exactly equal to I, which makes RE-HE equivalent to
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TransMeta.Indep in terms of testing (although they use different approaches to obtain
p-values). As a result, RE-HE and TransMeta.Indep have similar power in all five
scenarios in Figure 2.2. When we have three studies per ancestry group (Figure 2.1),
RE-HE treats each study as its own cluster. In contrast, TransMeta.Indep groups
studies in the same ancestry. As a result, TransMeta.Indep yields higher power than
RE-HE in nearly all scenarios in Figure 2.1.
Our proposed method is based on the score test which does not require estimating
parameters under the alternative hypothesis. Score test enables fast computation of p-
values, however, it does not provide an estimate for the overall effect size. Estimating
the overall effect size under our proposed model framework may be considered as one
possible direction for future work.
The rapid technological advances in high-throughput sequencing platforms have
made it possible to test for rare variant associations (here defined as alleles with a
frequency less than 1%) to accelerate our knowledge of complex trait genetics. One
of the challenge in the design and analysis of sequencing-based GWAS is that rare
variant tests are usually underpowered without exceptionally large sample size or large
enough number of rare alleles captured (Bansal et al., 2010). A popular strategy to
boost the study power is to combine rare variants based on a gene or a region to bring
a synergy of information (Lee et al., 2013; Tang and Lin, 2014; Liu et al., 2014). In
the next chapter, we will extend the framework of using genetic distance for modeling
the genetic effect heterogeneity to gene/region based rare variant tests in trans-ethnic
meta-analysis.
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2.5 Supplementary Materials
2.5.1 Kernel Matrix K for Trans-Ethnic Meta-Analysis
In Section 2.2.3, we propose two choices of K for trans-ethnic meta-analysis. In
this section, to help better understand the two proposed kernel matrix K, we provide
more details on how to construct those two kernels. Suppose that the first n1 studies
belong to the first ancestry group, followed by another n2 studies belonging to the
second ancestry group, and so on. With B ancestry groups among the n studies, we
have n1 + n2 + . . . + nB = n. Let Ab denote a set of indices for the studies in the
bth ancestry group, b = 1, . . . , B. According to the order of arranging the studies, we
thus have A1 = {1, . . . , n1},A2 = {n1 + 1, . . . , n1 + n2}, . . . ,Ab = {n1 + . . . + nb−1 +
1, . . . , n1 + . . .+nb−1 +nb}. Based on those notations, we propose two choices for K:
Choice 1. Group-wise independent kernel structure
Define each entry of the K matrix as
Kij =

1 if i, j ∈ Ab for some b ∈ {1, . . . , B}
0 otherwise
,
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where i, j ∈ {1, . . . , n}. The K matrix can be written as
K =

1 . . . 1 0 . . . 0 0 . . . 0
...
...
. . .
...
1 . . . 1 0 . . . 0 0 . . . 0
0 . . . 0 1 . . . 1 0 . . . 0
...
...
. . .
...
0 . . . 0 1 . . . 1 0 . . . 0
. . . . . . . . . . . .
0 . . . 0 0 . . . 0 . . . 1 . . . 1
...
...
...
...
0 . . . 0 0 . . . 0 . . . 1 . . . 1

.
2. Genetic similarity (Fst) kernel structure
Define each entry of the K matrix as
Kij = 1−
Fst
bb
′
D
, with D = max
b,b′∈{1,...,B}
{Fst
bb
′ },
where i ∈ Ab for some b ∈ {1, . . . , B}, j ∈ Ab′ for some b′ ∈ {1, . . . , B}, and Fstbb′ is
the pairwise Fst between ancestry group b and b
′
. Since Fst
bb
′ ≤ D, ∀ t and t′ , as a
consequence, 0 ≤ Kij ≤ 1,∀ i and j. In general, the K matrix under this assumption
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can be written as
K =

1 . . . 1 1− Fst12D . . . 1−
Fst12
D 1−
Fst1B
D . . . 1−
Fst1B
D
...
...
. . .
...
1 . . . 1 1− Fst12D . . . 1−
Fst12
D 1−
Fst1B
D . . . 1−
Fst1B
D
1− Fst21D . . . 1−
Fst21
D 1 . . . 1 1−
Fst2B
D . . . 1−
Fst2B
D
...
...
. . .
...
1− Fst21D . . . 1−
Fst21
D 1 . . . 1 1−
Fst2B
D . . . 1−
Fst2B
D
. . .
. . .
. . .
. . .
1− FstB1D . . . 1−
FstB1
D 1−
FstB2
D . . . 1−
FstB2
D 1 . . . 1
...
...
. . .
...
1− FstB1D . . . 1−
FstB1
D 1−
FstB2
D . . . 1−
FstB2
D 1 . . . 1

.
2.5.2 Derivation of the Asymptotics
After computing the test statistic T , the next step is to obtain the corresponding
p-value for ascertaining the association evidence. If we had just used the minimum
p-value (which is denoted as our test statistic T ) to assess the significance, we would
ignore the multiple comparisons between different pρ values, which then leads to an
inflated type I error control. Thus, we derive the asymptotic distribution of T to
obtain its p-value, details provided as follows:
Recall that the score test statistics can be written as:
Sρ = (1− ρ)β̂
T
Σ̂−1KΣ̂−1β̂ + ρβ̂
T
Σ̂−111T Σ̂−1β̂. (2.5.1)
And for any given ρ, the null distribution of Sρ asypototically follows
n∑
j=1
λjχ
2
1,j, (2.5.2)
where (λ1, . . . , λn) are the eigenvalues of Σ̂
−1/2VρΣ̂−1/2, and {χ21,j} are independent
χ21 random variables.
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Let u = Σ̂−1/2β̂, Z = Σ̂−1/21 and M = Z(ZTZ)−1ZT , then M is a projection
matrix onto the space spanned by Z. Based on those notations, the first term of the
right side of (2.5.1) can be written as:
(1− ρ)β̂T Σ̂−1KΣ̂−1β̂ = (1− ρ)uT Σ̂−1/2KΣ̂−1/2u
= (1− ρ)uT (I−M)Σ̂−1/2KΣ̂−1/2(I−M)u (2.5.3)
+ 2(1− ρ)uT (I−M)Σ̂−1/2KΣ̂−1/2Mu (2.5.4)
+ (1− ρ)uTMΣ̂−1/2KΣ̂−1/2Mu, (2.5.5)
and the second term of the right side of (2.5.1) can be written as:
ρβ̂
T
Σ̂−111T Σ̂−1β̂ = ρuT Σ̂−1/211T Σ̂−1/2u
= ρuTMZZTMu. (2.5.6)
Following the derivation as in Lee et al. (2012), it can be easily shown that (2.5.3) +
(2.5.4) = (1− ρ)κ and (2.5.5) + (2.5.6) = τ(ρ)η0, where
κ = uT (I−M)Σ̂−1/2KΣ̂−1/2(I−M)u
+ 2uT (I−M)Σ̂−1/2KΣ̂−1/2Mu,
τ(ρ) = [a2b(1− ρ) + ρ]/a.
with a = (ZTZ)−1, b = ZT Σ̂−1/2KΣ̂−1/2Z, and η0 = (ZTZ)−1uTZZTu.
As a result, we have Sρ = (1− ρ)κ+ τ(ρ)η0.
The asymptotic distribution of Sρ can be approximated as (1 − ρ)(
∑m
k=1 λ
′
kηk +
ζ)+τ(ρ)η0, since under the null, each elements of u has mean 0 and variance 1, u
T (I−
M)Σ̂−1/2KΣ̂−1/2(I−M)u asymptotically follows ∑mk=1 λ′kηk, where {λ′1, . . . , λ′m} are
non-zero eigenvalues of (I−M)Σ̂−1/2KΣ̂−1/2(I−M), ηks are iid χ21 random variables,
η0 = (Z
TZ)−1uTZZTu asymptotically follows χ21 distribution. Furthermore, since M
is a projection matrix, (I−M)u and Mu are asymptotically independent. Therefore,
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ζ = 2uT (I−M)Σ̂−1/2KΣ̂−1/2Mu satisfies the following conditions:
E(ζ) = 0, var(ζ) = 4trace(Σ̂−1/2MΣ̂−1/2KΣ̂−1/2(I−M)Σ̂−1/2K),
corr(η0, ζ) = 0, and corr(u
′
(I−M)Σ̂−1/2KΣ̂−1/2(I−M)u, ζ) = 0
In addition, due to the asymptotic independence between (I−M)u and Mu, it can be
shown that uT (I−M)Σ̂−1/2KΣ̂−1/2(I−M)u and (ZTZ)−1uTZZTu are also asymp-
totically independent. Since the Pearson correlation between κ and η0 is zero, we can
approximate Sρ as the mixture of two independent variables. We can approximate
the distribution of κ by using the moment matching or the characteristic function
inversion method (Davis, 1980) after adjusting for the extra variance term of ζ.
To estimate the distribution of T = min{pρ1 , . . . , pρν}, let qmin(ρ) denote the
(1− T )th percentile of the distribution of Sρ for each ρ in the grid. The p-value of T
can be computed from
1 − P (Sρ1 < qmin(ρ1), . . . , Sρν < qmin(ρν))
= 1 − E[P (κ < min{(qmin(ρi)− τ(ρi)η0)/(1− ρi)})|η0], (2.5.7)
which can be obtained by one-dimensional numerical integration.
To sum up, our proposed method can be implemented through the following algo-
rithm:
Step 1: Set a grid 0 ≤ ρ1 ≤ ρ2 ≤ . . . ≤ ρν ≤ 1.
Step 2: Compute Sρ1 , . . . , Sρν using equation (2.5.1).
Step 3: Compute Z, M, λ
′
ks, τ(ρi),
µS =
m∑
k=1
λ
′
k, σζ = 2
√
trace(Σ̂−1/2MΣ̂−1/2KΣ̂−1/2(I−M)Σ̂−1/2K),
and σS =
√√√√2 m∑
k=1
(λ
′
k)
2 + σ2ζ .
Step 4: For each ρi, i ∈ {1, . . . , ν}, computer pρi and qmin(ρi) from the mixture of
χ2 distribution in equation (2.5.2), and set T = min{pρ1 , . . . , pρν}.
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Step 5: Numerically integrate F (δ(x)|λ)f(x|χ21), where
δ(x) = (min{(qmin(ρi)− τ(ρi)x)/(1− ρi)} − µS)
√
σ2S − σ2ζ
σS
+ µS,
f(x|χ21) is the density function of χ21, and F (δ(x)|λ) is a distribution function of a
mixture of chi-square distribution
∑
λ
′
kχ
2
k. The p-value is computed as
p− value = 1−
∫
F (δ(x)|λ)f(x|χ21)dx.
2.5.3 Using Z-scores Instead of Effect-size Estimates
Based on p-values (pi), sample sizes (ni) and direction of effects (∆i), we can
construct a signed Z-score Zi = Φ
−1(1 − pi/2) ∗ sign(∆i) for each study, where Φ(·)
is the standard normal distribution function. Now we show how to transform the
Z-scores as input data for our proposed method.
2.5.3.1 Continuous Traits
For continuous traits, the linear regression model can be written as
yik = β0 + βigik + ik,
where yik is a trait value of individual k in study i , gik is a minor allele count,
and ik ∼ N(0, ω2i ) is the error term. We further denote xik = (1, gik) and Xi =
(xi1, . . . ,xini)
T . Then the estimator of βi follows the normal distribution
β̂i ∼ N(βi, σ2i ),
where σ2i = ω
2
i (X
T
i Xi)
−1
2,2 and (X
T
i Xi)
−1
2,2 is the (2,2) element of (X
T
i Xi)
−1. The two
side p-value is pi = 1− 2Φ(|β̂i/σi|), and thus the Z-score Zi follows N(βi/σi, 1). This
result implies that we can reconstruct β̂i using a Z-score by estimating σ
2
i . Since
(XTi Xi)
−1 =
1
ni
∑ni
k=1 g
2
ik − (
∑ni
k=1 gik)
2
 ∑nik=1 g2ik −∑nik=1 gik
−∑nik=1 gik ni
 ,
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we then have under the Hardy-Weinberg equilibrium
niω
2
i
ni
∑ni
k=1 g
2
ik − (
∑ni
k=1 gik)
2
≈ ω
2
i
ni2qi(1− qi) ,
where qi is a minor allele frequency (MAF) for the corresponding queried SNP. As a
result, under the Hardy-Weinberg equilibrium β̂i is equivalent to
√
ω2i
ni2qi(1−qi)Zi. With
an additional assumption that the variance of error term (ω2i ) are the same across
studies, we can use
β˜i = Zi/
√
niqi(1− qi)
and its standard error
σ˜i = 1/
√
niqi(1− qi)
as inputs for our proposed method.
2.5.3.2 Binary Traits
For binary traits, the logistic regression model can be written as
logitPr(yik = 1) = β0 + βigik.
Asymptotically, var(β̂i) = J
−1(βi), where J(βi) =
∑ni
k=1 xikx
T
ikµik(1 − µik), and
µik =
exp(βTi xik)
1+exp(β
′
ixik)
. Since
xikx
T
ik =
 1 gik
gik g
2
ik
 ,
we then have
J(βi) =
ni∑
k=1
exp(βTi xik)
[1 + exp(βTi xik)]
2
 1 gik
gik g
2
ik
 .
If we use ri = ncase,i/ni to denote the proportion of case samples for study i and
assume that its effect size βi is very small, then
exp(βTi xik)
[1+exp(βTi xik)]2
≈ ri(1 − ri) for any
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k ∈ {1, . . . , ni}, and J(βi) reduces to
J(βi) = ri(1− ri)
ni∑
k=1
 1 gik
gik g
2
ik
 = ri(1− ri)
 ni ∑ gik∑
gik
∑
g2ik
 .
The remaining derivations then follow the same calculation as in the continuous traits
case. As a result, for binary traits, the log odds ratio estimate β̂i is asymptotically
equivalent to Zi/
√
niri(1− ri)qi(1− qi). If all studies have similar ratios of cases and
controls, the ri(1− ri) term can be ignored. Consequently,
β˜i = Zi/
√
niqi(1− qi)
and its standard error
σ˜i = 1/
√
niqi(1− qi)
can be used as inputs for both continuous and binary traits.
2.5.4 Prior Density Function for MANTRA
MANTRA uses the Bayesian partition model to adaptively determine the number
of ethnic clusters and the cluster membership and assesses the association evidence
by means of the Bayes factor. We use the same prior density functions as suggested
in Morris (2011) in our simulation studies and data analysis. Specifically, let M0
denote the null model with β = 0, in which there is no association of the variant with
the trait in any population, and M1 denotes the alternative model with β 6= 0, then
the evidence in favor of the alternative model can be assessed by means of the Bayes
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factor (Kass and Raftery, 1995) given by
∆ =
f(βˆ,Σ|M1)
f(βˆ,Σ|M0)
,
where f(βˆ,Σ|M) ∝
∫
β
f(βˆ,Σ|β)f(β|M)∂β,
and f(βˆ,Σ|β) =
n∏
i=1
f(βˆi, σ
2
i |βi),
with f(βˆi, σ
2
i |βi) ∝
1
σi
exp{−(βˆi − βi)
2
2σ2i
}.
Suppose the n populations can be allocated toB cluster centers C = {C1, C2, . . . , CB}
with the corresponding cluster allelic effects Ψ = {Ψ1,Ψ2, . . . ,ΨB}. The true effect
size β is determined by the assignment of populations to ethnic clusters under a
Bayesian partition model. The assignment is given by T, where Tib = 1 if the i
th
population is allocated to the cluster with center Cb and 0 otherwise. Under such an
assignment, the marginal likelihood can be written as
f(βˆi, σ
2
i |βi) = f(βˆi, σ2i |B,C,Ψ) ∝
1
σi
exp{−(βˆi −
∑B
b=1 TibΨb)
2
2σ2i
}.
Under the null model M0, the population-specific allelic effect are all zero, and
hence any clustering of populations is irrelevant. Consequently, f(β|M0) = 1 if β = 0,
and 0 otherwise. Under the alternative model M1, population-specific allelic effects
are determined by the Bayesian partition model, in which the prior density of the
number of clusters of populations is given by
f(B) =

1 if B = 1
2n−1
2B(2n−1−1) otherwise
.
Given B, each population is equally likely, a priori, to be a cluster center, and
the cluster allelic effect have a prior N(µ, θ) distribution, independent of C, where
µ has a prior uniform distribution and θ has a prior exponential distribution with
expectation 1. Combining the components of the prior density function, it follows
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that
f(β|M1) ∝ f(B)(n−B)!exp{−θ}
θ
B∏
b=1
exp{(Ψb − µ)
2
2θ2
}.
2.5.5 Estimation of Bayes Factor Threshold
We carried out 20 million null simulations for MANTRA to find Bayes factor
thresholds corresponding to genome-wide p-value significance levels. Following our
type I error simulations as in Section 2.3, each simulated dataset had 27 studies (9
ancestry groups in triplicate) and each study has 500 cases and 500 controls. We then
applied MANTRA to those 20 million nulls to obtain the Bayes factors, and computed
the empirical type I error rates as the proportion of Bayes factors (out of the 20
million) that were greater than a given Bayes factor threshold. When we set log10
Bayes factor = 5 as a threshold, the empirical type I error rate was 1.8×10−6 with the
exact binomial confidence interval (1.25×10−6, 2.4×10−6). Supplementary Figure 2.6
ploted the obtained empirical type I error rates (illustrated in -log10(empirical type
I error rate) on the vertical axis) and the Bayes factors (illustrated in log10(Bayes’
factor) on the horizontal axis).
Due to our limited computing resources, it would take us months to run MANTRA
on billions of null simulations that are required to find a comparable Bayes factor
threshold to the commonly used genome-wide significance level (α = 5×10−8); there-
fore, we performed a regression analysis between the Bayes factor thresholds and the
empirical type I error rates. We first obtained the empirical type I error rates for a
sequence of Bayes factor thresholds, and then fitted a linear regression model using
-log10(Empirical type I error rate) as a response variable and the log10 Bayes’ factor
threshold as a predictor. The resulting regression intercept and slope were 1.08577
(p-value < 2 × 10−16) and 0.98106 (p-value < 2 × 10−16) respectively. Based on
those regression parameters, we estimated that Bayes factor threshold (on the log10
base) which corresponds to the genome-wide significance level was 6.34. We noted
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that from this linear model, the estimated significance level that corresponds to log10
Bayes factor = 5 was α = 1.0 × 10−6, which was slightly lower than the observed
threshold α = 1.8 × 10−6. We employ both α = 1.8 × 10−6 and 1.0 × 10−6 to the
power simulations and observed that the results were very similar (data not shown).
To sum up, we defined the level of significance as a p-value less than 1.8 × 10−6,
or as a log10 Bayes factor larger than 5. We also employed the significance level as a
p-value less than 5× 10−8 or as a log10 Bayes factor larger than 6.34.
2.5.6 Supplementary Tables and Figures
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Table 2.2: Type-I error rate estimates for TransMeta at different α levels,
with one study in each ancestry group. Type-I error rate estimates
at different α levels based on 100 million replicates. Each entry represents
an estimated type I error rate calculated using the proportion of p-values
smaller than the given level α. One integrated study was simulated per
ancestry group, and each study had 1500 cases and 1500 controls.
α = 10−2 10−3 10−4 10−5 10−6
TransMeta.Fst 1.051× 10−2 1.1× 10−3 1.079× 10−4 1.1× 10−5 1.05× 10−6
TransMeta.Indep 1.008× 10−2 0.9× 10−3 8.589× 10−5 7.4× 10−6 9.0× 10−7
Table 2.3: Pairwise Fst values used for the T2D meta-analysis. The Fst values
were extracted from Supplementary Table 6 of International HapMap 3
Consortium. (2010). Integrating common and rare genetic variation in
diverse human populations. Nature, 467(7311), 52-58.
Ancestry European east Asian south Asian Mexican and
Mexican-American
European 0 0.111 0.035 0.031
east Asian 0.111 0 0.077 0.070
south Asian 0.035 0.077 0 0.035
Mexican and 0.031 0.070 0.035 0
Mexican-American
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Table 2.4: Meta-analysis results for the 24 SNPs with TransMeta.Fst p-
value < 5× 10−8 from the T2D trans-ethnic meta-analysis data.
P-values and Bayes’ factors of the six meta-analysis methods for the 24
SNPs with TransMeta.Fst p-value < 5 × 10−8 among the 69 SNPs from
the T2D trans-ethnic meta-analysis data. Values in the parenthesis are
the optimal ρ values for our proposed method. Values in the last column
are the I2 statistic for measuring the heterogeneity level.
SNP F.ST (ρ) INDEP(ρ) FE RE RE-HE Bayes I2
rs7903146 6.17e-77 (0.00) 3.59e-84 (0.25) 6.44e-75 2.89e-07 3.55e-76 74.13 0.83
rs10811661 4.42e-27 (1.00) 4.42e-27 (1.00) 1.11e-27 1.28e-24 2.74e-27 25.36 0.10
rs7756992 4.04e-26 (0.25) 3.57e-31 (0.25) 3.39e-26 2.19e-04 1.88e-27 24.87 0.81
rs3802177 6.55e-19 (0.09) 2.10e-19 (0.25) 1.61e-18 1.61e-18 3.39e-18 16.27 0
rs1111875 1.12e-18 (1.00) 1.33e-20 (0.25) 2.80e-19 2.49e-05 3.29e-19 17.12 0.65
rs4402960 5.51e-18 (0.25) 4.22e-18 (0.25) 7.50e-18 1.54e-17 1.55e-17 15.52 0.01
rs163184 4.12e-14 (1.00) 2.63e-14 (0.25) 1.03e-14 4.80e-07 1.64e-14 12.41 0.55
rs9936385 3.32e-12 (0.25) 9.15e-13 (0.25) 9.65e-13 3.01e-10 1.67e-12 10.63 0.11
rs7178572 5.70e-11 (0.25) 4.91e-11 (0.25) 1.47e-11 1.47e-11 2.45e-11 9.35 0
rs5215 1.25e-10 (1.00) 1.07e-10 (0.25) 3.12e-11 8.47e-05 3.24e-11 8.98 0.57
rs12571751 2.19e-10 (1.00) 2.43e-10 (1.00) 2.19e-10 2.19e-10 3.46e-10 8.22 0
rs1801282 3.86e-10 (1.00) 2.89e-10 (0.25) 4.24e-10 4.24e-10 6.41e-10 7.99 0
rs849135 3.88e-10 (0.00) 2.21e-10 (0.25) 1.06e-09 2.84e-03 1.07e-09 7.62 0.53
rs17791513 1.01e-09 (0.00) 1.11e-08 (0.09) 2.42e-08 4.71e-03 1.76e-08 6.60 0.65
rs4430796 1.06e-09 (1.00) 2.59e-09 (1.00) 1.16e-09 1.10e-07 1.71e-09 7.53 0.24
rs4458523 1.72e-09 (1.00) 1.79e-09 (1.00) 1.91e-09 1.91e-09 2.88e-09 7.32 0
rs11257655 2.06e-09 (1.00) 5.31e-09 (1.00) 1.92e-09 8.71e-04 2.22e-09 7.33 0.61
rs2943640 6.52e-09 (1.00) 6.63e-09 (1.00) 7.01e-09 7.01e-09 9.96e-09 6.73 0
rs7612463 8.25e-09 (1.00) 1.7e-08 (0.25) 6.28e-09 6.28e-09 9.21e-09 6.86 0
rs11717195 1.46e-08 (0.25) 3.17e-08 (1.00) 2.26e-08 2.26e-08 3.25e-08 6.20 0
rs4812829 2.09e-08 (0.00) 1.59e-08 (0.25) 4.21e-08 1.42e-04 5.98e-08 6.07 0.4
rs12970134 2.98e-08 (1.00) 4.79e-08 (1.00) 2.48e-08 2.48e-08 3.55e-08 6.06 0
rs10830963 2.98e-08 (0.25) 3.76e-08 (0.25) 1.99e-07 2.91e-03 2.48e-07 5.60 0.50
rs2261181 3.05e-08 (1.00) 7.51e-09 (0.25) 2.34e-08 1.31e-05 3.11e-08 6.24 0.27
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Table 2.5: Table 2.4 continued: Meta-analysis results for the remaining 45
SNPs from the T2D trans-ethnic meta-analysis data. P-values and
Bayes’ factors of the six meta-analysis methods for the remaining 45 SNPs
among the 69 SNPs from the T2D trans-ethnic meta-analysis data.
SNP F.ST (ρ) INDEP(ρ) FE RE RE-HE Bayes I2
rs7845219 6.56e-08 (1.00) 8.63e-08 (1.00) 5.84e-08 5.84e-08 8.57e-08 5.99 0
rs516946 6.57e-08 (0.09) 6.60e-08 (0.25) 1.11e-07 1.11e-07 1.63e-07 5.59 0
rs1552224 1.35e-07 (1.00) 7.71e-08 (0.25) 9.61e-08 2.11e-03 9.68e-08 5.81 0.63
rs17168486 3.86e-07 (1.00) 4.36e-07 (0.09) 3.74e-07 4.38e-03 3.65e-07 5.08 0.58
rs12899811 6.29e-07 (1.00) 1.40e-06 (1.00) 7.42e-07 2.05e-05 1.09e-06 4.74 0.16
rs2028299 6.48e-07 (1.00) 9.0e-07 (1.00) 7.741e-07 2.35e-04 9.09e-07 4.81 0.42
rs1535500 1.45e-06 (0.00) 1.53e-06 (0.25) 5.36e-06 1.13e-02 5.61e-06 4.10 0.52
rs3923113 1.96e-06 (0.25) 2.29e-06 (1.00) 2.31e-06 1.51e-02 5.47e-07 4.62 0.74
rs2796441 1.96e-06 (1.00) 2.43e-06 (1.00) 1.63e-06 1.63e-06 2.39e-06 4.42 0
rs2075423 2.03e-06 (1.00) 2.52e-06 (1.00) 2.17e-06 9.69e-04 3.17e-06 4.34 0.45
rs12427353 3.11e-06 (0.00) 3.13e-06 (0.25) 3.41e-06 3.41e-06 4.17e-06 4.14 0
rs243088 3.49e-06 (1.00) 3.56e-06 (0.25) 3.73e-06 3.73e-06 5.46e-06 4.25 0
rs7163757 4.76e-06 (1.00) 6.51e-06 (1.00) 4.14e-06 4.14e-06 6.04e-06 4.11 0
rs10842994 4.76e-06 (0.25) 6.92e-06 (1.00) 6.75e-06 6.75e-06 9.84e-06 3.93 0
rs8108269 4.98e-06 (1.00) 6.86e-06 (1.00) 4.60e-06 1.97e-03 6.71e-06 3.90 0.43
rs7041847 5.31e-06 (1.00) 7.21e-06 (1.00) 4.03e-06 4.12e-06 5.88e-06 4.20 0
rs11634397 6.29e-06 (0.00) 7.85e-06 (0.25) 1.60e-05 2.58e-03 2.16e-05 3.62 0.31
rs1359790 9.61e-06 (0.25) 2.46e-06 (0.25) 1.08e-05 8.73e-03 1.07e-05 3.60 0.47
rs780094 1.45e-05 (1.00) 1.62e-05 (1.00) 1.29e-05 2.76e-02 5.34e-06 3.81 0.75
rs10203174 3.29e-05 (0.00) 7.11e-06 (0.09) 7.28e-05 1.64e-01 4.99e-05 2.59 0.65
rs7955901 3.11e-05 (0.00) 1.62e-05 (0.00) 1.86e-03 3.68e-01 1.79e-04 2.15 0.76
rs6795735 3.59e-05 (0.00) 1.41e-04 (0.25) 2.00e-04 4.65e-03 2.80e-04 2.60 0.27
rs7593730 3.6e-05 (0.00) 1.13e-05 (0.00) 4.74e-04 1.89e-01 1.34e-04 2.41 0.68
rs7202877 4.32e-05 (0.00) 2.28e-04 (0.09) 5.53e-04 6.23e-02 2.09e-04 2.43 0.72
rs13233731 1.11e-04 (0.00) 1.97e-06 (0.00) 4.08e-03 3.42e-01 1.35e-05 3.90 0.85
rs16861329 2.68e-04 (0.00) 1.46e-05 (0.00) 5.06e-02 6.95e-01 1.01e-04 2.45 0.90
rs11063069 3.33e-04 (0.00) 4.02e-04 (0.25) 9.97e-04 3.87e-02 1.40e-03 1.78 0.25
rs3786897 3.83e-04 (1.00) 3.20e-04 (0.25) 3.34e-04 2.22e-01 1.45e-05 3.84 0.83
rs9470794 3.95e-04 (0.00) 2.61e-04 (0.09) 1.75e-03 3.48e-01 1.53e-03 1.81 0.68
rs6815464 4.39e-04 (0.00) 4.39e-04 (0.00) NA NA NA 2.13 0
rs6878122 5.81e-04 (0.25) 3.23e-04 (0.25) 5.75e-04 1.36e-01 4.64e-05 2.23 0.82
rs1802295 6.97e-04 (0.00) 1.22e-03 (0.25) 1.10e-03 1.56e-01 1.95e-04 1.97 0.81
rs831571 6.84e-04 (1.00) 3.99e-04 (0.25) 5.26e-04 2.10e-01 4.56e-04 2.25 0.73
rs459193 1.06e-03 (1.00) 1.51e-03 (1.00) 8.20e-04 8.20e-04 1.15e-03 1.84 0
rs2334499 1.61e-03 (1.00) 1.64e-03 (0.25) 1.38e-03 1.38e-03 1.93e-03 1.69 0
rs10923931 3.03e-03 (0.00) 1.01e-03 (0.00) 7.10e-03 3.55e-01 8.61e-03 0.95 0.46
rs10401969 3.91e-03 (0.00) 3.35e-03 (0.09) 7.18e-03 1.62e-01 6.19e-03 1.15 0.68
rs6467136 6.72e-02 (0.00) 5.93e-02 (0.00) 2.14e-01 4.63e-01 1.80e-02 0.80 0.76
rs10278336 1.08e-01 (0.00) 1.21e-01 (0.09) 1.11e-01 1.73e-01 1.33e-01 0.11 0.16
rs7403531 1.54e-01 (0.25) 3.78e-02 (0.00) 1.28e-01 7.23e-01 6.81e-02 0.20 0.68
rs6723108 3.49e-01 (1.00) 4.30e-01 (1.00) 3.17e-01 3.17e-01 3.64e-01 -0.21 0
rs17584499 4.98e-01 (0.00) 4.63e-01 (0.00) 5.20e-01 5.62e-01 5.60e-01 -1.18 0.52
rs7560163 5.76e-01 (1.00) 6.06e-01 (1.00) 4.72e-01 4.72e-01 5.08e-01 -0.37 0
rs10886471 5.86e-01 (0.00) 6.45e-01 (0.00) 6.46e-01 6.46e-01 7.05e-01 -0.45 0
rs391300 8.42e-01 (1.00) 8.78e-01 (1.00) 7.40e-01 7.40e-01 7.90e-01 -0.55 0
49
Table 2.6: Summary of the computed I2 statistic in the power simulations.
The I2 statistic for each of the 2000 SNPs in the five power comparison
scenarios. In each cell of the table, we first present the median of the
I2 statistic for all the SNPs (out of 2000) whose optimal ρ value from
TransMeta.Fst is as specified at beginning of the row, then we present the
corresponding inter-quartile range (IQR) in the parenthesis.
The optimal ρ value Scenario (a) Scenario (b) Scenario (c) Scenario (d) Scenario (e)
ρ = 0 0.05 (0.28) 0.55 (0.27) 0.69 (0.17) 0.50 (0.29) 0.70 (0.17)
ρ = 0.09 0 (0.17) 0.39 (0.45) 0.65 (0.33) 0.21 (0.45) 0.64 (0.18)
ρ = 0.25 0 (0.11) 0.20 (0.51) 0.36 (0.38) 0.11 (0.36) 0.63 (0.23)
ρ = 1 0 (0.18) 0.03 (0.32) 0.27 (0.36) 0.12 (0.33) 0.53 (0.32)
Overall median (IQR) 0 (0.21) 0.52 (0.33) 0.68 (0.19) 0.45 (0.38) 0.67 (0.20)
Table 2.7: Contingency Table of the selected optimal ρ value from Trans-
Meta.Fst for each of the 2000 SNPs in the five power comparison
scenarios. In each cell of the table, the entry represents the total number
of SNPs (out of 2000) which has the selected optimal ρ value as listed at
the beginning of the row under the scenario specified at the top of the
column.
The optimal ρ value Scenario (a) Scenario (b) Scenario (c) Scenario (d) Scenario (e)
ρ = 0 480 1674 1864 1573 1385
ρ = 0.09 309 136 58 120 109
ρ = 0.25 276 77 36 122 143
ρ = 1 935 113 142 185 363
Total counts 2000 2000 2000 2000 2000
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Figure 2.6: Calibration of the Bayes’ factor to the empirical type I error
rate. The vertical axis measures the empirical type I error rate on a -log10
scale, the horizontal axis measures the Bayes’ factor on a log10 scale. The
blue straight represents the fitted regression line -log10(empirical type I
error rate) = 1.08577 + 0.98106 × log10(Bayes’ factor).
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Figure 2.7: Empirical power for TransMeta under different effect-size het-
erogeneity configurations, with three sub-studies in each ances-
try group, and significance level at α = 5×10−8. Empirical power
for TransMeta and existing methods under the five effect size scenarios.
Three studies are simulated per ancestry group, each with 500 cases and
500 controls. The empirical power is obtained based on 2000 replicates
with the level of significance defined as a p-value less than 5×10−8 or as a
log10 Bayes’ factor larger than 6.34. The five effect size scenarios are (a)
‘Trans-ethnic fixed-effect’, where no heterogeneity exists in allelic effects
at the causal SNP between populations; (b) ‘Out-of-Africa effect’, where
only studies from the non-African populations carry the causal variant;
(c) ‘Europe and south Asia effect’, where only studies from the European
and south Asian populations carry the causal variant; (d) ‘Heterogeneous
Out-of-Africa effect’, where the causal variant has genetic effects only in
non-African populations, but the effect size in the east Asian popula-
tions is different from that in the European and south Asian populations;
(e) ‘Environment modifying effect’, where the causal variant has genetic
effect only in the populations living in Europe and USA.
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Figure 2.8: Empirical power for TransMeta under different effect-size het-
erogeneity configurations, with one integrated study in each an-
cestry group, and significance level at α = 5 × 10−8. Empirical
power for TransMeta and existing methods under the five effect size sce-
narios. One integrated study is simulated per ancestry group, each with
1500 cases and 1500 controls. The empirical power is obtained based on
2000 replicates with the level of significance defined as a p-value less than
5 × 10−8 or as a log10 Bayes’ factor larger than 6.34. The five effect
size scenarios are (a) ‘Trans-ethnic fixed-effect’, where no heterogeneity
exists in allelic effects at the causal SNP between populations; (b) ‘Out-of-
Africa effect’, where only studies from the non-African populations carry
the causal variant; (c) ‘Europe and south Asia effect’, where only studies
from the European and south Asian populations carry the causal variant;
(d) ‘Heterogeneous Out-of-Africa effect’, where the causal variant has ge-
netic effects only in non-African populations, but the effect size in the
east Asian populations is different from that in the European and south
Asian populations; (e) ‘Environment modifying effect’, where the causal
variant has genetic effect only in the populations living in Europe and
USA.
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Figure 2.9: Power comparison of the effect-size-based and Z-score-based
TransMeta, with one integrated study in each ancestry group,
and significance level at α = 1.8 × 10−6. Power comparison of the
effect-size and Z-score based TransMeta under the five effect size scenar-
ios. One integrated study is simulated per ancestry group, each with
1500 cases and 1500 controls. The empirical power is obtained based
on 2000 replicates with the level of significance defined as a p-value less
than 1.8× 10−6. The left panel is based on TransMeta.Fst and the right
panel is based on TransMeta.Indep. In each plot, the x-axis denotes
empirical power of the Z-score based TransMeta and the y-axis denotes
empirical power of the effect-size based TransMeta. The solid dots repre-
sent the power of transformed Z-scores using only sample sizes, and the
solid squares represent transformed Z-scores using both sample sizes and
MAFs.
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Figure 2.10: Power comparison of TransMeta under a coarse grid v.s. a
dense grid, with three sub-studies in each ancestry group, and
significance level at α = 1.8 × 10−6. Comparison of the empirical
power for TransMeta under the five effect size scenarios, using different
grid searches for ρ . Three studies are simulated per ancestry group, each
with 500 cases and 500 controls. The empirical power is obtained based
on 2000 replicates with the level of significance defined as a p-value less
than 1.8×10−6. The two grids being compared are: ρ = (0, 0.09, 0.25, 1)
v.s ρ = (0, 0.1, 0.2, . . . , 0.8, 0.9, 1). The left panel is based on Trans-
Meta.Fst and the right panel is based on TransMeta.Indep. The five
effect size scenarios are (a) ‘Trans-ethnic fixed-effect’, where no hetero-
geneity exists in allelic effects at the causal SNP between populations;
(b) ‘Out-of-Africa effect’, where only studies from the non-African popu-
lations carry the causal variant; (c) ‘Europe and south Asia effect’, where
only studies from the European and south Asian populations carry the
causal variant; (d) ‘Heterogeneous Out-of-Africa effect’, where the causal
variant has genetic effects only in non-African populations, but the effect
size in the east Asian populations is different from that in the European
and south Asian populations; (e) ‘Environment modifying effect’, where
the causal variant has genetic effect only in the populations living in
Europe and USA.
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CHAPTER III
Trans-Ethnic Meta-Analysis of Rare Variants in
Sequencing Association Studies
Abstract
Trans-ethnic meta-analysis is a powerful tool at detecting novel loci in genetic
association studies. However, under the presence of inter-study genetic effect het-
erogeneity, existing approaches may be unsatisfactory because they do not consider
genetic similarity or dissimilarity among different ancestry groups. In response, we
propose a unified score test under a modified random effects model framework for
rare variants associations. Specifically, we adapt the kernel regression framework to
construct the modified random effects model, and incorporate the genetic similarities
across ancestry groups into modeling the heterogeneity structure of the genetic effect
coefficients. In addition, we use the adaptive variance component test to achieve
robust power regardless of the degree of heterogeneity. A resampling-based cop-
ula method is employed to approximate the asymptotic distribution of the proposed
test, which enables efficient estimation of p-values. Simulation studies show that our
proposed method controls type I error rates at the exome-wide significance level and
improves power over existing approaches under the presence of heterogeneity. We fur-
ther illustrate our method by analyzing the Type 2 Diabetes Genetic Exploration by
Next-generation sequencing in multi-Ethnic Samples (T2D-GENES) consortia data, a
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multiethnic sample of 12,940 individuals which focuses on exome sequence variations.
Keywords: Effect-size heterogeneity; GWAS; Kernel regression; Random effect
model; Rare variants; Trans-ethnic meta-analysis.
3.1 Introduction
The rapid technological advances in high-throughput sequencing platforms have
made it possible to test for rare variant (here defined as alleles with a frequency
less than 1%) associations to accelerate our knowledge of complex trait genetics.
In rare variant association studies, testing for only a single rare variant is usually
underpowered due to the limited number of study participants carrying the rare allele
and the penalty of multiple testing (Bansal et al., 2010). To enrich the strength of the
rare variant association tests, a commonly used strategy is to group the variants in a
gene or a functional unit to perform the association tests. For example, the burden
test collapses the variants into a burden score and tests its association with the trait
of interest (Madsen and Browning, 2009; Morris and Zeggini, 2010); the variable
threshold test (VT) performs burden tests at each defined minor allele frequency
(MAF) threshold and evaluates the significance for the maximum of these statistics
(Price et al., 2010); the variance component tests, such as sequence kernel association
test (SKAT), account for variants with opposite effects in a gene through tailored
aggregation of individual variant test statistics in a gene (Wu et al., 2011); and the
SKAT-O (Lee et al., 2012) and MiST (Sun et al., 2013) tests take convex combination
of a burden test and a SKAT variance component test to enhance the robustness and
power of the existing approaches.
Since rare variant tests are usually underpowered without an exceptionally large
sample size or a sufficient number of rare alleles captured, a practical strategy to
enlarge the sample size is to aggregate studies through meta-analysis. To date, most
57
meta-analyses have been undertaken in a single population, usually of European de-
scent; as a result, most existing meta-analysis methods for rare variant associations
usually assume that the underlying genetic effects are the same across all studies.
Under this homogeneity assumption, Hu et al. (2013) and Liu et al. (2014) proposed
practical rare variants meta-analysis approaches to increase the study power by ag-
gregating summary statistics across studies to increase sample sizes.
Trans-ethnic meta-analysis is a natural extension of the single-ancestry-based
meta-analysis, as it aims to include samples from as many studies as possible, even
if they come from different ancestries. With the further increased sample size, trans-
ethnic meta-analysis is expected to be more powerful at detecting novel loci (Cooper
et al., 2008; Li and Keating, 2014). However, in performing trans-ethnic analysis, one
of the challenges is to properly account for the expected heterogeneity across studies
from different ancestry groups. Heterogeneity can arise due to several reasons. First,
for a gene-level test, different studies may present different sets of rare variants, due
to the fact that rare variants are likely to be population specific and thus may not
exist in all populations. Therefore, the gene-level association strengths will likely be
unequal among studies, even when effect size across studies is the same for each vari-
ant. Second, if environmental risk factors differ among ancestry groups and interact
with the causal variants, it is possible that the marginal genetic effects would vary
between populations (Morris, 2011) due to the gene-environment interaction.
In the presence of between-study heterogeneity in multi-ethnic meta-analysis, tra-
ditional fixed effects meta-analysis approaches, which assume the same genetic effects
among all participating studies, do not account for the expected variability in ge-
netic effects. In response, several researchers have proposed using the random effects
meta-analysis approach, which assumes a different underlying genetic effect for each
population. For example, Lee et al. (2013) developed unified score tests that combine
features of both the burden test and SKAT to incorporate genetic effect heterogene-
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ity; Tang and Lin (2014) derived the random effects version of all commonly used
rare variants association tests – such as the burden test, VT and SKAT – to allow
varying genetic effects among studies.
However, these random effects-based meta-analysis approaches ignore some of the
underlying characteristics of trans-ethnic meta-analysis. Specifically, these methods
only assume varying genetic effects between studies, but do not consider that studies
which share more similar genetic architectures can have more homogeneous genetic
effects than those which consist of very disparate ancestries. In addition, these meth-
ods were developed for unrelated subjects, and thus cannot properly handle the cor-
related/clustered structure when the participating studies contain samples of related
individuals. To avoid the type I error inflation due to failure of handling the corre-
lated structure, a typical strategy is to remove the related individuals for analysis,
which may result in power loss.
To take full advantage of the strengths of multi-ethnic meta-analysis, in this chap-
ter, we propose a unified score test under a modified random effects model framework
for rare variants associations, which can adjust for sample relatedness. The proposed
method is capable not only of accounting for the expected heterogeneous genetic
effects among studies, but also of flexibly modeling varying levels of heterogeneity
due to the difference of genetic architectures between the populations. Specifically,
we adapt the kernel regression framework to construct the modified random effects
model, and incorporate the genetic similarity among ancestry groups into modeling
the heterogeneity structure of the genetic effect coefficients. In addition, we use the
adaptive variance component test to achieve robust power regardless of the degree of
genetic effect heterogeneity. When meta-analyzing family-based studies, to account
for sample relatedness, we incorporate the generalized linear mixed model association
test (GMMAT) developed by Chen et al. (2016) into our score statistic to properly
handle the correlated/clustered structure among samples. We employ a resampling-
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based copula approach to estimate the asymptotic distribution of the proposed test,
which enables time-efficient estimation of p-values.
The rest of this chapter is organized as follows. In Section 3.2, we propose a unified
score test, TransMeta-Rare, under a modified random effects model to conduct rare
variants association tests in trans-ethnic meta-analysis. We then evaluate the size
and power of our proposed method and report results from simulation studies under
different scenarios in Section 3.3. As a real data application, we further apply our
proposed method to the Type 2 Diabetes Genetic Exploration by Next-generation
sequencing in multi-Ethnic Samples (T2D-GENES) consortia data in Section 3.4.
We conclude this chapter with a discussion in Section 3.5. Supplementary texts,
tables and figures are presented in Section 3.6.
3.2 Methods
Suppose one conducts a meta-analysis of K independent studies to investigate the
effects of rare variants on a particular phenotype. In the kth study, a total of mk
SNPs are sequenced in a region for each of the nk subjects. For simplicity, we assume
that all variants are observed in all K studies, so that m = m1 = m2 = . . . = mk. We
also assume that the K studies come from different ancestries. We will relax these
assumptions later. Let yki be the phenotype value of the ith subject in the kth study
(for i = 1, . . . , nk and k = 1, . . . , K); let Gki· = (gki1, . . . , gkim)T be the genotype
vector of m variants in the region, where gkij denotes the number of rare allele the ith
subject carries at the jth SNP in the kth study (gkij ∈ {0, 1, 2}); and let Xki denote
a set of qk covariates including an intercept. For the kth study, to associate the rare
variants in a region to the phenotype, we consider the linear regression model
yki = X
T
kiαk + G
T
ki·βk· + ki, ki ∼ N(0, σ2k) (Model: Linear)
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for continuous traits and the logistic regression model
logitP(yki = 1) = X
T
kiαk + G
T
ki·βk· (Model: Logistic)
for binary traits, where αk = (αk1, . . . , αkqk)
T is the vector of regression coefficients
for the qk covariates; βk· = (βk1, . . . , βkm)
T is the vector of regression coefficients
for the m observed SNPs in the region; and ki is an error term with a mean 0 and
variance 2k. Under both linear and logistic regression models, evaluation of no genetic
associations between variants in the region and the phenotype across the K studies
corresponds to testing the null hypothesis
H0 : β1· = . . . = βK· = 0.
To construct our proposed test TransMeta-Rare, we first present the random ef-
fects model rare variants association test for a single study. We then extend the model
to the meta-analysis framework.
3.2.1 The Random Effects Model for a Single Study
In this section, we summarize the random effects model for rare variants associa-
tion test in a single study. For the kth study, denote Skj =
∑nk
i=1 gkij(yki− µˆki)/φˆk as
the score statistic of the jth variant obtained from a linear regression model (for con-
tinuous traits) or a logistic regression model (for binary traits), where µˆki is the esti-
mated mean of yki under either the null linear model yki = X
T
kiαk+ki, ki ∼ N(0, σ2k)
or the null logistic model logitP(yki = 1) = X
T
kiαk; φˆk = σˆ
2
k for continuous traits with
σˆ2k being estimated under the null linear model, and φˆk = 1 for binary traits.
The random effects model assumes
1
wkj
βkj = µj + ηkj, ηkj ∼ N(0, τ1), (3.2.1)
where µj represents the mean genetic effect of the jth variant, ηkj represents the
deviation of the genetic effect from µj in the kth study. Under this model framework,
the Burden (Madsen and Browning, 2009), SKAT (Wu et al., 2011), and SKAT-O
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(Lee et al., 2012) tests for ascertaining H0 : βk· = 0 in study k can all be summarized
into the following score statistic:
U(ρ) = STk·W
T
k· · R(ρ) ·Wk·Sk·,
where Sk· = (Sk1, Sk2, . . . , Skm)T is the score vector of the m variants in study k,
Wk· = diag{wk1, wk2, . . . , wkm} is a diagonal weighting matrix, and the matrix R(ρ)
models the correlation structure of the effect sizes among the variants. The Burden
test is constructed through testing µj = 0 when fixing τ1 = 0 in the random effects
model in Equation (3.2.1), which corresponds to setting R(ρ) = 1m1Tm, where 1m =
(1, . . . , 1)T is an m×1 vector with all elements being 1. The SKAT test is constructed
through testing τ1 = 0 when fixing µj = 0 in Equation (3.2.1), which corresponds
to setting R(ρ) = Im, the m ×m diagonal matrix. The SKAT-O test is constructed
through jointly testing µj = 0 and τ1 = 0 in Equation (3.2.1), which corresponds to
R(ρ) = ρ1m1Tm + (1 − ρ)Im, a convex combination of the correlation structures for
Burden and SKAT.
3.2.2 The Random Effects Model for Meta-analyzing K Studies
We now extend the random effects model for rare variant association tests in a sin-
gle study into the a meta-analysis over multiple studies. Let β·j = (β1j, β2j, . . . , βKj)
T
denote the vector of regression coefficients for the jth SNP among the K independent
studies, then the random effects model in Equation (3.2.1) can be written as
W−1·j β·j = µj1K + η·j, η·j ∼MVN(0, τ1IK), (3.2.2)
with j ∈ {1, . . . ,m}, W·j = diag{w1j, w2j, . . . , wKj}, 1K = (1, . . . , 1)TK×1, IK as the
identity matrix with dimension K × K. To account for the expected genetic ef-
fect heterogeneity of common variants in GWAS trans-ethnic meta-analysis, Shi and
Lee (2016) adapted the kernel machine framework to flexibly model the genetic ef-
fect distributions. For a given variant j, instead of treating {ηkj} (k ∈ {1, . . . , K})
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as identically and independently distributed normal samples, they assumed that η·j
follows a mean 0 Gaussian process with kernel function τ1Ψ(·, ·), where Ψ(·, ·) is a
bivariate function representing the genetic similarity between two groups. In addi-
tion, they imposed a hierarchical structure in Equation (3.2.2) by treating µj as a
random variable with distribution N(0, τ2), which is independently distributed with
η·j. We adopt their modeling strategy and extend it to meta-analysis of rare variants
associations in sequencing studies as follow.
Given the hierarchical random effects model
W−1·j β·j = µj1K + η·j, with η·j ∼MVN(0, τ1Ψ), µj ∼ N(0, τ2), µj ⊥ η·j, (3.2.3)
we first re-parameterize τ1, τ2 as τ1 = τ(1 − ρK) and τ2 = τρK , with τ ≥ 0 and
0 ≤ ρK ≤ 1. τ measures the size of the average genetic effect µj; ρK reflects the
level of heterogeneity among the studies at any given variant. As ρK approaches 1,
the size of the genetic effect β·j is primarily due to the population effect µj, with
negligible contribution from the deviation measurement η·j. Conversely, the closer
ρK approaches 0, the larger degree of variability there is among the deviation {ηkj}
(k = 1, . . . , K), and the population average effect µj becomes minuscule. Under such
re-parameterization, the null hypothesis H0 : β1· = . . . = βK· = 0 corresponds to
testing H0 : µj = 0,η·j = 0 for any j, or equivalently, H0 : τ = 0. Thus, one can
show that the score test statistic for H0 : τ = 0 is
Uτ (ρm, ρK) = vec(S)
T ·WT · [RK(ρK)⊗ Rm(ρm)] ·W · vec(S), (3.2.4)
where vec(·) denotes the vectorization function with vec(S) = (ST1·,ST2·, · · · ,STK·)T ;
W = diag{W1·,W2·, . . . ,WK·} is a diagonal weighting matrix of the variants across
K studies; Rm(ρm) and RK(ρK) are two kernel matrices with nuisance parameters
ρm ∈ {0, 1} and 0 ≤ ρK ≤ 1; and ⊗ denotes the Kronecker product. In Section 3.6.1
of the Supplementary Materials, we provide detailed derivations of the score statistic
Uτ (ρm, ρK) under different modeling assumptions for the kernels Rm(ρm) and RK(ρK).
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We note that Sk· = (Sk1,Sk2, · · · ,Skm)T , the score vector of all the variants in study
k, can be obtained from
Sk· = GTk·Σ
−1
k (yk − µˆk), (3.2.5)
where Gk· = (Gk1·,Gk2·, . . . ,Gknk·)
T is the nk × m genotype matrix in study k;
Σk = φˆkInk with φˆk = σˆ
2
k for continuous traits (σˆ
2
k computed under the null linear
regression model) and φˆk = 1 for binary traits; yk = (yk1, . . . , yknk)
T is an nk × 1
vector of the observed phenotype values; and µˆk = (µˆk1, . . . , µˆknk) is an nk× 1 vector
of estimated means of yk under the null regression model.
We note that the two kernel matrices Rm(ρm) and RK(ρK) model the between-
variant and between-ancestry heterogeneity respectively. Specifically, Rm(ρm) models
the correlation structure of the average genetic effects {µj} (j = 1, . . . ,m) across the
m variants in the hierarchical random effects model (Equation (3.2.3)); in contrast,
RK(ρK) models the correlation structure of the deviation {ηkj} (k = 1, . . . , K) for
the jth variant across the K studies in Equation (3.2.3). The two kernels provide
us double-flexibility in controlling the dependence of genetic effects. From the test
statistic construction perspective, any positive semi-definite matrix can be used as
Rm(ρm) and RK(ρK). From the modeling perspective, to properly account for re-
lationships of the variants within and across studies, we propose several choices for
Rm(ρm) and RK(ρK) in the following sections.
3.2.2.1 The Kernel Structure RK(ρK)
Following the approaches in SKAT and SKAT-O on modeling the effect sizes of
multiple variants in a single study, here, we adapt the kernel matrix R(ρ) from the
SKAT-O test to construct RK(ρK). Specifically, we propose to use
RK(ρK) = ρK1K1TK + (1− ρK)Ψ, 0 ≤ ρK ≤ 1, (3.2.6)
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where Ψ is a kernel matrix which models the correlation structure of the deviation
{ηkj} for the jth variant across the K studies, and we provide two choices for modeling
Ψ.
Choice 1. Group-wise independent kernel structure:
We first consider a simple scenario in which the deviation measurement η·js for
the genetic effects are independently distributed across ancestry groups. It can be
easily shown that such an assumption is equivalent to assuming Ψ = IK .
Choice 2. Genetic similarity kernel structure:
Rather than assuming independently distributed genetic effect deviations between
studies, an alternative strategy is to consider that studies which share more similar
genetic architectures can have more homogeneous genetic effects than those which
consist of very disparate ancestries. Under this assumption, we propose to use the
proportion of shared variants over all the target gene regions between two ancestry
groups as a measure of their genetic similarity. We then accommodate the genetic
similarity measure in constructing Ψ to model effect size similarity. Specifically, for
two different studies k and k
′
(k, k
′ ∈ {1, · · · , K}), the corresponding element in the
kernel matrix Ψ is calculated as
Ψk,k′ =
∑
Gene
∑
variant∈Gene I(the variant is observed in both study k and k
′
)∑
Gene
∑
variant∈Gene 1
.
The element Ψk,k′ defines an overall measure of genetic similarity between any two
studies based on their proportion of shared variants among all the gene regions of
interest. We propose to use this kernel to model the situation that the studies’ genetic
effects are more homogeneous when their genetic architectures are more similar. In
Sections 3.6.2 and 3.6.3 of the Supplementary Materials, we provide a mock example
to illustrate how to construct the genetic similarity kernel Ψ, and justification that
the proposed kernel structure is positive-definite.
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3.2.2.2 The Kernel Structure Rm(ρm)
To properly model the between-variant correlation structure, we adapt the kernel
structure R(ρ) from the SKAT method. Specifically, we propose to use
Rm(ρm) = ρm1m1Tm + (1− ρm)Im, ρm ∈ {0, 1}. (3.2.7)
It can be easily shown that when setting ρm = 1, the kernel structure is equivalent
to assuming that the average genetic effects µjs are homogeneous with µ1 = µ2 =
. . . = µm ∼ N(0, τ2) in Equation (3.2.3); in contrast, setting ρm = 0 is equivalent to
assuming the µjs are heterogeneous across the m variants with µ1, µ2, . . . , µm
i.i.d∼
N(0, τ2) in Equation (3.2.3).
3.2.3 The Score Test Statistic: TransMeta-Rare
In Section 3.2.2, we proposed a score test statistic for rare variants association
tests in trans-ethnic meta-analysis:
Uτ (ρm, ρK) = vec(S)
T ·WT · [RK(ρK)⊗ Rm(ρm)] ·W · vec(S), (3.2.8)
where RK(ρK) = ρK1K1TK + (1− ρK)Ψ, 0 ≤ ρK ≤ 1,
Rm(ρm) = ρm1m1Tm + (1− ρm)Im, ρm ∈ {0, 1}.
The parameters ρm and ρK model different aspects of heterogeneity. ρm models
whether the population average genetic effects among the observed variants are ho-
mogeneous (ρm = 1) or not (ρm = 0); whereas ρK models the degree of heterogeneity
for the deviation measurements by accounting for the genetic similarities between
populations. Specifically, it incorporates the assumption that studies which share
more similar genetic architectures can have more homogeneous genetic effects than
those which consist of very disparate ancestries.
Given ρm and ρK , it can be shown that Uτ (ρm, ρK) asymptotically follows a mix-
ture of chi-square distribution
∑
λlχ
2
l,1 , where χ
2
l,1s are independent chi-square ran-
dom variables with one degree of freedom; and the λls are the non-zero eigenvalues
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of Φ
1
2 [RK(ρK)⊗Rm(ρm)]Φ 12 , where Φ is the covariance matrix of W · vec(S). For the
kth study, let Gk· = (Gk·1, . . . ,Gk·m) be its nk×m genotype matrix, Xk be its nk×qk
covariate matrix. Under the null linear regression model yki = X
T
kiαk + ki or null
logistic regression model logitP(yki = 1) = X
T
kiαk, the the study-specific score vector
Sk· = (Sk1, . . . , Skm)T has mean 0 and covariance matrix Φk = GTk·PkGk·, where Pk =
V−1k − VkXk(XTkV−1k Xk)−1XTkV−1k is the projection matrix; Vk = Σk = σˆ2kInk for
continuous traits, and Vk = diag{ 1µˆk,1(1−µˆk,1) , . . . , 1µˆk,nk (1−µˆk,nk )} for binary traits, with
µˆk,i being the estimated mean of yki under the null logistic regression model. And fi-
nally, the covariance matrix Φ has the form Φ = diag{W1·Φ1W1·, . . . ,WK·ΦKWK·}.
In practice, however, we rarely have prior information on which set of (ρm, ρK)
is optimal in terms of maximizing power. Shi and Lee (2016) approached a similar
problem by using the minimum p-value over a grid values of the nuisance parameter
ρ as their test statistic. We adopt the same strategy here and set the test statistic as
TTransMeta-Rare = inf
ρm∈{0,1},0≤ρK≤1
pρm,ρK , (3.2.9)
where pρm,ρK is the p-value of Uτ (ρm, ρK) in Equation (3.2.8) for a given set of
(ρm, ρK). We name the infimum p-value test in Equation (3.2.9) as TransMeta-
Rare, our proposed rare variants association test for trans-ethnic meta-analysis.
TransMeta-Rare can be obtained by a simple grid search over sets of (ρm, ρK)s:
given grid ρm ∈ {0, 1}, 0 ≤ ρK1 ≤ ρK2 ≤ . . . ≤ ρKv ≤ 1, the test statistic is
TTransMeta-Rare = min{pρm=0,ρK=ρK1 , . . . , pρm=0,ρK=ρKv , pρm=1,ρK=ρK1 , . . . , pρm=1,ρK=ρKv},
and the optimal (ρm, ρK) set is the one which yields TTransMeta-Rare. We observe that
a dense grid of ρK does not necessarily improve power comparing to a coarse grid.
Therefore, we suggest using ρK = (0, 0.09, 0.25, 1) for simulations and real data anal-
ysis.
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3.2.4 Adjusting for Sample Relatedness
In Section 3.2.2 and Section 3.2.3, we formulate the score vector in Equation (3.2.5)
under the assumption that each of the participating study is population-based with
unrelated subjects. However, when the studies are family-based or contain related
individuals, the score vector in Equation (3.2.5) is no longer appropriate, since it
ignores sample relatedness. As a result, the score test in Equation (3.2.9) may have
inflated type I error rates if the score vector in Equation (3.2.5) were used. To
appropriately model sample relatedness, we use the framework of generalized linear
mixed model to incorporate an additional random effect term to account for the
correlation structure among related individuals (Chen et al., 2013, 2016).
3.2.4.1 Linear Mixed Models (LMM) and Score Statistic
Following Chen et al. (2013), for study k, we consider the following LMM for
continuous traits: Following Chen et al. (2013), for study k, we consider the following
LMM for continuous traits:
yki = X
T
kiαk + G
T
ki·βk· + bki + ki, (Model: Linear Mixed)
where bk = (bk1, . . . , bknk)
T is an nk× 1 genetic effect vector for the random effects of
familial correlation, and the remaining notations are as defined before. We assume the
genetic effect vector bk is normally distributed with mean 0 and covariance σ
2
kGΩk,
where Ωk is twice the kinship matrix of size nk×nk obtained from familial information
only. We assume bk is uncorrelated with the error term k = (k1, . . . , knk)
T , which
models the non-shared environmental effects. In summary,
bk ∼MVN(0, σ2kGΩk), k ∼MVN(0, σ2kInk), and bk ⊥ k.
Under those assumptions, the score statistic for H0 : βk· = 0 can be obtained as
Sk· = GTk·Σ
−1
k (yk − µˆk),
where Σk = σˆ
2
kGΩk + σˆ
2
kInk , with σˆ
2
kG and σˆ
2
k estimated from the null LMM yki =
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XTkiαk + bki+ ki; and µˆk = (µˆk1, . . . , µˆknk)
T is the estimated mean vector of yk under
the null LMM. It can be easily shown that under the null LMM, Sk· has mean 0 and
covariance matrix Φk = G
T
k·PkGk·, where Pk = V
−1
k −VkXk(XTkV−1k Xk)−1XTkV−1k
is the projection matrix with Vk = Σk = σˆ
2
kGΩk + σˆ
2
kInk .
3.2.4.2 Logistic Mixed Models and Score Statistic
To adjust for the familial correlation with binary traits, we consider the following
logistic mixed model for study k:
logitP(yki = 1) = X
T
kiαk + G
T
ki·βk· + bki. (Model: Logistic Mixed)
Following Chen et al. (2016), one can show that the corresponding score statistic for
H0 : βk· = 0 is
Sk· = GTk·Σ
−1
k (Yk − µˆk),
where Yk is the “working vector” from the working null LMM Yk = X
T
kαk +
bk + k, k ∼ MVN(0,W˜−1k ) with W˜k = diag{µˆk1(1 − µˆk1), . . . , µˆk1(1 − µˆk1)};
µˆk = (µˆk1, . . . , µˆknk)
T is the estimated mean vector of Yk; and Σk = W˜
−1
k + σˆ
2
kGΩk,
with σˆ2kG and W˜k estimated from the working null LMM. Similarly for a contin-
uous trait, the covariance matrix of Sk· is Φk = GTk·PkGk·, where Pk = V
−1
k −
VkXk(X
T
kV
−1
k Xk)
−1XTkV
−1
k is the projection matrix with Vk = Σk = σˆ
2
kGΩk + W˜k.
With those modified score statistic and the corresponding covariance matrices,
our score test in Equation (3.2.9) now have controlled type I error rates under the
presence of sample relatedness.
3.2.5 Weights and Missing Variants
Proper choice of weights can increase power in rare variant association analysis.
We adopt the flexible beta density function proposed by Wu et al. (2011) as the
pre-specified weights for the variants. Specifically, wkj = Beta(MAFkj, 1, 25) for the
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jth variant in the kth study. This weight function increases the contributions of rare
variants to the score test while keeping decent contributions of variants with MAF
1%− 5%. To compute TransMeta-Rare, we use the ancestry-specific MAFs.
Since rare variants tend to be population specific, if the jth variant is not present
in the kth study, we impose a zero weight on it (wkj = 0), or equivalently, set Skj = 0
and φkj′j = 0 for all j
′ ∈ {1, . . . ,m}, where φkj′j is the (j ′ , j)th element of Φk.
3.2.6 Multiple Studies from the Same Ancestry Group
In trans-ethnic meta-analysis, studies can be naturally grouped based on their
ethnicities. Suppose now the K studies can be grouped into B ancestries and the
bth ancestry contains Kb studies, b ∈ {1, . . . , B}. Without loss of generality, we
assume that the first K1 studies belong to the first ancestry group, followed by the
next K2 studies belonging to the second ancestry group, and so forth. Let K˜0 =
0, K˜b = K1 + K2 + . . . + Kb, for b ∈ {1, . . . , B}. We assume that studies from the
same ancestry group share the same underlying genetic effects, whereas studies from
different ancestry groups have different underlying genetic effects, so that βk· = βk′ ·
if and only if study k and k
′
belong to the same ethnicity. Under these assumptions,
the unified score test in Equation (3.2.4) becomes
Uτ (ρm, ρK) = vec(S˜)
T · [RB(ρB)⊗ Rm(ρm)] · vec(S˜), (3.2.10)
where RB(ρB) = ρB1B1TB + (1− ρB)Ψ, 0 ≤ ρB ≤ 1,
Rm(ρm) = ρm1m1Tm + (1− ρm)Im, ρm ∈ {0, 1}.
Here, we define vec(S˜) = (S˜T1··, S˜
T
2··, . . . , S˜
T
B··)
T with S˜b·· = WK˜b−1+1,· · SK˜b−1+1,· +
WK˜b−1+2,· · SK˜b−1+2,· + . . . + WK˜b1 ,· · SK˜b1 ,· for b ∈ {1, . . . , B}, 1B is a B × 1 vector
with all elements being 1, and and Ψ is a B ×B kernel.
It can be seen that the unified score test in Equation (3.2.10) first collapses the
weighted study-specific score vectors in the same ancestry group and then aggregates
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the collapsed scores with the kernel matrices which account for the between-ancestry
and between-variant relationships. Also notice that Equation (3.2.8) is a special case
of Equation (3.2.10), in which B = K and K1 = K2 = . . . = KB = 1.
3.2.7 Asymptotic Distribution Approximation
In this section, we propose a resampling-based algorithm to approximate the
asymptotic null distribution of TTransMeta−Rare. Denote t as the observed value of
TTransMeta−Rare. The p-value can be obtained as
P (TTransMeta−Rare ≥ t)
= P (min{pρm=0,ρK=ρK1 , . . . , pρm=0,ρK=ρKv , pρm=1,ρK=ρK1 , . . . , pρm=1,ρK=ρKv} ≥ t)
= P (pρm=0,ρK=ρK1 ≥ t, . . . , pρm=0,ρK=ρKv ≥ t, pρm=1,ρK=ρK1 ≥ t, . . . , pρm=1,ρK=ρKv ≥ t).
Since we know the marginal distribution of pρm,ρK for any given (ρm, ρK) follows
a Uniform(0,1) distribution under the null hypothesis, here we adapt a re-sampling
based algorithm to estimate the correlation structure among pρm,ρK s and employ the
copula method to approximate the their joint distribution.
Under the null hypothesis, Φ−
1
2 ·W ·vec(S) approximately follows an uncorrelated
normal distribution MVN(0, ImK), where ImK is an identity matrix with dimension
mK×mK. Therefore, the following resampling-based algorithm can be implemented
to estimate the correlation structure between the Uτ (ρm, ρK)s:
Step 1: Generate n samples, say u, from the multivariate normal distribution
MVN(0, ImK). Here, we use n = 500 for the simulation studies and data application.
Step 2: Calculate the null scores as
U0τ (ρm, ρK) = u
T ·Φ 12{[(1− ρK)Ψ + ρK1K1TK ]⊗ [(1− ρm)Im + ρm1m1Tm]}Φ
1
2 · u
for each (ρm, ρK) ∈ {(0, ρK1), . . . , (0, ρKv), . . . , (1, ρK1), . . . , (1, ρKv)}.
Step 3: Calculate the correlation matrix Σ2v×2v of the null score U0τ (ρm, ρK)s,
where v is the length of the ρK grid.
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Step 4: With the estimated correlation matrix Σ2v×2v, we use the Gaussian copula
to approximate the null joint distribution of the pρm,ρK s, which yields
P (TTransMeta−Rare ≥ t) = 1− FΣ2v×2v(F−1(1− t), . . . ,F−1(1− t)),
where F−1 is the inverse cumulative distribution function of a standard normal,
FΣ2v×2v is the joint cumulative distribution of a multivariate normal with zero mean
vector and covariance matrix equal to Σ2v×2v.
When calculating the correlation matrix Σ2v×2v in the resampling-based algorithm,
Pearson’s correlation coefficient can yield unreliable estimates due to its strong de-
pendent on the normality and homoscedasticity assumptions (Hauke and Kossowski,
2011). Instead, we use Spearman’s correlation, a non-parametric version of the Pear-
son’s correlation based on ranks of the random variables.
3.2.8 A Backward Elimination Algorithm to Order Relative Contribu-
tions of Participating Studies to Association Strength
After identifying the gene or region that is associated with the phenotype of inter-
est, one important question to answer for further follow-up is to pinpoint those studies
with true association signals. Inspired by the work of Ionita-Laza et al. (2014) for
identifying rare causal variants in sequence-based study, here we present a simple
backward elimination algorithm to iteratively remove relatively less important par-
ticipating studies. We note that although our procedure does not narrow down a
subset of the studies with true associations, it provides us the relative prioritization
of the studies in driving the association strength.
Step 1: Start with a set of k studies StudySetcurrent = {1, 2, . . . , k} and compute
the TransMeta-Rare meta-analysis p-value using the studies that are included in
StudySetcurrent. Denote the p-value as pcurrent.
Step 2: Remove each of the study one at a time from the set StudySetcurrent =
{1, 2, . . . , k} . Denote the resulting set as StudySet−i = {1, 2, . . . , i− 1, i+ 1, . . . , k}
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for i = 1, 2, . . . , k, and compute the corresponding p-value p−i using TransMeta-Rare.
Step 3: Identify the study j that leads to the smallest p-value, in other words,
j = argmin{p−1, p−2, . . . , p−k}. Remove the identified study j from the participating
studies and update StudySetcurrent to StudySet−j.
Step 4: Continue removing the participating studies till only one study is left.
3.3 Simulation Studies
To evaluate the performance of TransMeta-Rare, we ran a series of simulations
with varying assumptions on genetic effect heterogeneity among multiple ancestries.
We generated 10,000 haplotypes of length 250kb under a calibrated coalescent model
using Cosi2 (Shlyakhter et al., 2014) to mimic LD patterns and MAFs observed in
the European (EU), African-American (AA), Asian (AS) and African (AF) popula-
tions. For each simulated data set, we randomly selected a 3kb sub-region to generate
causal variants and test for association strengths between the selected sub-region and
phenotypes. We only keep rare variants with MAFs < 1%. To assess type I error rate
calibration and power estimation, we conducted meta-analysis of four studies with
either equal or different sample sizes. Specifically, we considered an equal sample size
scenario with 2,000 subjects from each of the EU, AA, AS and AF populations (8,000
samples in total), and an unequal sample sizes scenario with 2,000 subjects from
each of the AA, AS and AF populations and 6,000 subjects from the EU population
(12,000 samples in total).
For population-based studies, we generated the phenotypes according to the lin-
ear regression model (Model: Linear) for continuous traits and the logistic regres-
sion model (Model: Logistic) for binary traits. We set the covariates Xki as a vec-
tor of length 2, in which the first covariate was generated from a standard normal
distribution and the second covariate was generated from a Bernoulli distribution
with 0.5 probability of success. The associated regression coefficient αk was set as
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αk = (0.5, 0.5)
T . The Gki· genotype vector contains genotypes of all causal variants
and βk· is the regression coefficient vector of genetic effects for the causal variants.
For continuous traits, we generated the random error kis from a standard normal
distribution. For binary traits, we set the prevalence rate to be 0.05 when there is no
genetic effect and there is a balanced case-control ratio in each of the four studies.
For family-based studies, we generated the phenotypes from the linear mixed
model (Model: Linear Mixed) for continuous traits and the logistic mixed model
(Model: Logistic Mixed) for binary traits. We assumed each family has 10 members
with a pedigree10 structure (Figure 3.1). Consequently, for the equal sample size sce-
nario, each of the four populations contained 200 families; in contrast, for the unequal
sample size scenario, EU contained 600 families, whereas the remaining three popula-
tions each contained 200 families. To generate the genotypes for the family members,
we carried out gene-dropping simulations (Abecasis et al., 2002) using the selected
sequences from Cosi2 as founder haplotypes which propagate through the pedigree10
structure. The random effect term bki which accounts for the correlation structure
among related individuals was generated from a standard normal distribution; the
remaining model specifications were the same as in the population-based studies.
3.3.1 Type I Error Rates
We evaluated type I error rates of the proposed method by generating 2.5 ×
107 datasets under the null model of no associations. To reduce the computational
burden, we first generated 50,000 sets of genotypes for randomly selected sub-regions
from the coalescent model, and then generated 500 phenotype sets for each of the
genotype data sets. We evaluated the type I error rate at various nominal levels α
from 10−3, 10−4, 10−5, to 2.5 × 10−6, where α = 2.5 × 10−6 corresponds to exome-
wide studies of 20,000 genes. The empirical type I error rate was estimated as the
proportion of p-values that are less than the nominal level α. Results of TransMeta-
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Figure 3.1: Pedigree of families, each with 10 members, in the family-based
simulation studies.
Rare were presented in Table 3.1a and Table 3.1b for the equal sample size and
unequal sample size scenarios, respectively. For both continuous and dichotomous
phenotypes, regardless of the kernel used, the proposed method yielded controlled
type I error rates under both the population-based and family-based study designs.
3.3.2 Power Comparisons
For power simulations, to allow the possibility of rare variants having large effects,
we modeled the genetic regression coefficient β in the linear model and logistic model
as β = c| log10(MAF )|. We considered several possible configurations of the genetic
effect heterogeneity to compare performances of TransMeta-Rare with existing meta-
analysis approaches. In the first scenario, we simulated a homogenous genetic effect
case by assuming that the causal variants were observed in all four ancestry groups.
In the second scenario, we mimiced a heterogeneous genetic effect case which assumed
that the causal variants were only present in the African-American and African popu-
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(a) Type I error rates of TransMeta-Rare at different α levels based on 2.5 × 107 simulations.
Data are generated under the equal sample size scenario with 2,000 subjects from each of the
EU, AA, AS and AF populations. The ‘Genetic Similarity’ and ‘Indep’ categories refer to the
two kernel choices we provide for Ψ in Section 3.2.2.1.
Data Type Size α
Population-based Family-based
Genetic Indep Genetic Indep
Similarity Similarity
Gaussian
10−3 9.79× 10−4 9.99× 10−4 9.86× 10−4 9.96× 10−4
10−4 1.02× 10−4 1.03× 10−4 9.75× 10−5 9.84× 10−5
10−5 1.06× 10−5 1.12× 10−5 1.09× 10−5 1.10× 10−5
2.5× 10−6 2.83× 10−6 2.84× 10−6 2.85× 10−6 2.88× 10−6
Binary
10−3 9.85× 10−4 1.01× 10−3 9.88× 10−4 9.87× 10−4
10−4 1.03× 10−5 1.03× 10−5 9.84× 10−5 9.90× 10−5
10−5 1.00× 10−5 1.02× 10−5 1.06× 10−5 1.07× 10−5
2.5× 10−6 2.12× 10−6 2.12× 10−6 2.58× 10−6 2.67× 10−6
(b) Type I error rates at different α levels based on 2.5× 107 simulations. Data are generated
under the unequal sample size scenario with 2,000 subjects from each of the AA, AS and AF
populations and 6,000 subjects from the EU population. The ‘Genetic Similarity’ and ‘Indep’
categories refer to the two kernel choices we provide for Ψ in Section 3.2.2.1.
Data Type Size α
Population-based Family-based
Genetic Indep Genetic Indep
Similarity Similarity
Gaussian
10−3 9.87× 10−4 9.86× 10−4 1.03× 10−3 1.14× 10−3
10−4 9.82× 10−5 9.93× 10−5 1.09× 10−4 1.14× 10−4
10−5 1.10× 10−5 1.13× 10−5 1.15× 10−5 1.16× 10−5
2.5× 10−6 2.73× 10−6 2.81× 10−6 2.86× 10−6 2.84× 10−6
Binary
10−3 9.75× 10−4 9.84× 10−4 9.74× 10−4 9.75× 10−3
10−4 9.87× 10−5 9.94× 10−5 9.98× 10−5 1.09× 10−4
10−5 9.96× 10−6 9.97× 10−6 1.05× 10−5 1.03× 10−5
2.5× 10−6 2.04× 10−6 2.05× 10−6 2.56× 10−6 2.65× 10−6
Table 3.1: Type I error rates of TransMeta-Rare at different α levels based
on 2.5× 107 simulations.
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lations. In the third scenario, we generated another heterogeneous genetic effect case
by assuming that the causal variants were only present in the Asian population. In
each setting, we assumed either all causal variants were risk increasing or 80% are risk
increasing and the remaining 20% were risk decreasing. We illustrated in Figure 3.2
the pool of candidate SNPs where the causal variants can be drawn from for each of
those three scenarios. We assumed a spectrum of varying percentages of the causal
rare variants. At any given percentage of causal variants, the expected genetic varia-
tions were assumed as 0.005 and 0.05 for the continuous and binary traits respectively.
We calculated the constant c in the regression coefficient β as the one that yields the
desired variation level (i.e. 0.005 for continuous traits and 0.05 for binary traits).
In Table 3.7 of Supplementary Materials, we summarized the percentages of causal
variants and the corresponding c values in each of the three effect size heterogeneity
scenarios.
Figure 3.2: Venn diagrams to illustrate causal variants selections. The pool
of candidate SNPs from which the causal variants are drawn from. Each
circle in each Venn diagram represents the observed variants in a pop-
ulation, and the area colored in blue represents the pool of candidate
SNPs where the causal variants can be drawn from for each of these three
scenarios.
We ran 1,000 replicates to evaluate the power at the exome-wide significance level
α = 2.5×10−6. The plots in Figure 3.3 and Figure 3.4 summarized the empirical power
of TransMeta-Rare as well as the competing methods for continuous traits and binary
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traits respectively, under the setting where all causal variants were risk increasing
and the sample sizes were the same among the four ancestries with population-based
studies. For the 80% risk increasing causal variants configuration, we summarized the
results in Figure 3.5 and Figure 3.6 for continuous traits and binary traits respectively,
in which the four populations had the same sample size with unrelated individuals.
Figure 3.3 to 3.6 showed that the performance of TransMeta-Rare varied de-
pending on the genetic effect heterogeneity level and the percentage of causal vari-
ants. Under all scenarios, TransMeta-Rare with the genetic similarity kernel consis-
tently achieved comparable or higher power than the group-wise independent ker-
nel. We note that when the meta-analysis consists of one study per ancestry group,
TransMeta-Rare with the group-wise independent kernel (Ψ = IK) is equivalent to
RE-VC-O, the random-effect version of SKAT-O developed by Tang and Lin (2014).
Although the two approaches have equivalent test statistics, RE-VC-O uses an adap-
tive Monte Carlo procedure to approximate the asymptotic distribution, which can
be computationally expensive when estimating the tail probabilities.
In the first scenario where the underlying genetic effects were homogeneous across
ancestries, TransMeta-Rare achieved comparable results to the most powerful com-
peting test Hom-MetaSKAT-O by Lee et al. (2013), which assumes homogeneous
genetic effects. In the two scenarios which assumed heterogeneous genetic effects
across studies, TransMeta-Rare, especially with the genetic similarity kernel, outper-
formed the existing methods across different percentages of the causal variants. In
addition, the power gain in Scenario 3 was generally higher than in Scenario 2, which
was in line with the underlying genetic structures among the four group, as sum-
marized in Table 3.2 for the genetic similarity kernel used in the simulation studies.
Those values indicated that the genetic structure of Asians was very different from
the remaining groups; African Americans and Africans were genetically more closely
related; Europeans and African Americans had moderate genetic similarity compare
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Figure 3.3: Power comparison results for the continuous traits under different hetero-
geneity configurations, with population-based study design, equal sample
size and all the causal variants being trait increasing. The empirical powers
were evaluated at α = 2.5×10−6 for the three scenarios. TransMeta.Genetic-Similarity
and TransMeta.Indep refers to our proposed method TransMeta-Rare with the two ker-
nel choices we provide for Ψ ; Hom-MetaSKAT-O and Het-MetaSKAT-O refer to the
methods proposed by Lee et al. (2013); RE-VC-O refers to the method proposed by
Tang and Lin (2014). For Scenario 2 and Scenario 3, the first line on the X-axis denotes
the percentage of causal variants that are drawn from the designated populations as
illustrated in Figure 3.2; while the second line on the X-axis denotes the corresponding
average percentage of causal variants among the total number of variants from the four
populations.
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Figure 3.4: Power comparison results for the binary traits under different heterogene-
ity configurations, with population-based study design, equal sample size
and all the causal variants being trait increasing. The empirical powers were
evaluated at α = 2.5×10−6 for the three scenarios. TransMeta.Genetic-Similarity and
TransMeta.Indep refer to our proposed method TransMeta-Rare with the two kernel
choices we provide for Ψ ; Hom-MetaSKAT-O and Het-MetaSKAT-O refer to the
methods proposed by Lee et al. (2013); RE-VC-O refers to the method proposed by
Tang and Lin (2014). For Scenario 2 and Scenario 3, the first line on the X-axis denotes
the percentage of causal variants that are drawn from the designated populations as
illustrated in Figure 3.2; while the second line on the X-axis denotes the corresponding
average percentage of causal variants among the total number of variants from the four
populations.
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Figure 3.5: Power comparison results for the continuous traits under different hetero-
geneity configurations, with population-based study design, equal sample
size and 80% of the causal variants being trait increasing. The empirical
powers were evaluated at α = 2.5× 10−6 for the three scenarios. TransMeta.Genetic-
Similarity and TransMeta.Indep refer to our proposed method TransMeta-Rare with
the two kernel choices we provide for Ψ; Hom-MetaSKAT-O and Het-MetaSKAT-O
refer to the methods proposed by Lee et al. (2013); RE-VC-O refers to the method
proposed by Tang and Lin (2014). For Scenario 2 and Scenario 3, the first line on the
X-axis denotes the percentage of causal variants that are drawn from the designated
populations as illustrated in Figure 3.2; while the second line on the X-axis denotes
the corresponding average percentage of causal variants among the total number of
variants from the four populations.
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Figure 3.6: Power comparison results for the binary traits under different heterogeneity
configurations, with population-based study design, equal sample size and
80% of the causal variants being trait increasing. The empirical powers were
evaluated at α = 2.5 × 10−6 for the three scenarios. TransMeta.Genetic-Similarity
and TransMeta.Indep refer to our proposed method TransMeta-Rare with the two
kernel choices we provide for Ψ; Hom-MetaSKAT-O and Het-MetaSKAT-O refer to
the methods proposed by Lee et al. (2013); RE-VC-O refers to the method proposed by
Tang and Lin (2014). For Scenario 2 and Scenario 3, the first line on the X-axis denotes
the percentage of causal variants that are drawn from the designated populations as
illustrated in Figure 3.2; while the second line on the X-axis denotes the corresponding
average percentage of causal variants among the total number of variants from the four
populations.
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to other groups. As a result, when such a genetic similarity kernel was used, the ef-
fect size heterogeneity in Scenario 3 is more consistent with the presumption of using
the genetic similarity kernel for modeling the effect size heterogeneity. In contrast,
although Scenario 2 assumed the genetic effect similarity between African Americans
and Africans according to the similarity between their genetic architectures, it ignored
the moderate genetic similarity level between African Americans and Europeans by
assuming no causal variants in the European group. Consequently, we observed less
power gain of TransMeta-Rare over other approaches in Scenario 2 than in Scenario
3.
Table 3.2: The genetic similarity kernel Ψ for simulation studies.
Ancestry European African American Asian African
European 1
African American 0.108 1
Asian 0.020 0.002 1
African 0.024 0.352 0.010 1
We summarized the power comparison results for the family-based studies and/or
unequal sample size scenarios in Figure 3.10 to Figure 3.21 in Section 3.6.4 of the
Supplementary Materials. We observed that the patterns in these supplementary
figures were very similar to the results shown in Figure 3.3 to Figure 3.6. In addition,
we conducted more simulations with three participating studies in each of the four
groups. Figure 3.7 summarized the empirical power of TransMeta-Rare as well as the
competing methods for continuous traits with three sub-studies per ancestry group,
under the setting where all causal variants were risk increasing and sample sizes were
the same among the four ancestries in the population-based studies. We observed
that the performances had very similar patterns with the single study per ancestry
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group case in Figure 3.3, except that TransMeta-Rare.Indep yielded higher power
than RE-VE-O. This is because rather than collapsing studies within each ancestry,
RE-VC-O treated the 12 studies as if they all came from different ancestries, yielding
less power than the other approaches. In addition, we observed that the power gain of
TransMeta-Rare over existing approaches was even higher in the two heterogeneous
configurations. The results for binary traits, family-based studies and unequal sample
size scenarios were very similar to the single study per ancestry group case (data not
shown).
3.3.3 Computing Time
TransMeta-Rare provides scalable computation time for gene/region-based rare
variants meta-analyses. To analyze 1,000 genes/regions in the power simulations,
TransMeta-Rare took 50 minutes on average on a Linux cluster node with 2.80 GHz
CPU. To analyze 20,000 genes in a genome-wide dataset, TransMeta-Rare would
require less than 17 hours. An R package ‘TransMeta-Rare’ has been developed to
implement our proposed method and can be downloaded at the authors’ website
(https://www.leelabsg.org/).
3.4 Data Application
The Type 2 Diabetes Genetic Exploration by Next-generation sequencing in multi-
Ethnic Samples (T2D-GENES) consortia focused on sequencing variations that are
attributable to T2D risk. T2D-GENES assembled data from a multi-ethnic sample
of 12,940 unrelated individuals drawn from 5 ancestry groups: 2,350 cases and 2,168
controls of European origin; 1,012 cases and 1,152 controls of East Asian origin;
1,087 cases and 1,112 controls of South Asian origin; 1,016 cases and 9,22 controls of
Hispanic origin and 1,009 cases and 1,016 controls of African American origin. The
sequenced DNA samples identified 3.04 million variants, with an 82X mean coverage
84
Figure 3.7: Power comparison results for the continuous traits under different het-
erogeneity configurations, with population-based study design, three sub-
studies per ancestry group, equal sample size and all the causal variants
being trait increasing. The empirical powers were evaluated at α = 2.5 × 10−6
for the three scenarios. TransMeta.Genetic-Similarity and TransMeta-Indep refer to
our proposed method TransMeta-Rare with the two kernel choices we provide for Ψ;
Hom-MetaSKAT-O and Het-MetaSKAT-O refer to the methods proposed by Lee et al.
(2013); RE-VC-O refers to the method proposed by Tang and Lin (2014). For Sce-
nario 2 and Scenario 3, the first line on the X-axis denotes the percentage of causal
variants that are drawn from the designated populations as illustrated in Figure 3.2;
while the second line on the X-axis denotes the corresponding average percentage of
causal variants among the total number of variants from the four populations.
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across the coding sequence of 18,281 genes.
We applied our proposed method to the T2D-GENES data for multi-ethnic rare
variants association analysis. The phenotypes being considered included both the bi-
nary trait T2D and the continuous trait BMI. To investigate the associations between
rare variants and phenotypes of interest, we employed the variant list (‘mask’) defined
in Fuchsberger et al. (2016) based on MAFs and functional annotations for the genes.
The mask was comprised of variants that were predicted to be protein-truncating
and protein-altering variants with MAF < 1% that were predicted to be deleterious
by at least one of the five annotation prediction algorithms: Polyphen2-HumDiv,
PolyPhen2-HumVar, LRT, Mutation Taster, and SIFT.
In each of the five ancestry groups, to obtain the summary statistics such as the
score test statistic and associated information matrix, we first carried out the logis-
tic regression model in (Model: Logistic) for T2D and the linear regression model
(Model: Linear) for BMI. We then meta-analyzed the five groups using TransMeta-
Rare as well as other existing gene-level meta-analysis methods. For the dichotomous
phenotype T2D, the adjusting covariates used in each ancestry-specific logistic re-
gression model included age, gender, BMI and principal components calculated from
the sequencing data. The principal components were included in the model to ac-
count for potential population stratification. We adjusted for the top four principal
components in each of the ancestry groups. For the continuous trait BMI, we applied
inverse normal transformation to BMI in order for the transformed responses to more
closely approximate the Gaussian distribution.
The QQ plots in Figure 3.8a and Figure 3.8b displayed the TransMeta-Rare p-
values with the genetic similarity kernel for both T2D and BMI, while the genetic
similarity kernel used in the data analysis were summarized in Table 3.4. The QQ
plots showed that TransMeta-Rare had controlled type I error rate for both T2D and
BMI. In addition, the protein coding gene PLCD1 (Phospholipase C Delta 1) achieved
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the exome-wide significance level for its association with BMI. We presented the meta-
analysis p-values for this gene as well as its characteristic in Table 3.3a and Table 3.3b
respectively, and the Venn Diagram in Figure 3.9 summarized the number of shared
variants among the five populations for this gene. PLCD1 encodes a member of the
phospholipase C family, while phospholipases are a group of enzymes that hydrolyze
phospholipids into fatty acids and other lipophilic molecules (Hu, 2011). Previous
studies have shown that PLCD1 is involved in obesity. For example, the GTEx Data
portal has identified the Adipose tissue specific gene expression for PLCD1, where
increase in the number and size of adipocytes is viewed as a hallmark of obesity
(www.gtexportal.org/home/eqtls/byGene?geneId=PLCD1&tissueName=All); and Hi-
rata et al. (2011) have experimented on PLCD1 knockout mice and observed pro-
tection from diet-induced obesity and higher metabolic rate among those PLCD1
knockout mice through thermogenesis and adipogenesis regulation.
(a) The meta-analysis p-values of gene PLCD1 for its association with BMI.
TransMeta-Rare. TransMeta-Rare.
Hom-MetaSKAT-O Het-MetaSKAT-O
Genetic Similarity Indep
5.67× 10−7 6.06× 10−7 5.87× 10−7 7.78× 10−7
(b) Characteristics of gene PLCD1.
Gene Band Start (bp) End (bp) Size
] of SNPs
EA SA EUR HIS AA
PLCD1 3p22.2 38,049,337 38,065,843 16,570 17 22 21 16 24
Table 3.3: Analysis results and characteristics of gene PLCD1.
We applied the backward elimination algorithm to the PLCD1 gene to investigate
the relative contributions of the five studies in driving the association signal. The
elimination results was summarized in Table 3.5. When we removed each of the five
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(a) QQ plots of TransMeta-Rare with the genetic similarity kernel for T2D.
(b) QQ plot of TransMeta-Rare with the genetic similarity kernel for BMI.
Figure 3.8: QQ plot of TransMeta-Rare with the genetic similarity kernel
for T2D and BMI. QQ-plots of -log10 p-values of TransMeta-Rare with
the genetic similarity kernel. A total of 18,281 genes are tested for their
associations with T2D (top panel) and BMI (bottom panel) in the T2D-
GENENS data.
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Figure 3.9: Venn Diagram for the number of shared SNPs in gene PLCD1
among the five ancestry groups.
Table 3.4: The genetic similarity kernel Ψ for T2D-GENES data.
Ancestry East-Asian South-Asian European Hispanic African-American
East-Asian 1
South-Asian 0.101 1
European 0.119 0.138 1
Hispanic 0.095 0.111 0.163 1
African-American 0.097 0.105 0.153 0.151 1
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populations one at a time and computed TransMeta-Rare based on the remaining
four populations, we observed that the association strength improves the most when
SA was eliminated, with the p-value decreased from 5.67× 10−7 to 1.50× 10−7. This
suggested that among the five groups, SA had the least contribution to the association
signal. After removing SA, HIS was the next study to be eliminated, which indicated
that HIS had the next lowest contribution after SA. Further carrying out the proposed
algorithm, we next removed EA and EUR in order. In other words, AA remained as
the last study in the elimination sequence, suggesting that it had the strongest driving
signal for the association between PLCD1 and BMI. This was in agreement with
the single study SKAT-O results (Table 3.8 in Supplementary Materials). We also
applied TransMeta-Rare to each of the 72 variants in PLCD1 to conduct the single-
variant meta-analysis over the five populations (results summarized in Table 3.9, 3.10
and 3.11 in the Supplementary Materials). It can be seen from those tables that
none of the single-marker meta-analysis p-values achieved genome-wide significance,
which suggested that multiple variants were associated with BMI. We noted that
SNP rs116413856, which yielded the smallest single-variant meta-analysis p-value,
was an AA-specific variant. This result was in line with our backward elimination
order, which suggested that AA was the strongest driver of the association signal for
PLCD1.
3.5 Discussion
We have proposed a statistical framework, TransMeta-Rare, for meta-analyzing
rare variant association tests in multi-ethnic samples. TransMeta-Rare incorpo-
rates the kernel regression framework to provide double-flexibility in modeling both
between-ancestry and between-variant genetic effect heterogeneity. In addition, it uses
the adaptive variance component test to achieve robust power regardless of degree
of heterogeneity. To enable efficient approximation of the asymptotic distribution of
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Table 3.5: The backward elimination sequence for gene PLCD1.
Removed Population
p-value
Note
Genetic Similarity Indep
- 5.67× 10−7 6.06× 10−7 TransMeta-Rare p-value
based on 5 populations
SA 1.50× 10−7 3.42× 10−7 TransMeta-Rare p-value
based on EA, EUR, HIS and AA
HIS 1.14× 10−6 2.48× 10−6 TransMeta-Rare p-value
based on EA, EUR and AA
EA 8.69× 10−9 3.63× 10−8 TransMeta-Rare p-value
based on EUR and AA
EUR 8.15× 10−5 8.15× 10−5 SKAT-O p-value
based on AA
the proposed method, we employed a resampling-based copula approach to estimate
the p-values analytically.
In contrast to joint analysis, which requires sharing of individual-level data, the
proposed gene-/region-based multi-marker test is based on study-specific summary
statistics for each target region. Specifically, it only requires sharing of the single
variant score statistics and the between-variant information matrix which accounts
for the LD structure of the gene regions.
TransMeta-Rare can be viewed as a multi-marker extension of the modified single-
variant random-effect model proposed by Shi and Lee (2016). The difference is that
instead of taking the regression coefficients as input data, the rare variant association
test is based on score statistics of multiple variants. There are several advantages
of using score statistics instead of the regression coefficients for rare variants. First,
estimation of the regression coefficients for rare variants in sequencing studies tends to
be unstable with large variances, which would make the meta-analysis results unstable
if the regression coefficients and the associated variance estimates are used as input
data. Second, since rare variants tend to be population-specific, for those variants
that are only present in some but not all studies, one can easily modify the summary
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statistics input by setting the score statistics as 0 for those unobserved variants in a
given study.
Shi and Lee (2016) have shown that for a single variant meta-analysis, in the
presence of genetic effect heterogeneity, the modified random effect framework can
increase power over the traditional fixed-effect as well as the random-effect models,
when heterogeneity is properly modeled. Our simulation results are consistent in this
regard in multi-variant settings.
One important feature of TransMeta-Rare is that it allows for flexible modeling of
the varying levels of genetic effect heterogeneity across studies, and the power simula-
tions confirm that the proposed method can improve power over existing approaches
when the genetic effect heterogeneity is properly modeled. Although TransMeta-Rare
was developed to account for heterogeneous genetic effects across studies, our simu-
lations demonstrate that when genetic effects are homogeneous across ancestries, the
proposed method yields comparable results to those tests which assume homogeneous
genetic effects. The T2D-GENES application suggests that TransMeta-Rare works
well in practice.
The genetic similarity kernel Ψ is proposed to account for the situation where
studies which share more similar genetic architectures can have more homogeneous
genetic effects than those which consist of very disparate ancestries. The power
simulations demonstrate that when such an underlying assumption is in line with the
sources of genetic effect heterogeneity, using the genetic similarity kernel can achieve
power gain over the other methods. We recommend using the genetic similarity kernel
as the primary choice when fitting TransMeta-Rare. However, if there is evidence
suggesting that the genetic effects are modified by non-genetic exposures such as
environmental or lifestyle factors, then the group-wise independence kernel may be a
better choice under such situations. To avoid data fishing, the choice regarding which
kernel structure to use should be determined prior to the data analysis.
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3.6 Supplementary Materials
3.6.1 Derivation of the Score Test Statistics
(Model:Linear) and (Model:Logistic) can be summarized as the following gener-
alized linear model with a canonical link function h(·):
h[E(yki)] = X
T
kiαk + G
T
ki·βk·, (3.6.1)
where h(·) is an identity function for the continuous traits and a logistic function for
the binary traits. Based on Equation (3.6.1), the regression model over the K studies
can be written as:
h[E(y1)]
h[E(y2)]
...
h[E(yK)]

=

X1 0 · · · 0
0 X2 · · · 0
...
...
...
...
0 0 · · · XK


α1
α2
...
αK

+

G1 0 · · · 0
0 G2 · · · 0
...
...
...
...
0 0 · · · GK


β1·
β2·
...
βK·

, (3.6.2)
and evaluation of no genetic associations between variants in the region and the
phenotype across the K studies corresponds to testing the null hypothesis
H0 : β1· = . . . = βK· = 0.
We assume that the regression coefficients β·js for any given variant j (j ∈ {1, . . . ,m})
across the K studies are random variable which follow the modified random effects
model
W−1·j β·j = µj1K + η·j, η·j ∼ N(0, τ1Ψ), (3.6.3)
where µj represents the average genetic effect of the jth variant over the K studies,
and η·j represents the deviation of the genetic effect from µj across the K studies.
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3.6.1.1 Meta-Analysis Assuming Homogeneous Average Genetic Effects
of the Variants
If the average genetic effects µjs are homogenous among the m variants, the mod-
ified random effects model (Equation (3.6.3)) under this assumption can be written
as
W−1·j β·j = µj1K + η·j, η·j ∼MVN(0, τ1Ψ) for j ∈ {1, . . . ,m},
µ1 = µ2 = . . . = µm ∼ N(0, τ2), µj ⊥ η·j (Model: Hom)
We reparameterize τ1, τ2 as τ1 = τ(1 − ρK) and τ2 = τρK , with τ ≥ 0 and 0 ≤
ρK ≤ 1. τ measures the size of the average genetic effect µj, and ρK reflects the
level of heterogeneity among the studies at any given variant. As ρK approaches 1,
the size of the genetic effect β·j is primarily due to the population effect µj, with
negligible contribution from the deviation measurement η·j. Conversely, the closer
ρK approaches 0, the larger degree of variability there is among the deviation ηkjs
(k = 1, . . . , K), and the population average effect µj becomes minuscule. From this
reparameterization, testing the null hypothesis of no genetic associations between any
variant in the region and the phenotype corresponds to testing H0 : µj = 0,η·j =
0 for any j, or equivalently, H0 : τ = 0.
Under (Model: Hom), the meta-analysis score test for H0 : τ = 0 for a given ρK
is
Uτ (ρK) = vec(S)
TWT · [(1− ρK)Ψ⊗ 1m1Tm + ρK1K1TK ⊗ 1m1Tm] ·Wvec(S),(3.6.4)
where W = diag{W1·,W2·, . . . ,WK·} is a diagonal weighting matrix of the variants
across K studies; vec(S) is a vector of aggregated study-specific scores, and vec(·)
denotes the vectorization function with vec(S) = (ST1·,S
T
2·, · · · ,STK·)T , while Sk· =
(Sk1, . . . , Skm)
T is the score vector of the m variants in the kth study and Skj is
the individual score test statistic for testing the marginal effect of the jth marker
(H0 : βkj = 0) under the study-specific linear or logistic regression model for the kth
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study.
3.6.1.2 Meta-Analysis Assuming Heterogeneous Average Genetic Effects
of the Variants
If the average genetic effects µjs are heterogeneous among the m variants, the
modified random effects model under this assumption can be written as
W−1·j β·j = µj1K + η·j, η·j ∼MVN(0, τ1Ψ) for j ∈ {1, . . . ,m},
µ1, µ2, . . . , µm
iid∼ N(0, τ2), µj ⊥ η·j (Model: Het)
Applying the same reparameterization τ1 = τ(1 − ρK) and τ2 = τρK as in Sec-
tion 3.6.1.1, testing the null hypothesis of no rare variant associations is again equiv-
alent to testing H0 : τ = 0.
Under (Model: Het), the meta-analysis score test for H0 : τ = 0 for a given ρK
becomes
Uτ (ρK) = vec(S)
T ·WT · [(1− ρK)Ψ⊗ Im + ρK1K1TK ⊗ Im] ·W · vec(S), (3.6.5)
where Im is an identity matrix with dimension m, vec(S) and W have the same
definitions as in Section 3.6.1.1.
3.6.1.3 The Unified Score Statistics
It can be easily seen that the derived statistics in (3.6.4) and (3.6.5) are special
cases of the following unified score test
Uτ (ρm, ρK) = vec(S)
T ·WT · [RK(ρK)⊗ Rm(ρm)] ·W · vec(S), (3.6.6)
where RK(ρK) = ρK1K1TK + (1− ρK)Ψ, 0 ≤ ρK ≤ 1,
Rm(ρm) = ρm1m1Tm + (1− ρm)Im, ρm ∈ {0, 1}.
Specifically, the unified score statistics in Equation (3.6.6) reduces to the homogeneous
test in Equation (3.6.4) and the heterogeneous test in Equation (3.6.5) by setting
ρm = 1 and 0 respectively.
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Table 3.6: A mock example to demonstrate how to construct the genetic
similarity kernel Ψ.
Gene SNP
Study 1 Study 2 SNP present ] SNPs Total ] SNPs
MAF MAF in both present in in a gene
studies or not both studies
Gene1
rs001 0.001 0 0
1 3rs002 0.002 0.003 1
rs003 0 0.004 0
Gene2
rs004 0.005 0.006 1
2 4
rs005 0.007 0 0
rs006 0 0.008 0
rs007 0.009 0.009 1
3.6.2 Construction of the Genetic Similarity Kernel Ψ
In this section, we provide a mock example to illustrate how to construct the
genetic similarity kernel Ψ. Recall, given two different studies k and k
′
(k, k
′ ∈
{1, · · · , K}), the corresponding element in the kernel matrix Ψ can be computed as
Ψk,k′ =
∑
Gene
∑
variant∈Gene I(the variant is observed in both study k and k
′
)∑
Gene
∑
variant∈Gene 1
,
where the numerator measures the number of variants that are present in both studies
over all the targeted genes, and the denominator simply measures the total number
of variants that are included among all the targeted genes.
We consider a mock example where the meta-analysis consists of two studies and
we are interested in the associations of two target genes with a trait. We construct
the genetic similarity kernel Ψ based on the observed MAFs of the two target genes
in the two studies (Table 3.6).
The 5th column in Table 3.6 (denoted as “SNP present in both studies or not”)
measures whether each variant in the gene is observed in both studies (positive MAFs
in both studies) or not (at least one study has MAF = 0). The 6th column (denoted as
“] SNPs present in both studies”) sums up the number of variants that are observed
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in both studies in each of the defined gene. The very last column (denoted as “Total
] SNPs in a gene”) simply counts the number of variants that are listed in each of
the gene. Since we assume the meta-analysis only consists of two studies, the kernel
matrix Ψ is of dimension 2 × 2, with the diagonal elements always be 1 (since it
measures the % of shared variants over all target genes between a study and itself),
and the off-diagonal element calculated as Ψ1,2 = Ψ2,1 = (1 + 2)/(3 + 4) = 3/7. So
we obtain the kernel matrix as
Ψ =
 1 3/7
3/7 1
 .
3.6.3 Positive Definite Matrix Ψ under the Genetic Similarity Kernel
In this section, we demonstrate that the proposed genetic similarity kernel Ψ is a
positive definite matrix. We assume that the meta-analysis consists of K studies from
K ancestries, and the total number of variants defined among all the genes/regions of
interest is M , where M =
∑
Gene
∑
variant∈Gene 1. For the kth study, k ∈ {1, . . . , K},
let zk be a column vector of length M where each element has value either 0 or 1
which indicates whether the ith variant (i ∈ {1, . . . ,M}) is observed in the kth study
or not. Let Z = (z1, z2, . . . , zK) be the M ×K matrix whose columns are collections
of those zk column vectors. Based on these notations, it can be easily shown that the
genetic similarity kernel Ψ can be constructed as
Ψ =
1
M
[ZTZ +D], (3.6.7)
where D is a K×K diagonal matrix such that the diagonal elements of ZTZ+D are
all equal to M . Let v be a non-zero column vector of length K, we now show that
ZTZ +D is a positive definite matrix.
(1). D is a zero matrix
D is a zero matrix iff the M variants are observed in all K studies. In this case,
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Ψ reduces to Ψ = 1
M
ZTZ, with all elements in Z being 1. As a result,
vT (ZTZ)v = (Zv)T (Zv) = ||Zv||2 > 0,
since in this case at least one element in Zv has non-zero values. Consequently,
Ψ = 1
M
ZTZ is positive definite.
(2). D is a diagonal matrix with at least one non-zero entry
If D has at least one non-zero entry, then vTDv ≥ 0 and vT (ZTZ)v = ||Zv||2 ≥ 0
would both hold. Furthermore, due to the constraint that the diagonal elements in
ZTZ + D all have to equal to M , when vTDv = 0, we should have vT (ZTZ)v > 0,
and vice versa. Consequently, vT (ZTZ +D)v > 0 for any non-zero column vector v.
The above two cases thus suggest that Ψ = 1
M
(ZTZ +D) is positive definite.
3.6.4 Supplementary Tables and Figures
Table 3.7: The percentages of causal variants and the corresponding c values
in each of the three effect size heterogeneity scenarios.
Data Type Scenario
% of Causal Variants
10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Continuous
Scenario 1 0.467 0.324 0.263 0.228 - - - - - -
Scenario 2 0.714 0.474 0.379 0.326 0.292 0.264 0.243 0.227 0.217 0.203
Scenario 3 1.154 0.827 0.665 0.577 0.519 0.469 0.431 0.403 0.379 0.364
Binary
Scenario 1 1.477 1.026 0.833 0.719 - - - - - -
Scenario 2 2.258 1.499 1.197 1.032 0.925 0.835 0.768 0.717 0.673 0.643
Scenario 3 3.648 2.615 2.102 1.826 1.641 1.482 1.362 1.276 1.200 1.150
Table 3.8: The single study multi-variant SKAT-O p-values for gene
PLCD1.
EA SA EUR HIS AA
1.99× 10−2 2.35× 10−1 1.55× 10−1 7.03× 10−2 8.15× 10−5
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Figure 3.10: Power comparison results for the continuous traits under different het-
erogeneity configurations, with population-based study design, unequal
sample size and all the causal variants being trait increasing. The empirical
powers were evaluated at α = 2.5×10−6 for the three scenarios. TransMeta.Genetic-
Similarity and TransMeta.Indep refer to our proposed method TransMeta-Rare with
the two kernel choices we provide for Ψ; Hom-MetaSKAT-O and Het-MetaSKAT-O
refer to the methods proposed by Lee et al. (2013); RE-VC-O refers to the method
proposed by Tang and Lin (2014). For Scenario 2 and Scenario 3, the first line on the
X-axis denotes the percentage of causal variants that are drawn from the designated
populations as illustrated in Figure 3.2; while the second line on the X-axis denotes
the corresponding average percentage of causal variants among the total number of
variants from the four populations.
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Figure 3.11: Power comparison results for the binary traits under different hetero-
geneity configurations, with population-based study design, unequal sam-
ple size and all the causal variants being trait increasing. The empirical
powers were evaluated at α = 2.5×10−6 for the three scenarios. TransMeta.Genetic-
Similarity and TransMeta.Indep refer to our proposed method TransMeta-Rare with
the two kernel choices we provide for Ψ; Hom-MetaSKAT-O and Het-MetaSKAT-O
refer to the methods proposed by Lee et al. (2013); RE-VC-O refers to the method
proposed by Tang and Lin (2014). For Scenario 2 and Scenario 3, the first line on the
X-axis denotes the percentage of causal variants that are drawn from the designated
populations as illustrated in Figure 3.2; while the second line on the X-axis denotes
the corresponding average percentage of causal variants among the total number of
variants from the four populations.
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Figure 3.12: Power comparison results for the continuous traits under different hetero-
geneity configurations, with population-based study design, unequal sam-
ple size and 80% of the causal variants being trait increasing. The empirical
powers were evaluated at α = 2.5×10−6 for the three scenarios. TransMeta.Genetic-
Similarity and TransMeta.Indep refer to our proposed method TransMeta-Rare with
the two kernel choices we provide for Ψ; Hom-MetaSKAT-O and Het-MetaSKAT-O
refer to the methods proposed by Lee et al. (2013); RE-VC-O refers to the method
proposed by Tang and Lin (2014). For Scenario 2 and Scenario 3, the first line on the
X-axis denotes the percentage of causal variants that are drawn from the designated
populations as illustrated in Figure 3.2; while the second line on the X-axis denotes
the corresponding average percentage of causal variants among the total number of
variants from the four populations.
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Figure 3.13: Power comparison results for the binary traits under different heterogene-
ity configurations, with population-based study design, unequal sample
size and 80% of the causal variants being trait increasing. The empirical
powers were evaluated at α = 2.5×10−6 for the three scenarios. TransMeta.Genetic-
Similarity and TransMeta.Indep refer to our proposed method TransMeta-Rare with
the two kernel choices we provide for Ψ; Hom-MetaSKAT-O and Het-MetaSKAT-O
refer to the methods proposed by Lee et al. (2013); RE-VC-O refers to the method
proposed by Tang and Lin (2014). For Scenario 2 and Scenario 3, the first line on the
X-axis denotes the percentage of causal variants that are drawn from the designated
populations as illustrated in Figure 3.2; while the second line on the X-axis denotes
the corresponding average percentage of causal variants among the total number of
variants from the four populations.
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Figure 3.14: Power comparison results for the continuous traits under different hetero-
geneity configurations, with family-based study design, equal sample size
and all the causal variants being trait increasing. The empirical powers were
evaluated at α = 2.5 × 10−6 for the three scenarios. TransMeta.Genetic-Similarity
and TransMeta.Indep refer to our proposed method TransMeta-Rare with the two
kernel choices we provide for Ψ; Hom-MetaSKAT-O and Het-MetaSKAT-O refer to
the methods proposed by Lee et al. (2013). For Scenario 2 and Scenario 3, the first
line on the X-axis denotes the percentage of causal variants that are drawn from
the designated populations as illustrated in Figure 3.2; while the second line on the
X-axis denotes the corresponding average percentage of causal variants among the
total number of variants from the four populations.
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Figure 3.15: Power comparison results for the binary traits under different hetero-
geneity configurations, with family-based study design, equal sample size
and all the causal variants being trait increasing. The empirical powers were
evaluated at α = 2.5 × 10−6 for the three scenarios. TransMeta.Genetic-Similarity
and TransMeta.Indep refer to our proposed method TransMeta-Rare with the two
kernel choices we provide for Ψ. For Scenario 2 and Scenario 3, the first line on the
X-axis denotes the percentage of causal variants that are drawn from the designated
populations as illustrated in Figure 3.2; while the second line on the X-axis denotes
the corresponding average percentage of causal variants among the total number of
variants from the four populations.
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Figure 3.16: Power comparison results for the continuous traits under different het-
erogeneity configurations, with family-based study design, equal sample
size and 80% of the causal variants being trait increasing. The empirical
powers were evaluated at α = 2.5×10−6 for the three scenarios. TransMeta.Genetic-
Similarity and TransMeta.Indep refer to our proposed method TransMeta-Rare with
the two kernel choices we provide for Ψ; Hom-MetaSKAT-O and Het-MetaSKAT-O
refer to the methods proposed by Lee et al. (2013). For Scenario 2 and Scenario 3,
the first line on the X-axis denotes the percentage of causal variants that are drawn
from the designated populations as illustrated in Figure 3.2; while the second line on
the X-axis denotes the corresponding average percentage of causal variants among
the total number of variants from the four populations.
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Figure 3.17: Power comparison results for the binary traits under different heterogene-
ity configurations, with family-based study design, equal sample size and
80% of the causal variants being trait increasing. The empirical powers were
evaluated at α = 2.5 × 10−6 for the three scenarios. TransMeta.Genetic-Similarity
and TransMeta.Indep refer to our proposed method TransMeta-Rare with the two
kernel choices we provide for Ψ. For Scenario 2 and Scenario 3, the first line on the
X-axis denotes the percentage of causal variants that are drawn from the designated
populations as illustrated in Figure 3.2; while the second line on the X-axis denotes
the corresponding average percentage of causal variants among the total number of
variants from the four populations.
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Figure 3.18: Power comparison results for the continuous traits under different het-
erogeneity configurations, with family-based study design, unequal sam-
ple size and all the causal variants being trait increasing. The empirical
powers were evaluated at α = 2.5×10−6 for the three scenarios. TransMeta.Genetic-
Similarity and TransMeta.Indep refer to our proposed method TransMeta-Rare with
the two kernel choices we provide for Ψ; Hom-MetaSKAT-O and Het-MetaSKAT-O
refer to the methods proposed by Lee et al. (2013). For Scenario 2 and Scenario 3,
the first line on the X-axis denotes the percentage of causal variants that are drawn
from the designated populations as illustrated in Figure 3.2; while the second line on
the X-axis denotes the corresponding average percentage of causal variants among
the total number of variants from the four populations.
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Figure 3.19: Power comparison results for the binary traits under different heterogene-
ity configurations, with family-based study design, unequal sample size
and all the causal variants being trait increasing. The empirical powers were
evaluated at α = 2.5 × 10−6 for the three scenarios. TransMeta.Genetic-Similarity
and TransMeta.Indep refer to our proposed method TransMeta-Rare with the two
kernel choices we provide for Ψ. For Scenario 2 and Scenario 3, the first line on the
X-axis denotes the percentage of causal variants that are drawn from the designated
populations as illustrated in Figure 3.2; while the second line on the X-axis denotes
the corresponding average percentage of causal variants among the total number of
variants from the four populations.
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Figure 3.20: Power comparison results for the continuous traits under different hetero-
geneity configurations, with Family-based study design, unequal sample
size and 80% of the causal variants being trait increasing. The empirical
powers were evaluated at α = 2.5×10−6 for the three scenarios. TransMeta.Genetic-
Similarity and TransMeta.Indep refer to our proposed method TransMeta-Rare with
the two kernel choices we provide for Ψ; Hom-MetaSKAT-O and Het-MetaSKAT-O
refer to the methods proposed by Lee et al. (2013). For Scenario 2 and Scenario 3,
the first line on the X-axis denotes the percentage of causal variants that are drawn
from the designated populations as illustrated in Figure 3.2; while the second line on
the X-axis denotes the corresponding average percentage of causal variants among
the total number of variants from the four populations.
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Figure 3.21: Power comparison results for the binary traits under different hetero-
geneity configurations, with family-based study design, unequal sample
size and 80% of the causal variants being trait increasing. The empirical
powers were evaluated at α = 2.5×10−6 for the three scenarios. TransMeta.Genetic-
Similarity and TransMeta.Indep refer to our proposed method TransMeta-Rare with
the two kernel choices we provide for Ψ. For Scenario 2 and Scenario 3, the first
line on the X-axis denotes the percentage of causal variants that are drawn from
the designated populations as illustrated in Figure 3.2; while the second line on the
X-axis denotes the corresponding average percentage of causal variants among the
total number of variants from the four populations.
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Table 3.9: Meta-analysis p-value from TransMeta-Rare for each of the vari-
ant that is included in PLCD1. The variants are sorted with an
increasing order of the p-values. The ‘Genetic Similarity’ and ‘Indep’ cat-
egories refer to the two kernel choices we provide for Ψ in Section 3.2.2.1.
SNP ID
MAF (×10−3) p-value
EA SA EUR HIS AA
Genetic Indep
Similarity
rs116413867 0 0 0 0 2.97 4.83× 10−3 4.83× 10−3
var 3 38052863 0 0.23 0 0 0 1.19× 10−2 1.19× 10−2
var 3 38049748 0.69 0 0 0 0 1.35× 10−2 1.35× 10−2
rs141932732 1.62 2.05 1.78 1.09 10.20 1.41× 10−2 1.39× 10−2
var 3 38050599 0 0 0.77 0 0 3.44× 10−2 3.44× 10−2
var 3 38051432 0 0 0.22 0 0 5.90× 10−2 5.90× 10−2
var 3 38050895 0 0.23 0 0 0 7.63× 10−2 7.63× 10−2
rs142059541 0 0 0 0.27 0.25 7.63× 10−2 7.73× 10−2
var 3 38052047 0 0 0 3.26 0 0.12 0.12
var 3 38061760 0 0.23 0 0 0 0.12 0.12
rs78426951 0.23 0 2.89 1.63 0.99 0.15 0.15
rs115366708 0 0 0 0 1.98 0.15 0.15
var 3 38051233 0 0 0 0 0.74 0.17 0.17
var 3 38052764 0 0 0.11 0 0 0.17 0.17
var 3 38051263 0 0.23 0.11 0 0 0.17 0.17
var 3 38051630 0 0 0.11 0 0 0.22 0.22
var 3 338052849 0.23 0 0 0 0 0.22 0.22
var 3 38051475 0 0 0 0.54 0.25 0.24 0.24
var 3 38051293 0 4.10 0 0 0 0.24 0.24
var 3 38049848 2.32 0 0 0 0 0.24 0.24
var 3 38053121 0 0.23 0 0 0 0.27 0.27
var 3 38050885 0 0 0 0.54 0 0.30 0.30
var 3 38051537 0 0 0.11 0.27 0 0.32 0.32
var 3 38051657 0 0 0 0 0.25 0.32 0.32
var 3 38049598 0 0 0.11 0 0 0.33 0.33
var 3 38053082 0.23 0 0 0 0 0.37 0.37
var 3 38051543 0 0.23 0 0 0 0.37 0.37
var 3 38053165 0.23 0 0 0 0 0.37 0.37
var 3 38049533 0.46 1.37 0 0 0 0.38 0.38
var 3 38049337 0 0 0 0 0.25 0.39 0.39
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Table 3.10: Table 3.9 Continued. Meta-analysis p-value from TransMeta-
Rare on each of the variant that is included in PLCD1. The
variants are sorted with an increasing order of the p-values. The ‘Ge-
netic Similarity’ and ‘Indep’ categories refer to the two kernel choices we
provide for Ψ in Section 3.2.2.1.
SNP ID
MAF (×10−3) p-value
EA SA EUR HIS AA
Genetic Indep
Similarity
var 3 38058126 0 0.68 0.44 0.54 0.49 0.40 0.38
rs139342994 0 0 0.88 0 0 0.44 0.44
var 3 38050620 0.46 0 0 0 0 0.45 0.45
var 3 38049798 0 0.23 0 0 0 0.48 0.48
var 3 38049588 0 0 0.11 0 0 0.49 0.49
var 3 38050635 0 0.23 0 0.27 0.25 0.51 0.51
var 3 38050789 0.23 0 0 0 0 0.52 0.52
var 3 38058127 0 0.23 0.44 0.54 0.49 0.53 0.53
rs143961610 0 0 0 0 2.72 0.59 0.59
var 3 38057997 0 0.23 0 0 0 0.61 0.61
var 3 38058097 0 0.23 0 0 0.25 0.63 0.62
var 3 38049974 0 0 0.11 0 0 0.63 0.63
var 3 38049550 0 0 0 0 0.25 0.65 0.65
var 3 38049969 0.46 0 0 0 0 0.70 0.70
var 3 38052906 0 0 0 0 0.25 0.73 0.73
rs150106099 0 0 0.11 0.27 0 0.73 0.73
var 3 38050628 0 0 0.23 0 0 0.73 0.73
var 3 38052809 0 0 0 0 0.25 0.73 0.73
var 3 38052791 0 0 0 0 0.25 0.73 0.73
var 3 38053061 0 0 0.56 0 0 0.74 0.74
var 3 38049998 0 0 0.11 0 0 0.77 0.77
var 3 38049604 0 0.23 0 0 0 0.77 0.77
var 3 38061700 0.23 0 0 0 0 0.77 0.77
var 3 38050089 0 0 0.11 0 0 0.78 0.78
var 3 38050002 0 0 0 0.27 0 0.78 0.78
var 3 38051526 0 0 0.11 0 0 0.78 0.78
var 3 38065835 0.23 0 0 0 0 0.83 0.83
rs146357368 0 0.11 0 0 0.25 0.83 0.83
var 3 38051447 0.69 0 0.11 0 0 0.83 0.83
var 3 38052933 0 0.910 0 0 0 0.85 0.85
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Table 3.11: Table 3.9 Continued. Meta-analysis p-value from TransMeta-
Rare on each of the variant that is included in PLCD1. The
variants are sorted with an increasing order of the p-values. The ‘Ge-
netic Similarity’ and ‘Indep’ categories refer to the two kernel choices we
provide for Ψ in Section 3.2.2.1.
SNP ID
MAF (×10−3) p-value
EA SA EUR HIS AA
Genetic Indep
Similarity
var 3 38049534 0 0.23 0 0 0 0.87 0.87
var 3 38049999 0 0.23 0 0 0 0.87 0.87
var 3 38051675 0 0 0 0.28 0 0.89 0.89
var 3 38051746 0 0 0.11 0 0 0.89 0.89
var 3 38049574 0 0 0 0 0.25 0.89 0.89
var 3 38049589 0.23 0 0 0 0 0.880 0.90
rs150791261 0 0 0 0.28 0.25 0.92 0.90
var 3 38052830 0.23 0 0 0.27 0 0.93 0.93
var 3 38053066 0 0 0 0.27 0.25 0.94 0.94
var 3 38053120 0 0 0 0 0.25 0.96 0.96
var 3 38052711 0.23 0 0 0 0.25 0.96 0.96
rs139755577 0 0.23 0 0 0 0.96 0.96
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CHAPTER IV
A Score Test for Jointly Testing the Fixed and
Random Effects in Generalized Linear Mixed
Models
Abstract
The framework of jointly testing the fixed and random effects has many appli-
cations in biomedical studies. One example is to use such tests for ascertaining
associations when there exists heterogeneity in meta-analyzing genome-wide associ-
ation studies (GWAS); another example is the nonparametric test of spline curves.
Although extensive research has been conducted on testing random effect terms only,
little work has been done for the joint test of fixed and random effects, especially for
non-Gaussian outcomes. Here, we propose a score test for the joint test in Generalized
Linear Mixed Models (GLMMs). Our method first re-parameterizes the fixed effects
terms as a product of a scale parameter and a vector of nuisance parameters. With
such re-parameterization, the joint test is equivalent to testing whether the scale pa-
rameter is zero. Since the nuisance parameters are hidden under the null hypothesis,
we propose using the supremum of score test statistics over the nuisance parameters.
We employ a resampling-based copula method to approximate the asymptotic null
distribution of the proposed score test statistic. We investigate performances of our
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method through simulation studies and demonstrate its application to the Michigan
Genomics Initiative (MGI) data.
Keywords: Joint testing; Fixed and Random effects; Generalized Linear Mixed
Model (GLMM); Score test.
4.1 Introduction
We consider the problem of testing fixed and random effects jointly in a general-
ized linear mixed model (GLMM). Such a unified testing framework is applicable in
many different scenarios, for example assessing the significance of a functional form
in a semi-parametric additive mixed model (SAMM); testing an unspecified varying
coefficient in a varying-coefficient model; and meta-analyzing heterogeneous effects
in genetic association studies. Testing the random effects involves constraints on the
variance component parameters, in which classical inference with a standard null dis-
tribution no longer holds, because those parameters under the null hypothesis lie on
the boundary of the maintained hypothesis (Lin, 1997; Andrews, 2001). As a result,
appropriate test statistics need to be developed, with carefully derived corresponding
null distributions.
For the linear mixed model (LMM), Self and Liang (1987), Liang and Self (1996)
and Stram and Lee (1994) showed that when the data can be divided into independent
and identically distributed (i.i.d) subvectors, the asymptotic null distribution for the
likelihood ratio test (LRT) of the one-sided variance component is a 50:50 mixture
of χ2 distributions. Crainiceanu and Ruppert (2004) and Crainiceanu et al. (2005)
considered the LRT for testing both the fixed and random effects jointly under a
more general situation, in which the data cannot be divided into i.i.d subvectors.
They showed that if the conventional 50:50 mixture of χ2 is used as the asymptotic
null distribution under such a situation, the LRT can yield very conservative results.
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In response, they derived the exact null distribution of the (restricted) LRT through
spectral decomposition.
For inference of the joint testing in an LMM with Gaussian outcomes and (mul-
tiple) nuisance variance components, an exact distribution of the (R)LRT through
spectral decomposition cannot be easily obtained. To address this problem, Greven
et al. (2008) and Scheipl et al. (2008) employed a pseudo-likelihood ratio test approach
to approximate the null distribution of the (R)LRT. First, they substituted the nui-
sance parameters by their consistent estimators to obtain the corresponding best
linear unbiased predictors (BLUPs). Next, they constructed the pseudo-outcomes by
subtracting the BLUPs from the responses, and applied the theories developed by
Crainiceanu and Ruppert (2004) to the reduced model to derive the null distribution
of the (R)LRT. Through extensive simulation studies, Scheipl et al. (2008) demon-
strated that the pseudo-likelihood approach yields controlled type I error rates and
equivalent power to bootstrap-based tests, but can be overly conservative when the
nuisance variance component is very small and the covariates of the random effects
are highly correlated. Wang and Chen (2012) proposed a generalized F-test to con-
duct the joint test under the setting of an LMM for Gaussian responses with multiple
nuisance variance components. Through spectral decomposition of the residual sum
of squares, a computationally efficient algorithm was derived to compute the null
distribution of the proposed test statistic.
Although the statistical literature thus far offers an array of methods for testing
the fixed and random effects jointly for Gaussian responses, corresponding methods
for non-Gaussian outcomes remain limited. In fact, to the best of our knowledge, no
systematic research exists addressing the joint testing problem with respect to both
the Gaussian and non-Gaussian outcomes under the presence of nuisance variance
components. To bridge this methodological gap, we propose a score test for the
joint testing problem in the GLMM with or without the presence of nuisance random
116
effects. Our score test approach can handle both the Gaussian and non-Gaussian
response types, and is asymptotically equivalent to the corresponding LRT.
The rest of this chapter is organized as follows: In Section 4.2, we introduce several
motivating examples of the joint testing problem followed by the general modeling
framework. In Section 4.3, we propose a score test for the joint testing problem. In
Section 4.4, we evaluate the performance of our proposed method and report results
from simulation studies under diverse scenarios. We apply our score test to the
Michigan Genomics Initiative (MGI) data in Section 4.5 and conclude this chapter
with a discussion in Section 4.6. Supplementary texts, tables and figures are presented
in Section 4.7.
4.2 Motivating Examples and Statistical Model
In this section, we first introduce several examples to illustrate the motivations
for our joint testing problem, and then we present the model for our proposed score
test.
4.2.1 Motivating Examples
Example 1 Testing the significance of a functional form in a SAMM.
Consider modeling clustered data in a SAMM:
g(µij) = f(tij) + s
T
ijα+ z
T
ijbi, i ∈ {1, . . . ,m}, j ∈ {1, . . . , ni}, (4.2.1)
where g(·) is a link function; µij is the conditional mean of the outcome with given
bi for the jth observation in the ith cluster; f(tij) is a smooth function relating
the scalar covariate tij to the outcome; sijs are vectors of fixed effects covariates
with coefficients α; zijs are vectors of random effects covariates with cluster specific
coefficients bi, bi ∼ N(0, D0(θ)) with nuisance variance component vector θ. Suppose
we are interested in testing the significance of the regression function f(t); that is,
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H0 : f(t) = 0.
Zhang and Lin (2003) proposed a mixed model representation of the smoothing
spline estimator for f(t). Under such a representation, the hth order smoothing
spline estimator for f(t) can be written as f = Xβ+Ua, where f is the vector of f(t)
evaluated at all observed tij values, i ∈ {1, . . . ,m}, j ∈ {1, . . . , ni}; β = (β1, . . . , βh)T
is a vector of coefficients associated with the polynomial bases; and a ∼ N(0, τΣ)
with a non-negative scalar τ and a given scaled covariance matrix Σ. Specifications
of X,β,U,Σ and τ can be found in Supplementary Materials Section 4.7.1. Now,
the SAMM (4.2.1) can be written as the following matrix form:
g(µ) = Xβ + Sα+ Ua + Zb, (4.2.2)
where µ = (µ11, . . . , µ1n1 , . . . , µm1, . . . , µmnm); S is the fixed effects design matrix
with the ith row si = (si1, . . . , sini)
T ; Z = diag(z1, . . . , zm) is the random effects
design matrix with zi = (zi1, . . . , zini)
T ; and b = (bT1 , . . . ,b
T
m)
T ∼ N(0,D(θ)) with
D(θ) = diag(D0(θ), . . . , D0(θ)).
Under the working GLMM (4.2.2), the significance of f(t) can be assessed through:
H0 : β = (β1, . . . ,βh)
T = 0, a = 0,
or equivalently, H0 : β = (β1, . . . ,βh)
T = 0, τ = 0.
Example 2 Testing an unspecified varying coefficient in a varying-coefficient model.
The varying coefficient model is a natural extension to the classical parametric re-
gression model, allowing the coefficient to vary smoothly over the covariates. Consider
the following model with a varying coefficient:
g(µij) = β(tij)gij + s
T
ijα+ z
T
ijbi, i ∈ {1, . . . ,m}, j ∈ {1, . . . , ni}, (4.2.3)
where β(tij) is a smooth functional coefficient describing the relationship between
the covariate gij and the outcome, and the remaining of the model specifications is
as defined in Equation (4.2.1). As in the parametric regression model, it is often of
interest to assess the effect of gij on yij, that is, to evaluate whether the coefficient
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β(·) = 0. Applying the working GLMM representation by Zhang and Lin (2003) again
to the functional coefficient β(·), we can reformulate the varying coefficient model
(4.2.3) to a mixed model as represented in Equation (4.2.2), in which we effectively
transform the question of evaluating the effect of β(·) into the joint testing of fixed
effects β = (β1, . . . ,βh)
T = 0 and random effects a = 0 (or equivalently τ = 0).
Example 3 Meta-analysis of heterogeneous effects in association studies.
Meta-analysis is a practical approach to aggregate studies that have already
been conducted in order to boost power to identify association signals. Let β̂ =
(β̂1, . . . , β̂n)
T be the effect-size estimates from n independent studies. Assume that
β̂|β ∼MVN(β,Σ), with the true effect size vector denoted as β = (β1, . . . , βn)T and
covariance matrix Σ. To account for the situation where effect sizes among the studies
are significantly different from each other, one modeling strategy is to allow the true
effects across studies to vary around the overall mean, i.e. βi = µ+ ηi, ηi ∼ N(0, τ),
where the fixed scalar µ represents the overall mean, and the random effect ηi de-
notes the study-specific deviation. Consequently, testing for the association signal is
equivalent to jointly testing the fixed effect µ and random effects ηis; that is, the null
hypothesis now becomes H0 : µ = 0, τ = 0 (Han and Eskin, 2011). Han and Es-
kin (2011) proposed using the likelihood ratio framework to conduct such hypothesis
testing and provided pre-tabulated p-values to accurately approximate the statistical
significance.
Example 4 Testing rare-variants associations in sequencing studies.
The recent advance in sequencing technologies have prompted significant research
on developing statistical methods for testing associations between rare variants and
complex traits. Lee et al. (2012) proposed a unified score test approach, named SKAT-
O, to optimally combine the burden test and the sequence kernel association test
(SKAT). The regression model for SKAT-O is g(µi) = X
T
i α+G
T
i β, where µi denotes
the mean of phenotype yi of the ith subject, Xi is a vector of adjusting covariates
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with coefficients α, and Gi is a genotype matrix with regression coefficients β for the
genetic variants. SKAT-O was originally constructed as a weighted average of SKAT
and the burden test, but an alternative view for deriving SKAT-O is to assume that
the regression coefficient βj of each genetic variant j independently follows βj =
ωjβc, βc ∼ N(µ, τ). Under such an alternative modeling strategy, the SKAT-O test
statistic can be derived for testing the null hypothesis H0 : µ = 0, τ = 0.
4.2.2 Statistical Model
The above motivating examples can all be viewed as applications of jointly testing
fixed and random effects in a GLMM with or without the presence of nuisance random
effects. In summary, the goal is to test H0 : β = 0, τ = 0 in the GLMM
g(µ) = Xβ + Sα+ Ua + Zb, a ∼ N(0, τΣ), b ∼ N(0,D(θ)); (4.2.4)
where g(·) is a known link function; µ = (µ11, . . . , µ1n1 , . . . , µm1, . . . , µmnm) is the
vectorized conditional mean µij of the outcome variable yij for the jth observation
in the ith cluster (i ∈ {1, . . . ,m}, j ∈ {1, . . . , ni}); S and Z are the design matrices
for the fixed and random effects, respectively, to be adjusted for; X and U are the
design matrices of interest for the fixed and random effects, respectively, to be tested
for; and τ,Σ, and D(θ) have the same specifications as in Section 4.2 Example
1. We assume that conditional on the unobserved random effects vectors a and
b, the outcome yijs are independent with means E(yij|a,b) = µij and variances
var(yij|a,b) = V (µij) = φζ−1ij ν(µij), where φ is a scale parameter, ζij is a prior
weight, and ν(·) is a variance function.
Although we construct our framework with respect to the longitudinal/clustered
data structure, the setting is also adaptive to cross sectional data under the null
hypothesis, in which case j = 1 for every i ∈ {1, . . . ,m} and Zb will be eliminated
from model (4.2.4).
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4.3 Methods
4.3.1 The Score Test for Gaussian Responses
We first consider the scenario where the responses yijs follow a Gaussian distri-
bution with the identity link function. In this case, the model can be written as
y = Xβ + Sα+ Ua + Zb + , (4.3.1)
with  ∼ N(0, σ2In) for n =
∑m
i=1 ni. Here we propose a score test for our goal
H0 : β = 0, a = 0. First we re-parameterize the fixed effects parameters of interest
with an unknown nuisance parameter vector γ scaled by the variance component τ ,
i.e. let β = τγ. Under this re-parameterization, jointly testing β = 0 and a = 0 is
equivalent to testing τ = 0 alone, and the mixed model becomes
y = τXγ + Sα+ Ua + Zb + . (4.3.2)
Let ν = (αT ,θT , σ2)T and V = ZD(θ)ZT + σ2In. Denote l(τ,ν,γ; y) the log-
likelihood function of model parameters (τ,ν,γ) under the LMM in Equation (4.3.2).
It can be easily shown that given γ, the score statistic for testing H0 : τ = 0 is
Uτ (νˆ;γ) =
∂l(τ,ν ,γ ;y)
∂τ
∣∣∣∣
τ=0,ν=νˆ
= −1
2
tr(Vˆ−1UΣUT ) + 1
2
yTPT Vˆ−1UΣUT Vˆ−1Py + yTPT Vˆ−1Xγ,
where P = In − S(ST Vˆ−1S)−1ST Vˆ−1, and Vˆ = ZD(θˆ)ZT + σˆ2In. Uτ (νˆ;γ) has the
nuisance parameter γ that is hidden under the null hypothesis. Several researchers
have proposed methods for removing the unidentifiable nuisance parameters under
the null. For example, Davies (1987) suggested using the supremum of a test statistic
over all possible values of the nuisance parameter space. Similarly, Zhu et al. (2006)
used the supremum of the score statistic to assess the homogeneity in a GLMM.
Inspired by these works, we propose using the following test statistic T , which is the
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supremum of the standardized score Uτ (νˆ;γ):
T = sup
γ
Uτ (νˆ;γ)− E(Uτ (νˆ;γ))√
VAR(Uτ (νˆ;γ))
, (4.3.3)
where E(Uτ (νˆ;γ)) =
1
2
tr(P˜UΣUT P˜Vˆ)− 1
2
tr(Vˆ−1UΣUT ) for a given value of γ,
and VAR(Uτ (νˆ;γ)) =
1
2
tr[(P˜UΣUT P˜Vˆ)2] + γTXT P˜VˆP˜Xγ,with P˜ = Vˆ−1P.
In Supplementary Materials Section 4.7.4, we show that the proposed test statistic
in Equation (4.3.3) is asymptotically equivalent to the LRT.
Since it is difficult to explore the entire space of γ to obtain the supremum in
Equation (4.3.3), an alternative way to solve this is to view the test statistic T as an
optimization problem:
Maximize Uτ (νˆ;γ)− E(Uτ (νˆ;γ)) subject to VAR(Uτ (νˆ;γ)) = c, where c is a constant.
From this perspective, Lagrange multipliers can be applied to solve for γ, which
results in
γ̂ = η(XT P˜X)−1XT P˜y, (4.3.4)
where η is a non-negative scalar representing the strength of γ (see Supplementary
Materials Section 4.7.2 for derivation details). Notice that all quantities in Equation
(4.3.4) are known except for η, thus, determining the vector γ is essentially reduced
to determining the scalar η. Plug in (4.3.4) to the score statistic Uτ (νˆ;γ), we now
obtain
Uτ (νˆ;γ = γ̂) = ηQ1 +Q2 − 1
2
tr(Vˆ−1UΣUT ) (4.3.5)
where Q1 = y
T P˜TX(XT P˜X)−1XT P˜y, Q2 =
1
2
yT P˜TUΣUT P˜y.
Plugging in (4.3.5) to (4.3.3), we obtain T = sup
η≥0
ηQ1+Q2−E{ηQ1+Q2}√
VAR({ηQ1+Q2})
, where the
supremum is reduced from searching the vector space of γ to the scalar space of η.
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Re-parameterize η as η = ρ(1− ρ)−1, 0 ≤ ρ ≤ 1, we then obtain:
T = sup
0≤ρ≤1
ρQ1 + (1− ρ)Q2 − Eρ√
Vρ
, with Eρ = ρ · rank(X) + 1− ρ
2
tr(UΣUT P˜), (4.3.6)
and Vρ = 2ρ
2 · rank(X) + (1− ρ)
2
2
tr[(UΣUT P˜)2] + 2ρ(1− ρ)tr[X(XT P˜X)−1XT P˜UΣUT P˜].
Equation (4.3.6) is the final form of our proposed score test for assessing H0 : β =
0, a = 0. It shows that T is a weighted sum of two quadratic forms, in which Q1
represents the fixed effects and Q2 represents the random effects. In fact, Q1 is a score
test statistic for β when τ = 0, and Q2 is a score test statistic for τ when β = 0.
The value of T can now be obtained by a simple grid search across a range of ρs: set
a grid of B points as 0 = ρ1 ≤ · · · ≤ ρB = 1, then an approximated value of the test
statistic can be computed as
Tˆ = max
ρ=ρ1,...ρB
Sρ − Eρ√
Vρ
, where Sρ = ρQ1 + (1− ρ)Q2. (4.3.7)
We observe that a dense grid of ρ does not necessarily improve power over a coarse
grid. Therefore, we suggest using ρ = (0, 0.25, 0.5, 0.75, 1) for simulations and real
data analysis.
4.3.2 The Score Test for Non-Gaussian Responses
In this section, we extend the score test proposed in Section 4.3.1 for non-Gaussian
responses. For general response types, we assume that conditional on (xij, sij,uij, zij)
and (ai,bi), yij follows a distribution in the exponential family, and we consider
any canonical link function. As in the Gaussian responses case, we apply the re-
parameterization β = τγ. Let ∆ and W denote the n×n diagonal matrix which has
elements
δij = g
′(µij), wij =
[
V (µi) {g′(µij)}2
]−1
,
respectively, where µij = E(yij|ai,bi) and g(µij) = τxTijγ + sTijα + uTijai + zTijbi.
Following (Zhang and Lin, 2003), it can be shown that given the nuisance parameter
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vector γ, the score statistic of τ evaluated at τ = 0 is:
Uτ ≈ 1
2
E{(y − µb)T∆WUΣUTW∆(y − µb)− tr(WUΣUT )− (y − µb)T∆WXγ}
(4.3.8)
where ν = (αT ,θT )T and µb satisfies the null GLMM
g(µb) = Sα+ Zb. (4.3.9)
Denote the working vector as Y = Sα+ ∆(y−µ) under the null GLMM (4.3.9).
One can show that using the Laplace method, the score statistic in (4.3.8) can be
approximated as
Uτ ≈ −1
2
tr(P˜UΣUT ) +
1
2
(Y − Sα̂)T V̂−1UΣUT V̂−1(Y − Sα̂) + (Y − Sα̂)T V̂−1Xγ
(4.3.10)
where α̂ is the BLUP-type estimate of α; θ̂ is the REML estimate of θ; V̂ =
ZD(θ̂)ZT + Ŵ−1; and P˜ = V̂−1P = V̂−1 − V̂−1S(ST V̂−1S)−1ST V̂−1, as defined
in the Gaussian responses case.
Notice that equation (4.3.10) corresponds to the score statistic of τ evaluated at
τ = 0 under the working linear mixed model Y = τXβ + Sα + Ua + Zb + , with
a ∼ N(0, τΣ),b ∼ N(0,D(θ)), and  ∼ N(0,W−1). Consequently, by replacing y
in Section 4.3.1 with the working vector Y, we can apply the results in Section 4.3.1
to carry out the score test for non-Gaussian responses.
4.3.3 Assess Statistical Significance of the Test
In this section, we outline a resampling-based copula method (Xianglin Li, Xian-
glin Li) to approximate the asymptotic null distribution of the proposed score test.
Denote t as the observed value of the score test Tˆ , and the statistical significance for
t can be obtained from
P (Tˆ ≥ t) = P ( max
ρ=ρ1,...ρB
Sρ − Eρ√
Vρ
≥ t)
= 1− P (Fρ1(Sρ1) ≤ Fρ1(
√
Vρ1 · t+ Eρ1), . . . , FρB(SρB) ≤ FρB(
√
VρB · t+ EρB)),
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where Fρi(·) is the cumulative distribution function of Sρi . For any given ρ, it can
be shown that the marginal distribution of Sρ asymptotically follows a mixture of
chi-square distribution
∑
λlχ
2
l,1, where λls are the non-zero eigenvalues of
ρPˆV−
1
2X(XT P˜X)−1XTV−
1
2 Pˆ +
1
2
(1− ρ)PˆTV− 12UΣUTV− 12 Pˆ,
with Pˆ = I − V− 12S(STV−1S)−1STV− 12 ; and χ2l,1s are chi-square distributions with
one degree of freedom (see details in Supplementary Materials Section 4.7.3). As a
result, the value of Fρ(
√
Vρ · t + Eρ) can be easily obtained for any given ρ value by
using Davies’ method (Davies, 1980) to invert a characteristic function. We also notice
that under the null hypothesis, V−
1
2y approximately follows a multivariate normal
distribution N(0, In), where In is an identity matrix with dimension n×n. Therefore,
we propose the following resampling-based copula algorithm to approximate the null
joint distribution of (Fρ1(Sρ1), Fρ2(Sρ2), . . . , FρB(SρB)):
Step 1: Generate n0 samples, say u, from the standard normal distribution N(0, In).
We use n0 = 500 in our simulation studies and data application.
Step 2: For each ρ ∈ {ρ1, . . . , ρB}, calculate the null scores as
S0ρ = u
T · [ρPˆV− 12X(XT P˜X)−1XTV− 12 Pˆ + 1
2
(1− ρ)PˆTV− 12UΣUTV− 12 Pˆ] · u.
Step 3: Calculate the correlation matrix ΣB×B of the generated null score S0ρs among
any pair of ρ values, where B is the length of the (ρ1, . . . , ρB) grid.
Step 4: With the estimated null correlation structure ΣB×B, we next use the Gaussian
copula to approximate the null joint distribution of (Fρ1(Sρ1), Fρ2(Sρ2), . . . , FρB(SρB)),
which yields
P (Tˆ ≥ t) = 1−ΦΣB×B(Φ−1(1−Fρ1(
√
Vρ1 ·t+Eρ1)), . . . ,Φ−1(1−FρB(
√
VρB ·t+EρB))),
where 1 − Fρ(
√
Vρ · t + Eρ) is the p-value of Sρ obtained from Davies’ method, for
any given ρ value; Φ−1 is the inverse cumulative distribution function of a standard
normal (consequently, Φ−1(1−Fρ(
√
Vρ ·t+Eρ)) is the normal z value from the p-value
of Sρ); and ΦΣB×B is the joint cumulative distribution of a multivariate normal with
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zero mean vector and correlation matrix equal to ΣB×B.
It should be noted that when calculating the correlation matrix ΣB×B, Pearson’s
correlation coefficient can yield unreliable estimates due to its strong dependent on the
normality and homoscedasticity assumptions (Hauke and Kossowski, 2011). Instead,
we use Spearman’s correlation, a non-parametric version of the Pearson’s correlation
based on ranks of the random variables.
4.4 Simulation Studies
In this section, we conducted a series of simulation studies to evaluate the size
and power of our method with different types of responses under diverse scenarios.
We compared the power of our score test with other existing approaches for Gaus-
sian outcomes only, since to our knowledge, no solutions other than our method are
available for non-Gaussian outcomes.
4.4.1 Scenario 1 - Non-parametric Regression Tests in Cross Sectional
Studies
One key assumption in linear models is that the conditional mean of the response
variable depends on the covariates parametrically. For data with complex covariate
effects, such strong parametric assumption may not be appropriate. Thus, it is of
substantial interest to test whether a predictor is related to the outcome in a flexible
nonparametric fashion. We first performed such tests in cross sectional studies with
no nuisance random effects under the null. Consider the regression equation g(µi) =
fd(ti), where the link function g(·) is the identity function for Gaussian responses and
logit function for binary/binomial responses, fd(·) is an arbitrary smooth function.
Our goal was to test whether fd(·) is a constant value, i.e. whether H0 : fd(t) is a
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constant function in t. We considered two different forms of fd(·) :
(a) fd(t) = 0.5 + 0.25 · d · t · exp(2− 2 · t), d ∈ {0, 0.75, 1, 1.25}(4.4.1)
and (b) fd(t) = 1 + 0.05 · d · t+ 0.1 · cos(d · pi · t), d ∈ {0, 2, 2.5, 3}.
The functions fd(t) against t for different values of d were plotted in Figure 4.1, in
which the parameter d controls the level of the effect size: d = 0 corresponds to
the null hypothesis that fd(t) is a constant function in t; when d 6= 0, the larger d
becomes, the further away fd(t) deviates from being constant in t.
Figure 4.1: Functions fd(t) used in the simulation studies for the non-
parametric regression tests. The upper and lower panel correspond
to the first and second smooth functions defined in Equation (4.4.1) re-
spectively.
Each simulated dataset was composed of sample size n = 500, with one hundred
equally spaced points in the quintuple for ti in [0,2]. For Gaussian responses, the
residual term i was generated from a N(0, 0.65
2) . We adapted Zhang and Lin
(2003)’s mixed-model formulation of the natural smoothing spline estimator for the
nonparametric function fd(·). To ensure the desired flexibility, we considered different
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orders for the smoothing spline, namely, the linear, quadratic and cubic smoothing
splines. As discussed in Example 1 of Section 4.2.1, this smoothing spline estimator of
fd(·) reformulates the regression model into a GLMM. Consequently, testing whether
fd(·) is a constant value is equivalent to jointly testing the fixed and random effects
in the mixed model.
We first evaluated the empirical type I error rate of our proposed score test at
the 5% nominal level. Results of the obtained empirical type I error rates based
on 5000 simulations were presented in Table 4.1. Across various smoothing spline
representations for fd(·), our proposed score test behaved satisfactorily for both the
Gaussian and non-Gaussian responses. The likelihood ratio test with the exact finite
sample distribution developed by Crainiceanu and Ruppert (2004) also had controlled
nominal levels for Gaussian outcomes. As expected, approximating the asymptotic
distribution of the LRT using the 50:50 mixture χ2 distribution resulted in conserva-
tive type I error rates.
Table 4.1: Empirical sizes of the constancy test for Gaussian and non-
Gaussian responses based on 5000 simulation runs for non-
parametric regression test in cross sectional studies. LRT refers to
the likelihood ratio test with exact finite sample distribution developed by
Crainiceanu and Ruppert (2004); Mixture χ2 refers to the likelihood ratio
test with an approximated 50:50 mixture χ2 asymptotic distribution.
Data Type Test Size
Linear Quadratic Cubic
ScoreTest 0.052 0.051 0.050
Gaussian LRT 0.049 0.052 0.051
Mixture χ2 0.032 0.034 0.036
Binary ScoreTest 0.051 0.049 0.051
Binomial (N=6) ScoreTest 0.052 0.048 0.051
To compare the power of the various tests, we then simulated data under the
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alternative hypothesis with positive values for d. The barplots in Figure 4.2 sum-
marized the power comparisons for Gaussian responses. From the barplot, it can be
seen that for both smooth functions in (4.4.1), the power of our score test was very
similar or slightly better than that of the LRT by Crainiceanu and Ruppert (2004).
As expected, the power of the 50:50 mixture χ2 approach had the lowest power. The
power of all the tests increased as the effect size measure, d, increases. When fixing
d, we observed different trends of the power across different orders of the spline esti-
mator of fd(·). With a fixed d value for the smooth function (a) in Equation (4.4.1),
we observed that the power for all tests tends to increase as the order of splines in-
creases. In contrast, for the functional form (b) in Equation (4.4.1), we observed that
the power tends to decrease as the order of splines increases. The diverging results
may look contradictory at first glance, but are justifiable. For functional (a) (Fig-
ure 4.1), the addition of quadratic and cubic spline terms to the linear spline helped
better approximate the shape of the functional; as a result, inclusion of higher orders
of spline bases contributed to power gain. In contrast, for functional (b), although
the linear spline basis was capable of capturing the linear trend in the functional, the
quadratic and cubic spline bases did not contribute to approximating the periodic
cosine component in the functional; in this case, incorporation of the higher order
bases resulted in lower power than using the linear spline basis alone.
In Figure 4.3, we display the results of the power simulation for our score test
with respect to binary and binomial responses.
4.4.2 Scenario 2 - Non-parametric Regression Tests in Longitudinal
Studies
The next scenario we considered is testing the significance of a regression function
in longitudinal studies with a nuisance random effect under the null hypothesis. The
regression equation was then modeled as g(µij) = fd(tij) + bi, where the link function
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(a) Cross sectional studies, Exponential functional
(b) Cross sectional studies, Cosine functional
Figure 4.2: Power of the constancy test for Gaussian responses based on 5000
simulations in cross sectional studies. The upper and lower panel corre-
spond to the functional form (a), (b) defined in Equation (4.4.1), respectively.
LRT refers to the likelihood ratio test with the exact finite sample distribu-
tion developed by Crainiceanu and Ruppert (2004); Mixture χ2 refers to the
likelihood ratio test with an approximated 50:50 mixture χ2 asymptotic distri-
bution. 130
Figure 4.3: Power of the constancy test for binary and binomial responses
based on 5000 simulations in cross sectional studies. The left and
right panel correspond to the functional form (a), (b) defined in Equation
(4.4.1) respectively.
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g(·) and regression function fd(·) were the same as defined in Section 4.4.1. Each
simulated dataset still contained 500 observations, but with 100 clusters of size ni = 5.
We generated equally spaced values for t in [0,2] through tij = [trun{(i+ 4)/5}/50] +
0.4(j − 1) (i = 1, . . . , 100 and j = 1, . . . , 5), where trun(·) denoted a truncation
operator with trunc(x) = bxc for x ∈ R+, and the random intercept bi followed
N(0, 0.52).
To evaluate the empirical type I error rate and power of our proposed score test,
we simulated 5000 datasets. Results of the empirical type I error rate at the 5%
nominal level were summarized in Table 4.2. Similar to the cross sectional setting in
Scenario 1, our proposed score test yielded well controlled type I error rates for both
Gaussian and non-Gaussian responses under this longitudinal setting. The pseudo
likelihood ratio test approach developed by Greven et al. (2008) and generalized F-
test proposed by Wang and Chen (2012) also behaved satisfactorily for Gaussian
outcomes. Unsurprisingly, the approximated 50:50 mixture χ2 distribution for the
LRT still yielded a conservative type I error rate.
The barplots in Figure 4.4 summarized the power comparisons for Gaussian re-
sponses. Similar to the cross sectional setting in Scenario 1, the power of our score
test was very similar or slightly better than the pseudo-LRT by Greven et al. (2008)
and the generalized F-test by Wang and Chen (2012), with the power of the 50:50
mixture χ2 approach yielding the least powerful results among all. As the effect size
measure d increased, the power of all tests increased as expected. For a fixed d value,
regardless of the test used, the power improved as the spline representation more
closely approximates the underlying functional form. Results of the power simulation
for our score test with respect to binary and binomial responses were presented in
Figure 4.5. The power of the score test increased quickly as we increase the binomial
denominator from 1 (i.e. binary responses) to 6.
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(a) Longitudinal studies, Exponential functional
(b) Longitudinal studies, Cosine functional
Figure 4.4: Power of the constancy test for Gaussian responses based on 5000
simulations in longitudinal studies. The upper and lower panel correspond
to the functional form (a), (b) defined in Equation (4.4.1) respectively. F-test
refers to the generalized F-test proposed by Wang and Chen (2012); Pseudo-
LRT refers to the pseudo likelihood ratio test approach developed by Greven
et al. (2008); Mixture χ2refers to the likelihood ratio test with an approximated
50:50 mixture χ2 asymptotic distribution.133
Figure 4.5: Power of the constancy test for Binary and Binomial responses
based on 5000 simulations in longitudinal studies. The left and
right panel correspond to the functional form (a), (b) defined in Equation
(4.4.1) respectively.
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Table 4.2: Empirical sizes of the constancy test for Gaussian and non-
Gaussian responses based on 5000 simulation runs for non-
parametric regression tests in longitudinal studies. Pseudo-LRT
refers to the pseudo likelihood ratio test approach developed by Greven
et al. (2008); F-test refers to the generalized F-test proposed by Wang
and Chen (2012); Mixture χ2refers to the likelihood ratio test with an
approximated 50:50 mixture χ2 asymptotic distribution.
Data Type Test Size
Linear Quadratic Cubic
ScoreTest 0.049 0.051 0.050
Gaussian F-test 0.048 0.051 0.052
pseudo-LRT 0.049 0.051 0.051
Mixture χ2 0.033 0.036 0.038
Binary ScoreTest 0.047 0.046 0.048
Binomial (N=6) ScoreTest 0.051 0.052 0.051
4.4.3 Scenario 3 - Meta-analysis on Heterogeneous Effect-sizes
As outlined in Example 3 of Section 4.2.1, another application of the joint testing
framework is to assess the heterogeneous genetic effects in meta-analysis. We carried
out simulations to evaluate the performance of our proposed score test to existing
meta-analysis approaches. The power comparison showed that under the existence
of between-study heterogeneity, our method achieved very similar power to the LRT-
based approach, which was developed to explicitly model the heterogeneity (Han
and Eskin, 2011). Details of the simulation and comparison result can be found in
Supplementary Materials Section 4.7.5.1.
4.5 Data Application
Genome-wide association studies (GWAS) have identified more than 200 genetic
variants that influence blood lipid levels, such as the Low Density Lipoprotein Choles-
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terol (LDL-C) (Teslovich et al., 2010; Waterworth et al., 2010; Willer et al., 2013;
Surakka et al., 2015; Spracklen et al., 2017). For these variants, an important ques-
tion is whether their genetic effects vary with age. Knowing whether the variants
act during very early life, childhood or in adulthood would improve our understand-
ing of the genetics of lipid markers of cardiovascular disease. In addition, it would
help explain the proportion of lipid heritability that are attributable to gene-age in-
teraction. Previous evidence has shown that certain polymorphisms on LDL-C, a
quantitative blood lipid marker, is age-dependent (Giolo et al., 2010; Shirts et al.,
2011; Dumitrescu et al., 2011; Simino et al., 2014).
To illustrate performance of the proposed method in real data, we use the Michi-
gan Genomics Initiative (MGI) data to investigate whether genetic effects to LDL-C
can be modified by age. Launched in 2012, MGI was a biorepository effort to create
a longitudinal cohort of participants in Michigan Medicine. It enrolled participants
undergoing anesthesia prior to a surgery or diagnostic procedure, creating a patient
community with genome-wide data, electronic health information, and permission
for follow-up and re-contact in future studies. To date, more than 50,000 partici-
pants have been recruited through Michigan Medicine health system while awaiting
diagnostic or interventional procedures either during a preoperative visit prior to
the procedure or on the day of procedure that required anesthesia. Opt-in written
informed consent was obtained. In addition to coded biosamples and protected se-
cure health information, participants understood that all Electronic Health Records
(EHRs), claims, and national data sources linkable to the participant may be incor-
porated into the MGI databank. Each participant donated a blood sample for genetic
analysis, underwent baseline vital signs and a comprehensive history and physical, and
completed validated self-report measures of pain, mood and function, including NIH
Patient Reported Outcomes Measurement Information System (PROMIS) measures.
Data were collected according to Declaration of Helsinki principles. Study partici-
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pants provided written informed consent, and protocols were reviewed and approved
by local ethics committees (IRB ID HUM00099605) (Fritsche et al., 2018).
MGI genotyped the participants using the Illumina Human CoreExome v.12.1 ar-
ray, which is a combined genotyping plus exome array of > 500,000 targeted SNPs.
The phased MGI genotypes (SHAPEIT2 on autosomal chromosomes and Eagle2 on
chromosome X) were then imputed using Minimac3 with the Haplotype Reference
Consortium (chromosomes 1-22: HRC release; chromosome X: HRC release 1.1).
After excluding variants with low imputation quality (R2 < 0.3), over 39 million
quality-imputed genetic markers were obtained from the imputation. Since the im-
putation quality is low for very rare variants, we further filtered out the imputed
variants with MAF < 0.001, which resulted in around 13 million variants in our data
analysis. For methodology illustration purpose, we retrieved the first LDL-C lab mea-
surement from participants’ longitudinal EHRs and used it as the response variable.
Genotyped samples with missing LDL-C information are excluded from the analysis,
which results in 11,016 subjects with complete LDL-C and genotype information.
For those 11,016 unrelated European participants, we first performed the main
effect association analysis to relate the genetic variants to LDL-C. We assumed an
additive genetic model for the variant and applied an inverse normal transformation
to LDL-C, since the transformed variable more closely approximated the Gaussian
distribution. Specifically, we used the following linear regression model to conduct
the main effect association analysis:
yi = S
T
i α+Giβ0 + i, for i = 1, 2, . . . , 11016, (4.5.1)
where yi is the inverse-normal-transformed LDL-C level for the ith subject; Si is a
vector of adjusting covariates including gender, age, age-squared and four principal
components; Gi denotes the number of minor alleles (Gi = 0, 1, 2) of the variant to be
tested. Among the 13 million variants tested for main genetic effect association, four
reached the genome-wide significance level (i.e. p-value of β0 is less than 5×10−8), and
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three of those four SNPs have been identified by previous GWAS for their associations
with LDL-C (Willer et al., 2013; Surakka et al., 2015; Spracklen et al., 2017). Table 4.3
listed the genetic information and association signals for those significant SNPs.
Table 4.3: SNPs with significant main effect associations with LDL-C in
the MGI data. The main p-value refers to the hypothesis testing for
H0 : β0 = 0 in Equation (4.5.1); the interaction p-value refers to the
hypothesis testing for H0 : β(age) = 0 in Equation (4.5.2); and the optimal
ρ is the ρ value which yields the maximum score test value for our proposed
test statistic in Section 4.3, Equation (4.3.6).
dbSNP ID Position Allele MAF Nearest Main Interaction Optimal
Gene P-Value P-Value ρ
rs646776 1: 109,818,530 C > T 0.19 CELSR2 7.823× 10−12 0.054 1
rs76681713 16: 72,333,346 T > C 0.13 PMFBP1 1.771× 10−9 0.401 0
rs6511720 19: 11,202,306 G > T 0.1 LDLR 2.124× 10−9 0.792 0
rs7412 19: 45,412,079 C > T 0.062 APOE 2.617× 10−45 3.642× 10−4 0.75
Among those 4 significant SNPs, we further incorporated age into a varying co-
efficient model (4.5.2) to investigate the possible age-dependent genetic effects on
LDL-C. Specifically,
yi = S
T
i α +Giβ0 + β(agei)Gi + i fori = 1, 2, . . . , 11016, (4.5.2)
where β(agei) is an unspecified varying coefficient with respect to age. We note that
here the functional β(age) should not include an intercept term, since the main genetic
effect has already been accounted for in the Giβ0 part of the model. Testing for the
age-dependent genetic effect on LDL-C is equivalent to assessing H0 : β(age) = 0 in
Equation (4.5.2). We modeled the unspecified functional β(age) using a quadratic
smoothing spline estimator; the technique of mixed model representation for the
smoothing spline estimator effectively transformed the hypothesis testing of H0 :
β(age) = 0 into the problem of joint testing the fixed and random effects as outlined
in Section 4.2.1, Example 2.
Then we employed our proposed score test to assess for H0 : β(age) = 0 under
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its LMM representation. After using Bonferroni correction for multiple testing, the
resulting p-values suggested that the genetic effects for rs7412 appear to vary with
respect to age (Table 4.3). For rs7412, we also illustrated in Figure 4.6 the effect
of age on the LDL-C, with respect to different minor allele count values for this
SNPs. Regression curves were imposed to summarize the effect of age on the trait.
From Figure 4.6, it can observed that the variant has a stronger effect on LDL-C
in adulthood (before age 55), and that the effect tends to attenuate in older adults
(after age 55).
Figure 4.6: Scatter plot of inverse-normal-transformed LDL-C v.s. age from
the MGI data. Values of inverse-normal-transformed LDL-C measure-
ments plotted as a function of age in years. Separate regression curves are
fitted to the data for the number of minor alleles (G = 0 in blue line v.s.
G = 1 or 2 in red line), which suggests stronger genetic effect on LDL-C
in adulthood (before age 55), and attenuated effect in older adults (after
age 55).
This data application demonstrates that our proposed method can be a useful tool
for obtaining empirical evidence of whether the genetic effect on a phenotype is being
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modified by risk factors such as age. In addition, it confirms earlier findings that
the genotype-associated differences in LDL cholesterol can be age-dependent (Giolo
et al., 2010; Shirts et al., 2011; Dumitrescu et al., 2011; Simino et al., 2014)
4.6 Discussions
In this chapter, we developed a score test for jointly testing the fixed and random
effects in a GLMM. We address the following four issues in the construction of the
score test statistic: (a) a convenient re-parameterization which reformulates the joint
testing problem into testing the variance component alone; (b) the conversion of non-
Gaussian outcomes into pseudo-Gaussian outcomes through Laplace approximation;
(c) the asymptotic equivalence of the score test to the LRT for joint testing; (d) the
p-value calculation from the asymptotic distribution of the score test. An R package
‘JointScoreTest’ has been developed to implement our proposed method and can be
downloaded at the website https://sites.google.com/a/umich.edu/leeshawn/software.
The key idea is to re-parameterize the fixed effects parameter into the product
of the random effects variance component and a nuisance parameter vector; such
re-parameterization reformulates the null hypothesis into testing the variance com-
ponent alone. The nuisance parameter is unidentifiable under the null, to remove the
unknown nuisance parameter, we propose a test using the supremum of the standard-
ized score statistic over the unknown parameter space. By applying the method of
Lagrange multipliers, we reduce the test statistic from searching over the entire un-
constrained vector space into a constrained scalar space, which makes the test statistic
easily obtainable. For non-Gaussian responses, to avoid the high-dimensional inte-
gration, we employ the Laplace approximation to reform the outcomes into pseudo-
Gaussian responses and re-apply the Gaussian responses derivations to construct the
test statistic accordingly. Besides its capability of handling both Gaussian and non-
Gaussian responses, we show that the asymptotic null distribution of our score test
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is equivalent to the LRT.
Unlike the LRT and F-test, which require calculating the maximum likelihood
estimator under both the null and alternative hypothesis, the score test only requires
calculating the maximum likelihood under the null, which makes it computationally
less expensive given many tests. Our proposed score test does not have a standard
asymptotic distribution, we hence approximate the asymptotic null distribution using
a computationally efficient resampling-based copula method. The copula approxima-
tion provides scalable computing time, which makes it feasible to conduct the joint
testing in large scale experiments. In our power simulations, to run 5000 iterations,
our score test takes 1.11 hours on average on a Linux cluster node with 2.80 GHz
CPU.
We suggest using a coarse grid ρ = (0, 0.25, 0.5, 0.75, 1) for simulations and real
data analysis. In fact, in the three simulation scenarios, we also use a dense grid of ρ
with 50 equally spaced points from 0 to 1, and observe that the dense grid does not
meaningfully increase power (data not shown).
In both the simulation studies and data application, we reformulate the problem
into the joint testing framework by representing the SAMM and varying-coefficient
model as a working GLMM. Although we focus on using the penalized natural smooth-
ing spline estimator to represent the SAMM and varying-coefficient model, the results
are not limited to such a representation. Other types of basis functions such as trun-
cated polynomials and B-splines can also be employed. When assessing whether a
functional form holds constant value or not, we observe some power differences de-
pending on the order of the natural spline estimator for the nonparametric function.
In practice, when the true underlying model is unknown, our method does not provide
a guideline on how to choose the appropriate order of natural splines to avoid power
loss. We have left this for future research.
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4.7 Supplementary Materials
4.7.1 Mixed-effect Representation of the Natural Spline Estimator for
the Non-parametric Function
To model data with clustered structures, Zhang and Lin (2003) proposed using
the semiparametric additive mixed model (SAMM), which allows a predictor to be
associated with the outcome through a nonparametric function. In this section, we
summarize how to construct the mixed-effect representation of the natural spline
estimator for the nonparametric function.
Denote yij as the response variable for the jth observation in the ith cluster; sij’s
as the p × 1 vectors of fixed effects covariates with coefficients α; zij’s as the q × 1
vectors of random effects covaraites with cluster specific coefficients bi; and bi ∼
N(0, D0(θ)) with nuisance variance component vector θ. Assume that conditional
on the unobserved random effects vectors bi, the outcome yijs are independent with
means E(yij|bi) = µij and variances var(yij|bi) = V (µij) = φζ−1ij ν(µij), where φ is
a scale parameter, ζij is a prior weight and ν(·) is a variance function. Under those
assumptions, the conditional mean µij in a SAMM takes the form
g(µij) = f(tij) + s
T
ijα+ z
T
ijbi, (4.7.1)
where g(·) is a known link function, and f(t) is an arbitrary smooth function relating
the scalar covariate t to the outcome. In addition, it is assumed that there exists
a positive integer h such that f(t) has absolutely continuous derivatives up to the
order h − 1, and the area under the absolute function of f(t)’s hth order derivative
is bounded.
It can be shown that f(t) can be estimated as a natural spline of order h. Here, we
consider the smoothing spline representation of the natural spline estimator. Without
lost of generality, we assume that tijs are all bounded in [0, 1], and there are r distinct
values of tij with 0 < t
0
1 < . . . < t
0
r < 1. Denote {φk(t) = tk−1/(k−1)!}hk=1 as the basis
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for the polynomial space of order h−1, and R(t, t0l ) =
∫ 1
0
(t0l −u)h−1+ (t−u)h−1+ du/[(h−
1)!]2, where (t−u)+ = t−u if t ≥ u and 0 otherwise. The hth order smoothing spline
estimator for f(t) can be written as
f(t) =
h∑
k=1
βkφk(t) +
r∑
l=1
alR(t, t
0
l ), (4.7.2)
or equivalently in the matrix form
f(t) = Xβ + Ua, (4.7.3)
where t = (t11, . . . , t1n1 , . . . , tm1, . . . , tmnm)
T , β = (β1, . . . , βh)
T , a = (a1, . . . , ar)
T ∼
N(0, τΣ), and X = NT, U = NΣ−1 with
N =

I(t11 = t
0
1) I(t11 = t
0
2) · · · I(t11 = t0r)
...
...
...
...
I(t1n1 = t
0
1) I(t1n1 = t
0
2) · · · I(t1n1 = t0r)
...
...
...
...
I(tmn1 = t
0
1) I(tmn1 = t
0
2) · · · I(tmn1 = t0r)
...
...
...
...
I(tmnm = t
0
1) I(tmnm = t
0
2) · · · I(tmnm = t0r)

n×r
,
T =

φ1(t
0
1) φ2(t
0
1) · · · φh(t01)
φ1(t
0
2) φ2(t
0
2) · · · φh(t02)
...
...
...
...
φ1(t
0
r) φ2(t
0
r) · · · φh(t0r)

r×r
, Σ =

R(t01, t
0
1) R(t
0
1, t
0
2) · · · R(t01, t0r)
R(t02, t
0
1) R(t
0
2, t
0
2) · · · R(t02, t0r)
...
...
...
...
R(t0r, t
0
1) R(t
0
r, t
0
2) · · · R(t0r, t0r)

r×r
.
Under the mixed-effect representation of f(t), the SAMM in (4.7.1) can be repre-
sented in the following working generalized linear mixed model (GLMM):
g(µ) = Xβ + Sα+ Ua + Zb, (4.7.4)
a ∼ N(0, τΣ), b ∼ N(0,D(θ)),
where µ = (µ11, . . . , µ1n1 , . . . , µm1, . . . , µmnm) is the vectorized conditional mean val-
ues; in which µij represents the conditional mean value for the outcome variable
yij (i ∈ {1, . . . ,m}, j ∈ {1, . . . , ni}, n =
∑m
i=1 ni); S is the fixed effects design matrix
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with the ith row block being si = (si1, . . . , sini)
T ; and Z = diag{z1, . . . , zm} is the ran-
dom effects design matrix with zi = (zi1, . . . , zini)
T , b = (bT1 , . . . ,b
T
m)
T ∼ N(0,D(θ)),
and D(θ) = diag(D0(θ), . . . , D0(θ)).
4.7.2 Using Lagrange Multipliers to Determine the Form of γ
The proposed test statistic,
T = sup
γ
Uτ (νˆ)− E(Uτ (νˆ))√
V AR(Uτ (νˆ))
= sup
γ
−12 tr[Vˆ−1PUΣUT ] + yTPT Vˆ−1UΣUT + yTPT Vˆ−1Xγ√
1
2 tr[(Vˆ
−1PUΣU)2] + γTXT P˜VˆP˜Xγ
, (4.7.5)
requires searching over the entire space of γ in order to obtain the supremum. The
searching would be very challenging when the dimension of γ is high. An alternative
way to solve this problem is to view the test as follows:
Maximize Uτ (νˆ)− E(Uτ (νˆ)) subject to V AR(Uτ (νˆ)) = c, where c is a constant.
From this point of view, Lagrange multipliers can be applied to find the form of γ:
Let ∆(γ, λ) = −1
2
tr[Vˆ−1PUΣUT ] + yTPT Vˆ−1UΣUT + yTPT Vˆ−1Xγ
− λ{1
2
tr[(Vˆ−1PUΣU)2] + γTXT P˜VˆP˜Xγ − c}
⇒ ∂∆
∂γ
= yTPT Vˆ−1X− 2λγTXT P˜VˆP˜X = 0
and
∂∆
∂γ
= −{1
2
tr[(Vˆ−1PUΣU)2] + γTXT P˜VˆP˜Xγ − c} = 0
⇒ γ = η(XT P˜X)−1XT P˜y,
where η is a non-negative scalar representing the strength of γ.
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4.7.3 Asymptotic Distribution of Sρ
Recall, for a given ρ, Sρ can be written as:
Sρ = ρy
T P˜TX(XT P˜X)−1XT P˜y +
1− ρ
2
yT P˜TUΣUT P˜y
= yT P˜T {ρX(XT P˜X)−1XT + 1− ρ
2
UΣUT }P˜y,
where P˜ = V−
1
2 PˆV−
1
2 with Pˆ = I−V− 12 S(STV−1S)−1STV− 12 .
Thus, Sρ = y
T (V−
1
2 PˆV−
1
2 )T {ρX(XT P˜X)−1XT + 1− ρ
2
UΣUT }(V− 12 PˆV− 12 )y
= (V−
1
2 y)T {ρPˆV− 12 X(XT P˜X)−1XTV− 12 Pˆ + 1− ρ
2
PˆV−
1
2 UΣUTV−
1
2 Pˆ}(V− 12 y).
Under the null hypothesis, V−
1
2y approximately follows a multivariate normal distri-
bution MVN(0, In), where In is an identity matrix with dimension n. Consequently,
Sρ asymptotically follows a mixture of chi-square distribution
∑
λlχ
2
l,1, where χ
2
l,1s
are chi-square distributions with one degree of freedom; and λls are the non-zero
eigenvalues of ρPˆV−
1
2X(XT P˜X)−1XTV−
1
2 Pˆ + 1
2
(1− ρ)PˆTV− 12UΣUTV− 12 Pˆ.
4.7.4 Asymptotic Equivalency of the Score Test to the Likelihood Ratio
Test
In this section, we adopt the asymptotic properties from Zhu and Zhang (2006)
to establish the asymptotic equivalence of our proposed score test statistic to the
corresponding LRT for the joint testing of fixed and random effects in a GLMM.
We demonstrate the equivalence for Gaussian outcomes, and the conclusions for non-
Gaussian responses will follow naturally using the same working linear mixed model
and Laplace approximation techniques as in the test statistic derivation for non-
Gaussian outcomes.
Recall, for Gaussian outcomes, our mixed model can be written as
y = τXγ + Sα+ Ua + Zb + , (4.7.6)
where a ∼ N(0, τΣ), b ∼ N(0,D(θ)),  ∼ N(0, σ2In),
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and our goal is to test H0 : τ = 0. Denote ν = (α
T ,θT , σ2)T with true value
ν∗ = (αT∗ ,θ
T
∗ , σ
2
∗)
T . We assume that ν∗ is an interior point of the parameter space Ξ
and the length of vector α and θ is q1 × 1 and q2 × 1 respectively. Denote ξ = (τ,ν)
with true value ξ∗, and the corresponding log-likelihood function as LN(ξ|γ). Define
ξˆ as the maximum likelihood estimate of ξ under H0. One can easily see that ξˆ
does not depend on γ under H0, since LN(ξ|γ) is independent of γ when τ = 0.
Define ξ˜(γ) as the maximum likelihood estimate of ξ for any γ ∈ Γ under H1. The
log-likelihood function for ξ can be written as :
∂LN(ξ|γ)
∂ξ
= Uξ,N(γ|ξ) =
 Uτ,N(γ|ξ)
Uν ,N(γ|ξ)
 ,
with score Uξ,N(γ) = Uξ,N(γ|ξ)|ξ=ξ∗ =
 Uτ,N(γ)
Uν ,N(γ)
 ,
and information matrix Jξ,N(γ) = −E{∂2LN(ξ|γ)/∂ξ∂ξT}|ξ=ξ∗ .
In order to establish the asymptotic properties, Zhu and Zhang (2006) required that
the following regularity conditions to be satisfied.
Assumption S.1 supγ∈Γ ‖ ξ˜(γ)− ξ∗ ‖→ 0 and ‖ ξˆ − ξ∗ ‖→ 0 in probability.
Assumption S.2 Assume that
Op(1) = LN(ξ|γ) = LN(ξ∗|γ)+
√
N(ξ−ξ∗)TUξ,N(γ)−
N
2
(ξ−ξ∗)TJξ,N(γ)(ξ−ξ∗)T+op(1)
holds uniformly for all
√
N ‖ ξ−ξ∗ ‖≤ c0, where c0 is any positive scalar. In addition,
supγ∈Γ ‖ Uξ,N(ξ|γ) ‖= Op(1), and c2 ≥ supγ∈Γ µmin[Jξ,N(γ)] ≥ infγ∈Γ[Jξ,N(γ)] ≥
4c21 holds almost surely for some fixed c1 and c2, where µmax and µmin represents the
minimum and maximum eigenvalue of a matrix.
Assumption S.3 (Uξ,N(·), Jξ,N(·))⇒ (Uξ(·), Jξ(·)), where ⇒ denotes weak con-
vergence of a stochastic process under the uniform metric, (Uξ(·), Jξ(·)) has bounded
continuous sample paths with probability one. Moreover, the (q1+q2+1)×(q1+q2+1)
matrix Jξ(·) is symmetric and ∞ > supγ∈Γ µmax[Jξ(γ)] ≥ infγ∈Γ µmin[Jξ(γ)] > 0
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holds almost surely.
In addition to those assumptions, we define the following notations in order to
facilitate the asymptotic properties:
Uξ(γ) =
 Uτ (γ)
Uν(γ)
 , Jξ(γ) =
 Jττ (γ) Jτν(γ)
Jντ (γ) Jνν(γ)
 ,
zξ,N (γ) = J
−1
ξ,N
(γ)Uξ,N (γ) =
 zτ,N (γ)
zν ,N (γ)
 , zξ(γ) = J−1ξ (γ)Uξ(γ) =
 zτ (γ)
zν(γ)
 ,
and e1 = (1, 0, . . . , 0)
T ∈ Rq1+q2+1.
Under the assumptions S.1 - S.3, Zhu and Zhang (2006) established the following
theorems for the asymptotic null distribution of LRT as well as the score test statistic
for testing H0 : τ = 0 against H1.
Theorem S.1 Suppose assumptions S.1 - S.3 hold. Then, under the null hypothesis,
the asymptotic null distribution of LRT is
sup
γ∈Γ
[LN(ξ˜(γ))|γ]− LN(ξˆ)⇒ 0.5 sup
γ∈Γ
zτ (γ)
2/(eT1 J
−1
ξ
(γ)e1).
Theorem S.2 Suppose assumptions S.1 - S.3 hold. Then the score statistic Ss for
testing H0 against H1 has the following asymptotic null distribution:
Ss = sup
γ∈Γ
{UTξ,N(γ|ξˆ)J−1ξ,N(γ|ξˆ)Uξ,N(γ|ξˆ)} = supγ∈Γ{
zτ (γ)√
eT1 J
−1
ξ
(γ)e1
}2 + op(1). (4.7.7)
Together, Theorem S.1 and S.2 establish the asymptotic equivalence of LRT and score
test statistic Ss. We now show that our score statistic T defined in Equation (4.3.3)
has the same form as Ss in (4.7.7). Consequently, its asymptotic equivalence with the
corresponding LRT would follow naturally from Theorem S.1 and S.2.
The log-likelihood under the LMM (4.7.6) is
l(ξ) = −N
2pi
− 1
2
log|τUΣUT + ZD(θ)ZT + σ2I|
− 1
2
(y − τXγ − Sα)T (τUΣUT + ZD(θ)ZT + σ2I)−1(y − τXγ − Sα).
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It can be shown that
Uξ,N(γ|ξˆ) =

∂LN (ξ|γ)
∂τ
|τ=0,ν=νˆ
∂LN (ξ|γ)
∂α |τ=0,ν=νˆ
∂LN (ξ|γ)
∂θ
|τ=0,ν=νˆ
∂LN (ξ|γ)
∂σ2
|τ=0,ν=νˆ

=

Uτ,N(γ|τ = 0,ν = νˆ)
0p1×1
0p2×1
0

,
where Uτ,N(γ|τ = 0,ν = νˆ) = −12tr[Vˆ−1UΣUT ] + yTPT Vˆ−1UΣUT Vˆ−1Py +
yTPT Vˆ−1Xγ. And Jττ,N(γ|τ = 0,ν = νˆ) = 12tr[(Vˆ−1UΣU)2] + γTXT P˜VˆP˜Xγ,
with Vˆ = ZDZT + σˆ2I, P = I− S(ST Vˆ−1S)ST Vˆ−1, and P˜ = Vˆ−1P. Plug in these
values into equation (4.7.7), we obtain
Ss = sup
γ∈Γ
Uξ,N (γ|ξˆ)TJξ,N (γ|ξˆ)−1Uξ,N (γ|ξˆ)
= sup
γ∈Γ
{
√
Uτ,N (γ|τ = 0,ν = νˆ) · J−1ττ,N (γ|τ = 0,ν = νˆ) · Uτ,N (γ|τ = 0,ν = νˆ)}2
= sup
γ∈Γ
{−
1
2 tr[Vˆ
−1UΣUT ] + yTPT Vˆ−1UΣUT Vˆ−1Py + yTPT Vˆ−1Xγ√
1
2 tr[(Vˆ
−1UΣU)2] + γTXT P˜VˆP˜Xγ
}2. (4.7.8)
To account for the fact that ν = (αT ,θT , σ2)T is estimated by its MLE νˆ =
(αˆT , θˆ
T
, σˆ2)T , Zhang and Lin (2003) proposed to use a bias-corrected score statistic
SR for Ss, in which inverse of the marginal covariance matrix Vˆ
−1 = (ZDZT + σˆ2I)−1
for the response y is replaced by the projection matrix P˜ = Vˆ−1P. Applying this
bias-corrected version to the score statistic in (4.7.8), we obtain
SR = sup
γ∈Γ
{−
1
2
tr[Vˆ−1PUΣUT ] + yTPT Vˆ−1UΣUT + yTPT Vˆ−1Xγ√
1
2
tr[(Vˆ−1PUΣU)2] + γTXT P˜VˆP˜Xγ
}2,
which is just the square of our proposed score statistic T in Equation (4.3.3).
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4.7.5 Additional Simulations
4.7.5.1 Scenario 3 - Meta-analysis on heterogeneous effect-sizes
Meta-analysis is a practical and effective tool for combining multiple association
studies into a single aggregate analysis in order to identify association signals with
small effect sizes. To account for the effect size heterogeneity across studies, several
approaches have been proposed under the framework of jointly testing the fixed and
random effects in an LMM. For example, the random-effects meta-analysis method
(RE) is developed to explicitly model the heterogeneity; however, it implicitly as-
sumes heterogeneity under the null hypothesis, which causes power loss. To relax the
conservative assumption of RE, Han and Eskin (2011) proposed a new random-effects
method (RE-HE) under the LMM to appropriately model the expected heterogeneity
between different studies. Specification of the model set-up is as outlined in Example
3 in Section 4.2.1. RE-HE tests the null hypothesis H0 : µ = 0 and τ = 0 using
the likelihood ratio test approach and assesses the strength of association signals
based on pre-tabulated p-values. When heterogeneity exists, Han and Eskin (2011)
demonstrated in their simulation studies that RE-HE achieves higher statistical power
than RE and the traditional fixed-effects meta-analysis method (FE), which assumes
constant effect-size across all studies.
In order to generate a realistic spectrum of the effect-size estimates and the corre-
sponding standard errors, we adapted the neoadjuvant chemotherapy meta-analysis
data from the Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collab-
oration (for Locally Advanced Cervical Cancer Meta-analysis Collaboration et al.,
2003). The meta-analysis contained data from 11 trials to compare neoadjuvant
chemotherapy followed by radical radiotherapy versus the same radiotherapy alone.
The forest plot in the left panel of Supplementary Figure 4.7 summarized the log
hazard ratios of the neoadjuvant chemotherapy and the associated 95% CIs from the
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Figure 4.7: Meta-analysis simulation results. Left panel: Forest plot of the log
hazard ratios and 95% CIs of the neoadjuvant chemotherapy from the
11 trials in the Neoadjuvant Chemotherapy for Cervical Cancer Meta-
analysis Collaboration (2003). Right panel: Empirical power for score
test and existing methods for the meta-analysis simulations.
11 trials. The forest plot showed varying effect sizes among the trials, which indicates
the possible existence of between-study heterogeneity.
Under the Cox proportional hazard model, the time-independent hazard rate for
subject k with explanatory variable Zk has the form λ(Zk) = λ0 exp{βZk}, where
λ0 denotes the hazard function of the radical radiotherapy; β denotes the effect size
for neoadjuvant chemotherapy; Zk is an indicator variable with value 1 if subject k
receives neoadjuvant chemotherapy followed by radical radiotherapy, and value 0 if
the subject only receives the radiotherapy. Re-arranging the Cox proportional hazard
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model, we have:
log(hazard ratio of the neoadjuvant therapy) = log{λ(Zk = 1)
λ0
}
= β · (Zk = 1),
which suggests that the log hazard ratio can be linked to the neoadjuvant chemother-
apy assignment via a linear model. Thus, we propose to simulate βˆ, the effect-size
estimates of the log hazard ratio through the following approach:
Step 1: For the ith trial, generate ij ∼ N(0, σ2i ), where i = 1, . . . , 11; j = 1, . . . , ni;
σ2i is the listed variance value in the left panel of Figure 1 (on Page 2478) in the
Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration (2003)
; and ni is the total sample size of the ith trial.
Step 2: For the ith trial, denote ni1 and ni2 as the number of participants with
and without the neoadjuvant therapy respectively, and Zij as the treatment group
indicator for each of the jth participant in the ith trial. Under those notations, we
have Zij = 1 for j = 1, . . . , ni1 and Zij = 0 for j = 1 + ni1, . . . , ni1 + ni2. Obtain
yij = βiZij + ij for j = 1, . . . , ni1, where value of βi is equal to the log hazard ratio
as summarized in the forest plot of Supplementary Figure 4.7. Here, we consider yij
as an observed log hazard ratio.
Step 3: Regress yij on Zij to obtain the simulated log hazard ratio βˆi and the
associated standard error for the ith trial.
Step 4: Repeat Steps 1 to 3 for each i ∈ {1, . . . , 11}.
Following the above outlined steps, we carried out 5000 simulations and perform
meta-analysis using FE, RE, RE-HE and our score test . The right panel in Supple-
mentary Figure 4.7 summarized the power comparison results. The barplot showed
that our score test yields very similar but slightly higher power to the LRT-based
RE-HE; unsurprisingly, FE and RE were less powerful at identifying the association
signal due to the expected between-study heterogeneity.
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CHAPTER V
Summary and Discussion
5.1 Summary
The first two projects in this dissertation ware motivated by the observation that
the efficiency of genetic association studies – whether by genotyping or by sequencing
– depends critically on sample size (Chatterjee et al., 2013). Trans-ethnic meta-
analyses are increasingly being used to boost study power by enlarging the total
sample size. In addition to the improved power of disease/trait locus discovery in
trans-ethnic studies, differences in LD levels across genetically diverse populations
are potentially a powerful tool for fine mapping the rare or causal variants that
underlie disease associations (Kichaev and Pasaniuc, 2015). Despite the promising
potential, however, the between-study genetic effect heterogeneity among different
ethnic groups presents challenges in performing trans-ethnic meta-analysis. Since
traditional GWAS meta-analysis approaches do not appropriately account for the
expected between-study heterogeneity, in this dissertation, I have proposed two novel
statistical methods for modeling the effect-size heterogeneity in genetic association
studies.
In Chapter II, I developed a score test to detect the common variant associations
in trans-ethnic meta-analysis. To account for the expected genetic effect heterogene-
ity across diverse populations, I adapted a modified random effects model from the
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kernel regression framework. I specifically constructed the correlation structure for
the genetic effect coefficients to reflect the level of genetic effect similarities across
ancestry groups. Through analytical approximation of the asymptotic distribution of
the proposed test, I achieved efficient computing time for genome-wide datasets.
In Chapter III, I extended the score test in Chapter II to the gene- or region-
based rare variant trans-ethnic meta-analysis in sequencing association studies. The
proposed method again uses the kernel regression framework to construct the modified
random effects model, and incorporates the genetic similarities across ancestry groups
into modeling the heterogeneity structure of the genetic effect coefficients. To enable
efficient estimation of p-values, I employed a resampling-based copula method to
estimate the asymptotic null distribution of the proposed test.
The last project in this dissertation was motivated by the problem of testing an
unspecified varying-coefficient for assessing the possible modification of non-genetic
factors on the effect of genetic variants. I generalized the problem into a framework
of jointly testing the fixed and random effects in a GLMM, so that such a unified
framework is applicable in many different scenarios in biomedical studies. To the
best of my knowledge, it is the only systematic research which addresses the joint
testing problem with respect to both the Gaussian and non-Gaussian outcomes under
the presence of nuisance variance components. More specifically, in Chapter IV, I
developed a supremum score test for jointly testing the fixed and random effects
in a generalized linear mixed model (GLMM) for both Gaussian and non-Gaussian
outcomes. The modified random effect model (RE-HE) by Han and Eskin (2011) and
the gene-based rare variant association test (SKAT-O) by Lee et al. (2012) can both
be viewed as special cases of this general framework of jointly testing the fixed and
random effects. The proposed method can also be employed in the nonparametric
test of spline curves as well as in assessing the significance of the varying-coefficient
component in the varying-coefficient model. In terms of its application in genetic
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association studies, one can use the test to investigate whether the genetics effects to
any disease/trait of interest can be modified by confounders such as age.
5.2 Future Plans
The parallel advancement of DNA array platform, high-throughput sequencing
technology and genotyping imputation accuracy has opened a new era of genomics
and molecular biology. Availability of the high throughput data at relatively low cost
enables large-scale biobanks to genotype or sequence hundreds of thousands of partic-
ipants. For example, the HUNT study includes large total population-based cohorts,
covering 125,000 Norwegian participants (Krokstad et al., 2012); the UK Biobank
project is a large prospective cohort study of 500,000 participants from across the
United Kingdom (Bycroft et al., 2017); the National Heart, Lung and Blood Institute
(NHLBI) launched their TOPMed (Trans-Omics for Precision Medicine) program has
collected over 120,000 individual genomes for its WGS project (Lung et al., 2016). In
these biobank data, in addition to genotyping/sequencing the participants’ genomes,
either carefully designed surveys or electronic health records (EHRs) together with
the International Classification of Disease (ICD) billing codes are employed to obtain
participants’ phenotypic data and health-related information.
Despite the available rich variety of genotypic, phenotypic and health-related in-
formation in those biobanks, computing summary statistics from each of the enor-
mously large-scale GWAS to conduct trans-ethnic meta-analysis poses new statistical
and computational challenges. For example, given that most of the biobank data
are based on cohort study designs, one challenge of using EHR-derived phenotypes
is that most of them are dichotomized with imbalanced (< 1:10) or extremely imbal-
anced (<1:100) case-control ratios. Standard asymptotic tests (such as the score test)
for assessing the rare variant associations typically approximate the asymptotic null
distribution using a Gaussian density. However, under the imbalanced case-control
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ratio, the normal approximation will yield highly inflated type-I error rates, since
the underlying distribution is highly skewed and thus cannot be well-captured by the
symmetric Gaussian density. In addition, those large-scale cohort studies tend to
have a diverse mixture of family structures and/or contain samples with both famil-
ial and unrelated individuals. Consequently, methods that can accommodate familial
and cryptic relatedness are needed. Unfortunately, there exist few approaches which
can handle the sample relatedness and/or type-I error inflation due to imbalanced
case-control ratio. Efficient algorithms are needed to retain the computing time for
hundreds of millions of variants on hundreds of thousands of samples in a scalable
fashion.
The SAIGE method, developed by Zhou et al. (2017), is currently the only avail-
able mixed model approach which is practical for large-scale phenome-wide associ-
ation studies (PheWAS) while controlling for case-control imbalance and correcting
for sample relatedness. It uses the saddlepoint approximation (SPA) to calibrate the
distribution of score statistics, and utilizes optimization strategies such as the pre-
conditioned conjugate gradient (PCG) approach to reduce the computational burden
and memory cost. As a next step, I will seek to incorporate the SPA and optimization
strategies used in the SAIGE method into my trans-ethnic meta-analysis approaches,
to further boost the study power by taking advantages of data from the ever larger
cohorts, additional phenotypes and wider ethnic groups.
5.3 Closing Remarks and Perspective
Over the last decade, multi-ethnic studies have proved instrumental to unraveling
the genetic complexities of disease risks In particular, trans-ethnic meta-analysis are
increasingly being used for locus replication and discovery, as well as fine-mapping of
causal variants associated with complex diseases. One key advantage of using trans-
ethnic meta-analysis is to boost study power by leveraging LD structure and the
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underlying differential genetic architecture across disparate ancestral human genomes.
Based upon this concept, central to my thesis research is the goal of maximize study
power for locus discoveries when there is significant inter-study heterogeneity.
In the past few years, in response to the criticisms of the limited utility of
GWAS-findings, the genomics community has gradually shifted its focus to causal
or functional variant identifications. The widely available and economically feasi-
ble re-sequencing technologies have made it possible to conduct locus fine-mapping
through trans-ethnic GWASs. By including populations with more diverse haplo-
types, such as the African population, trans-ethnic GWASs can help pinpoint the
causal or functional variants of interest and identify candidate gene mutations. Find-
ings from several global genomics consortia have demonstrated that trans-ethnic fine-
mapping studies can identify functional gene mutations as well as increase the total
variance explained by the identified loci (Galarneau et al., 2010; Sanna et al., 2011;
Franceschini et al., 2012; Wu et al., 2013; Liu et al., 2014; Saunders et al., 2014).
New findings from trans-ethnic studies will enrich our understanding of the ge-
netic basis of complex diseases/traits. Although it is not a simple task to interpret
GWAS findings, given that most GWAS signals are either in the intronic or intergenic
non-coding regions of the genome, integration of multiple “omics” resources, such as
epigenetic features, eQTLs, tissue-specific transcript expressions, chromatin confor-
mation can help advance the identification of functional or mechanistic variations in
the post-GWAS era. The continued expansion of GWAS, and its integration with
other efforts capturing the molecular function of the human genome, will be a critical
asset for the study of gene coding and regulatory mechanisms and how they con-
tribute to complex diseases/traits. Disentangling the mechanism by which genotype
influences phenotype will ultimately lead to the identification of important biological
pathways and presentation of suitable targets for drug development and reposition-
ing of known therapeutics. Continuing steps toward filling the knowledge gap will
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bring us closer to elucidating disease etiology and offer opportunities of innovative
preventative and therapeutic strategies in precision medicine.
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